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Abstract 
 
Noble metal nanoparticles exhibit a unique optical property known as localized surface 
plasmon resonance (LSPR), which occurs when interacting light couples to the 
collective oscillations of the surface electrons. This work investigates the use of various 
nanoparticles for biosensing based on LSPR.  
Triangular silver nanoplates (TSNPs), synthesized using two different methods, and 
their derivatives, gold-coated TSNPs (AuTSNPs), were investigated for use in refractive 
index sensitivity-based solution assays. Refractive index sensitivities of these 
nanoplates were determined and benchmarked against the theoretical calculation 
predicted by Miller et al.. The first generation TSNPs and AuTSNPs were used for the 
detection of human C-reactive protein (CRP) and cardiac troponin I (cTnI) and the 
second generation AuTSNPs were used for the detection of human CRP. In order to 
address the complex assay design, a simpler aggregation-based assay for the detection 
of human IgG was implemented using spherical gold nanoparticles. Furthermore, a 
preliminary study on incorporating the AuTSNPs into a surface plasmon resonance 
(SPR) sensor was carried out to explore the enhancement effect of the nanoplates on 
SPR detection. 
Nobel metal nanoparticles are found to enhance fluorescence-based biosensing due to a 
phenomenon known as metal-enhanced fluorescence (MEF) when the nanoparticles are 
in the vicinity of fluorophores. In this work, the enhancement effects of the AuTSNPs 
and spherical silver nanoparticles (AgNPs) on the fluorescence were evaluated. A 
significant enhancement was observed for AgNPs whereas no enhancement was 
observed for AuTSNPs. Further MEF studies were conducted using various dyes and 
gold-coated AgNPs. AgNPs were used for enhancing the fluorescence-based assays for 
human IgG and CRP detection. The limits of detection (LODs) of the IgG and CRP 
assays were improved by ~ 9-fold and ~ 19-fold, respectively.  
This work establishes the potential of plasmonic nanoparticles for highly sensitive 
biosensing and holds much promise for the improvement of biomedical diagnostics. 
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Chapter 1  
Introduction 
 
1.1 Background 
In recent years there has been an increasing demand for highly sensitive detection of 
biomolecules such as proteins and nucleic acids in the biomedical area. Along with the 
rapid development of nanotechnology, optical sensing based on noble metal 
nanoparticles has paved a way for detecting biomolecules at low concentrations for 
biomedical applications. The work presented in this thesis explores the application of 
noble metal nanoparticles in the detection of proteins by taking advantage of their 
unique optical property known as localized surface plasmon resonance (LSPR). In this 
work, LSPR has been integrated in a range of assay designs including refractive index 
sensitivity-based, aggregation-based, surface plasmon resonance (SPR)-based and 
fluorescence-based assays. This opening chapter provides a brief overview of noble 
metal nanoparticles and their applications in the biomedical area. This is followed by an 
outline of the thesis structure and a statement of the main objectives of the work. 
1.2 Noble metal nanoparticles  
1.2.1 Historical development 
Noble metal nanoparticles are referred to as the particles produced from noble metals 
which have at least one dimension of the order of 100 nm or less. Noble metal 
nanoparticles, especially gold and silver nanoparticles, exhibit intense scattering and 
absorption of light in the visible spectrum which is the source of the beautiful colors in 
stained glass. Gold nanoparticles are probably the first nanomaterial used for therapeutic 
and decorative purposes, which can date back to 5
th
 or 4
th
 century B.C. in Egypt and 
China.
1
 A well-known example is the Lycurgus Cup that was fabricated in 4
th
 century 
A.D. It displays red in transmitted light and green in reflected light, due to the presence 
of colloidal gold and silver in the glass (Figure 1.1).  
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Figure 1.1 The Lycurgus Cup, appearing green in reflected light (A) and red in 
transmitted light (B). Courtesy of the British Museum. 
In 1857, Faraday reported the first scientific article on the synthesis of gold 
nanoparticles and he was the first to attribute the red color to finely divided gold 
particles.
2
 In 1908, Mie developed a solution to Maxwell’s equations that describes the 
scattering and absorption spectra of spherical particles of arbitrary size.
3
 At present, the 
most common approach to the synthesis of noble metal nanoparticles involves chemical 
reduction of a metal salt in a solution containing a stabilizer, which limits the growth of 
the nanoparticles, controls their shape and improves their stability.
4, 5
 While most of the 
one-step synthesis tends to yield approximately spherical nanoparticles,
6, 7
 seed-
mediated growth is used to fabricate non-spherical nanoparticles of controllable shape 
and size such as nanorods,
8-11
 nanocubes,
12
 nanodiscs
13
 and nanoprisms.
14, 15
 In seed-
mediated syntheses, seed particles are first formed by the reduction of a metal salt in a 
solution. Next, the nanoparticles are grown by adding the seeds to a growth solution 
where the metal salt is reduced directly on the surface of the seed particles. Detailed 
information on morphology control by colloidal methods can be found in reviews.
16, 17
 
Additionally, metal nanostructures on substrates can be fabricated using scanning beam 
lithographies such as electron beam lithography (EBL)
18-20
 and focused ion beam 
(FIB).
21, 22
 These techniques allow the preparation of patterned nanostructures with 
accurate control of size, shape and spatial distribution. However, the cost of such 
techniques is usually high and the patterned areas are small. Nanosphere lithography 
(NSL)
23, 24
 is an inexpensive and large scale method that involves evaporation of a metal 
on a close-packed monolayer of polystyrene nanospheres which serves as a material 
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deposition mask. Following the removal of the nanospheres, a periodic array of triangle-
shaped nanoparticles remains on the substrate.  
1.2.2 Current applications in biomedicine 
As numerous research efforts have been made to fabricate various noble metal 
nanoparticles and to investigate their optical properties, more and more studies have 
been carried out on the applications of these particles. Biomedicine is one of the most 
attractive fields where the use of gold and silver nanoparticles has been explored 
broadly. The potential biomedical applications of these particles primarily include 
biosensing/diagnosis,
25-27
 imaging
28-30
, targeted drug delivery
31-33
 and therapy.
34-37
 
The unique optical properties of noble metal nanoparticles (i.e. LSPR) provide a 
platform for biosensing by means of transducing a molecular recognition-induced 
change into a quantifiable signal. This type of application is typically developed on the 
basis of the following mechanisms: (i) local refractive index changes,
26, 38-40
 (ii) 
nanoparticle aggregation,
41-46
 (iii) surface enhanced Raman scattering (SERS)
47-51
 and 
(iv) metal-enhanced fluorescence (MEF).
52-57
 The signal measurement techniques 
mainly involve ultraviolet–visible (UV–vis) spectroscopy, dark-field microscopy, 
Raman spectroscopy and fluorescence spectroscopy. In addition, LSPR has been 
incorporated into the SPR biosensing to further amplify the signal.
58-62
 While the 
utilization of nanoparticles for biosensing is mostly active in the research laboratory, a 
few technologies have been commercialized. A good example is Nanosphere’s Verigene 
System which involves gold nanoparticle-based diagnostic applications including 
clinical microbiology tests, cardiac tests, human genetic tests and pharmacogenetic 
tests.
63
 During the course of my PhD program, a company called Plasmonix now sells 
the silver nanoparticle-coated 96-well microplates that are used for fluorescence-based 
assays to improve the assay sensitivities.
64
 
The scattering from a single gold or silver nanoparticle has been found to be many 
orders of magnitude greater than the signal from single fluorophores or quantum dots.
65, 
66
 Additionally, unlike fluorophores, nanoparticles neither photobleach or blink. These 
effects enable them to enhance the contrast of imaging systems based on microscopy 
such as dark-field microscopy for imaging cells and a microarray-based DNA assay.
29, 
30, 67
 Gold and silver nanoparticles have also been used as imaging labels for cell and 
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tissue imaging with surface enhanced Raman spectroscopy.
68-70
 In a fluorescence 
imaging study, silver nanoparticle-fluorophore coupled molecular probes have been 
developed for single cell imaging using scanning confocal microscopy.
71
 This approach 
provides a promising imaging agent with increased brightness, decreased lifetime and 
improved photostability.  
Recently, gold nanoparticles have been used as drug delivery systems due to their 
biocompatibility, optical properties and outstanding abilities to conjugate with small 
molecules like ligands, DNA and drugs.
72
 The absorption of light by noble metal 
nanoparticles yields a nanoscopic heat source, thus enabling thermal ablation treatment 
to tumors by locally and specifically applying heat to the diseased tissue.
34, 73
 A detailed 
review on the therapeutic applications of noble metal nanoparticles can be found in this 
article.
74
 
1.2.3 Roles of noble metal nanoparticles in this thesis 
This thesis focuses on the development of biosensing applications based on noble metal 
nanoparticles for potential diagnostic tests. Specifically, two main nanoparticle 
applications have been explored in this work. Firstly, nanoparticles, conjugated with 
specific probes, are used as biosensors to detect target analyte molecules including 
human C-reactive protein (CRP), human cardiac troponin I (cTnI) and human IgG. 
Secondly, nanoparticles are used as enhancers to amplify the signals from SPR and 
fluorescence-based assays. Both of these roles are based on their unique optical 
properties, i.e. LSPR.  
1.3 Thesis structure  
This thesis consists of seven chapters. 
Chapter 1 briefly introduces the development of noble metal nanoparticles and their 
applications in the field of biomedical sciences. A description of the roles that the 
nanoparticles play in this thesis is given. An outline of the thesis and the research 
objectives are presented. 
Chapter 2 describes the relevant background of immunoassays, the fundamental theories 
of fluorescence and the distinct optical properties of noble metal nanoparticles. The 
  Chapter 1: Introduction 
 
 
 
5 
principles of MEF are discussed. A review of biosensing based on LSPR in relation to 
this work is given. 
Chapter 3 describes the main characterization techniques used in this work. 
Chapter 4 reports the early work carried out at the National University of Ireland, 
Galway (NUIG) during the first year of my PhD program, where I worked on unique 
triangular nanoplates which had been developed by Prof. John Kelly in Trinity College, 
Dublin (TCD) and referred to the Kelly particles in this thesis. Prof. Kelly and one of 
my supervisors, Dr. Brennan-Fournet, optimized the refractive index sensitivities of 
these particles and my initial task was to investigate their use for highly sensitive 
homogeneous assays in solution. Dr. Brennan-Fournet moved to DCU after the first 
year and, due to intellectual property (IP) restrictions, my work on the Kelly particles 
had to be discontinued. The work presented here is preliminary work towards the use of 
the particles in real assays. 
Chapter 5 reports the development of homogenous assays using alternative triangular 
nanoplates and spherical gold nanoparticles (AuNPs). Firstly, a refractive index 
sensitivity-based assay using the alternative triangular nanoplates is described. Next, an 
aggregation-based assay using AuNPs is presented. In the last section of Chapter 5, 
preliminary work on a nanoparticle-enhanced SPR assay using triangular nanoplates is 
described. 
Chapter 6 reports the development of a fluorescence-based, solid-phase assay enhanced 
by noble metal nanoparticles. Firstly, the comparison of the enhancement effect of 
triangular nanoplates and spherical silver nanoparticles (AgNPs) on the fluorescence is 
presented. Secondly, the enhancement effect for two different dyes is outlined. This is 
followed by an investigation of the enhancement effect on the gold-coated AgNPs. 
Next, MEF assays using AgNPs are described. 
Chapter 7 summarizes the results obtained during the work and evaluates the results in 
the context of the state-of-the art for assays for the various analytes. Finally, the future 
work is also described.  
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1.4 Research objectives 
The central objective of this work was to develop LSPR assays with improved 
sensitivity for application in point-of-care diagnostics. Both solution-based and solid 
platform-based approaches were used and transduction methods ranged from refractive 
index-based, to aggregation, SPR and finally MEF. 
The specific objectives are: 
1. To experimentally investigate refractive index sensitivity-based assays using 
solution-phase triangular nanoplates  
2. To experimentally investigate aggregation-based assays using solution-phase 
spherical AuNPs and to explore the potential of enhanced SPR detection using 
AuTSNPs. 
3. To experimentally investigate MEF-based assays using silver and gold 
nanostructures on solid substrates. 
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Chapter 2 
Theory and background 
 
2.1 Introduction  
This chapter introduces the main elements of the work carried out, including the 
relevant background to immunoassays, the fundamentals of fluorescence theory, the 
concepts behind nanoparticle local surface plasmon resonance and the principles of 
plasmonic enhancement of fluorescence, herein referred to as metal-enhanced 
fluorescence (MEF). Also included is a comprehensive state-of-the-art review of LSPR 
biosensing based on cutting edge technologies and mechanisms.  
2.2 Assays and Immunoassays  
An assay is an analytical method that identifies and quantifies a substance. It is 
primarily used in pharmaceutical, food testing, biological, chemical and medical areas. 
An immunoassay is a ligand-binding assay that measures an analyte in a biological 
mixture through a specific antibody-antigen reaction.
1
 Immunoassays are being 
extensively employed in research laboratories and clinical diagnostics.  
An antibody, also known as immunoglobulin, is a protein produced by B cells in 
response to a foreign molecule (i.e. antigen). Its functionality enables it to specifically 
recognize and binds to a defined structure (i.e. epitope) on an antigen. Monoclonal 
antibodies produced by a single B cell clone recognize only one epitope, whereas 
polyclonal antibodies produced by multiple B cell clones recognize different epitopes 
on one antigen.
2
 Figure 2.1 illustrates a simplified structure of an antibody molecule. 
Typically, the antibody is depicted as a Y-shaped molecule comprising of two identical 
heavy chains and two identical light chains. Each chain contains both a variable (V) and 
a constant (C) region. Functionally, the antibody consists of two important parts 
including the Fab (fragment, antigen binding) region and Fc (Fragment, crystallizable) 
region. The Fab region is composed of one constant and one variable domain from each 
heavy and light chain, which contains the antigen binding site of the antibody. The 
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interaction between the antibody and antigen, similar to a lock and key, involves non-
covalent bonds including hydrogen bonds, ionic bonds, hydrophobic interactions and 
Van der Waals forces.
3
 There are many factors affecting the antibody-antigen reaction 
such as temperature, pH, ionic strength and duration of incubation time.
3
 The antibody-
antigen reaction can be optimized by adjusting these factors. The Fc region is the base 
of the antibody that plays a role in modulating immune cell activity.  
 
Figure 2.1 Simplified structure of an antibody molecule. Adapted from reference.
4
 
 
2.2.1 Immunoassay classifications 
Immunoassays can be classified in different ways and a thorough description of the 
immunoassay designs and formats can be found in reference.
5
 In this chapter, the 
immunoassay formats used in this work are described below. 
2.2.1.1 Homogeneous and heterogeneous immunoassays 
Based on the requirement of separation steps in an assay, immunoassays are classified 
as homogeneous or heterogeneous. Homogeneous immunoassays only involve the 
combination of an analyte and the reagents followed by detection.
5
 They do not require 
the physical separation of antibody-bound components from the free ones, which 
generally shortens the assay time and reduces the requirements for automation.
5
 On the 
other hand, heterogeneous immunoassays require separation steps, such as washing, in 
order to physically remove the interfering components from the antibody-analyte 
complexes.
6
 Due to the separation steps, heterogeneous immunoassays can be time-
consuming and labor-intensive.  
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2.2.1.2 Label-free and labeled immunoassays 
Depending on whether a label is introduced to the assay system, immunoassays are 
classified as labeled or label-free. Most conventional immunoassays use a label (e.g. 
radioisotope, enzyme or fluorophore) conjugated with one or more components in the 
assay system to generate detectable signals.
7
 These assays can be easily quantified 
because the number of antibody-antigen bindings is usually proportional to the level of 
the signal produced by the labels. Recently, label-free immunoassays have been widely 
developed, which are independent of labels for detection. A well known example of 
such an assay is based on SPR which detects the changes of reflective index in the 
vicinity of a thin metal film due to the occurrence of antibody-antigen bindings on the 
film.
8
 Noble metal nanoparticles have recently shown promise when employed in 
immunoassays. The performance of these assays is based on LSPR and both label-free 
and labeled formats have used.
9-11
 In these assays, the shifts in the LSPR wavelength are 
measured, depending on the refractive index changes of the local medium that are 
induced by the antibody-antigen bindings on the nanoparticle surface.  
2.2.1.3 Direct and sandwich immunoassays 
The direct immunoassay is usually considered to be the simplest form of immunoassay 
since it requires only one antibody for the specific detection of a target antigen. Figure 
2.2 A illustrates an example of a direct immunoassay using a solid phase, where the 
antibody is immobilized on a substrate. The concentration of the antigen is determined 
by measuring the signal of the labeled antigen which is captured by the antibody. This 
type of assay is relatively fast due to the simple procedure. The sandwich immunoassay 
involves the measurement of antigen between a layer of capture antibody and a layer of 
detection antibody. The antigen must contain at least two epitopes since at least two 
antibodies react with it. Figure 2.2 B illustrates a solid-phase sandwich immunoassay 
where the capture antibody is immobilized on a substrate and the detection antibody is 
conjugated to a label, e.g. a fluorophore. The immobilized antibody captures the antigen 
from a sample, followed by the introduction of labeled antibody that will bind to the 
free epitopes of the antigen. The level of signal generated by the labeled antibody is 
directly proportional to the antigen concentration.  
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Figure 2.2 Schematic illustrating (A) a direct immunoassay and (B) a sandwich 
immunoassay. 
2.3 Absorption and Fluorescence  
Fluorescence is the spontaneous emission of photons from a substance when it relaxes 
to its ground state after the absorption of photons. The processes of absorption and 
emission in a substance are demonstrated in the Jablonski diagram shown in Figure 
2.3.
12
 The singlet ground, first and second electronic states are depicted by S0, S1 and 
S2, respectively. A fluorescent substance known as a fluorophore is usually excited to a 
higher vibrational energy level (S1 or S2) when absorbing a photon, which occurs in 
about 10
-15
 s. Immediately following the absorption, the fluorophore may relax to the 
lowest vibrational level of S1 by non-radiative decay. This process known as internal 
conversion generally occurs within 10
-12
 s and completes before emission. The 
fluorophore then relaxes to its ground state (S0) by emitting a photon of energy.  
 
Figure 2.3 Jablonski diagram demonstrating the fluorescence process. IC denotes 
internal conversion. 
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The fluorescence quantum yield ( ) and lifetime (τ) are critical properties of a 
fluorophore. The fluorescence quantum yield refers to the ratio of the number of emitted 
photons to the number of absorbed photons, and is given by  
 
   
 
     
 (2.1) 
where   and     are the radiative and non-radiative decay rates, respectively. The 
quantum yield is always less than unity due to energy dissipation. 
The lifetime is defined as the average time the fluorophore spends in the excited state 
prior to emitting a photon of energy, and is expressed as:  
 
   
 
     
 (2.2) 
The radiative decay rate is determined by the extinction coefficient of the fluorophore 
according to the Strickler–Berg relationship13.   
               
    
  
  
     (2.3) 
where    is the wavenumber of the absorption maximum,   is the refractive index of the 
medium,    and    are the degeneracies of the ground and the first excited states,   is 
the molar extinction coefficient of the fluorophore. Since the extinction coefficient 
remains nearly constant in various environments, the radiative decay rate does not 
change substantially under most conditions. Therefore, the changes in quantum yield   
and lifetime   result from changes in the non-radiative decay rate    . The values of   
and   either both increase or decrease. 
2.4 Surface plasmon resonance  
When light interacts with a metal, such as a thin gold or silver film, its surface free 
electrons oscillate collectively while absorbing, scattering or reradiating the incident 
photons. The resulting surface electromagnetic waves propagate along the metal surface 
for distances on the order of tens to hundreds of microns, and decay exponentially in the 
z-direction with lengths on the order of 200 nm (Figure 2.4).
14-16
 As a result of the 
coherent oscillation of the surface electrons, the intensity of the electromagnetic field in 
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the z-direction is enhanced by a factor of 10 to 100 compared to the incident intensity.
15
 
These propagating electromagnetic modes are termed surface plasmon polaritons, but 
are usually referred to as surface plasmons (SPs). The enhancement of the 
electromagnetic field at the metal surface results in an extraordinary sensitivity of SPs 
to surface conditions.  
 
Figure 2.4 Schematic diagram of SPR. Adapted from reference.
16
 
 
2.5 Localized surface plasmon resonance and Mie theory 
Nanostructured noble metals such as gold and silver nanoparticles exhibit distinct 
optical properties from the bulk metals, typically exhibiting strong absorption bands in 
the visible region. This absorption band originates from the interaction between an 
electromagnetic field and the free electrons confined on the nanometer scale in the 
metal. When light interacts with nanoparticles that are much smaller than the incident 
wavelength the free electrons in the metal move to the surface and oscillate in resonance 
with the photon’s frequency (Figure 2.5).17 This collective oscillation of conduction 
electrons is confined to the surface of the nanostructure and is known as localized 
surface plasmon resonance (LSPR). Consequently, the induced electromagnetic field 
associated with the LSPR is considerably enhanced in the vicinity of the nanoparticle.  
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Figure 2.5 LSPR illustrating the oscillation of the electron cloud upon interaction with 
an electromagnetic field. Adapted from reference.
16
  
In 1908 Mie published a paper on a theoretical solution to Maxwell’s equations,18 
elucidating the scattering and absorption of electromagnetic radiation incident on a 
spherical particle of arbitrary material. Mie solution provides the simplest theoretical 
approach for demonstrating the optical properties of nanoparticles. It is given by,
19
  
 
         
      
    
   
         
 
  
            
    (2.4) 
where      is the extinction (extinction = scattering + absorption), NA is the number of 
nanoparticles,   is the radius of the nanosphere,    is the dielectric constant of the 
medium surrounding the nanosphere,   is the wavelength of the absorbing radiation,    
and    correspond to the imaginary and real portions of the spherical metal’s dielectric 
function and   is a shape factor dependent upon the aspect ratio of the nanoparticle 
(equal to 2 for a sphere). It is evident that the LSPR spectrum of a single metallic 
nanosphere suspended in a dielectric medium relies on the nanoparticle size (  , 
material (   and   ) and the dielectric constant of the surrounding environment (  ). 
Moreover, the extinction spectrum also depends upon the shape (χ) which becomes an 
important parameter in the case of non-spherical nanoparticles. 
2.5.1 Influence of material: dielectric function  
The dielectric properties of a material describe the interaction of electromagnetic 
radiation with the material. As discussed above, the dielectric properties of noble metal 
nanoparticles differ from those of the bulk metal such as, unlike bulk metals, 
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nanoparticles can exhibit strong absorption within the visible spectrum. The two most 
relevant metals in this work are gold and silver which have similar dielectric properties 
resulting from the cooperative behavior of the d-band electrons and conduction 
electrons on the nanoparticle surface.
20
 The difference in interband contributions to the 
plasmon resonance results in gold and silver spherical nanoparticles having plasmon 
resonance absorption bands at 520 nm and 400 nm respectively for a diameter of ~ 60 
nm. The dielectric constant has both real and imaginary contributions with the 
imaginary contribution contributing to the extinction properties of the nanoparticles. 
Importantly, silver has an imaginary dielectric constant lower value resulting in its 
higher extinction. As a result, silver nanoparticles have a factor of ten greater scattering 
strength than similar gold nanoparticles.
21
 
2.5.2 Influence of nanoparticle size 
When a particle is illuminated by an electromagnetic field, its electrons can be 
accelerated and they radiate electromagnetic energy in all directions via scattering 
processes. Additionally, the excited electrons can also transform the incident 
electromagnetic energy into other forms such as thermal energy via absorption 
processes. The sum of both processes is known as extinction.
22
 The relative 
contributions of absorption and scattering to extinction depend on the size and shape of 
the nanoparticles. In order to examine the size effect on the optical properties of a 
nanoparticle, a sphere is chosen for simplicity.   
For a spherical nanoparticle much smaller than the wavelength of the incident light (  ≤ 
10 nm), the electric field can be considered spatially constant, with a time dependent 
phase, which is known as the quasi-static approximation.
23
 Within this model, the 
conduction electrons experience homogenous polarization leading to a dipole mode 
resonance as depicted in Figure 2.6 A. This resonance is exclusively dependent on the 
shape of the nanoparticle and the electron density. The LSPR extinction results from the 
dipole absorption while the scattering process is negligible.
24
 The peak position and the 
width of the LSPR are influenced by the frequency dependent dielectric functions of the 
noble metals.
23
.  
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Figure 2.6 Electric field distributions of the (A) dipole, (B) quadrupole and (C) 
octupole resonances. Adapted from reference.
23
  
As the size of nanoparticle increases, the electron density is no longer polarized 
homogeneously by the incident light, resulting in higher multipole mode resonances 
such as quadrupole and octupole (Figure 2.6 B and C).
23
 Higher order resonances 
corresponding to individual polarizations of the electron density are observed at shorter 
wavelengths with respect to the dipole peak.
25-27
 In addition, the accelerated electrons in 
the larger nanoparticle can radiate energy in all directions, which is the scattering 
process. Due to this secondary radiation, the electrons experience energy loss (radiation 
damping), shifting the dipole resonance to longer wavelengths and broadening the 
spectrum.
28
 The scattering becomes dominant in the extinction spectra as the size of the 
nanoparticle increases. Figure 2.7 shows the contributions of absorption and scattering 
to the extinction for small and large silver nanospheres.
29
 For a small nanosphere (  = 
22 nm), both absorption and scattering are observed while the former plays a dominant 
role in the extinction. However, for a large nanosphere (  = 100 nm), the scattering 
process contributes almost the entire extinction.  
  Chapter 2: Theory and background 
 
 21 
 
Figure 2.7 Extinction (QE), absorption (QA) and scattering (QS) efficiencies for small 
and large silver spheres. Adapted from reference.
29
  
2.5.3 Influence of nanoparticle shape  
Mie theory only provides the exact solution for the spherical case. Although Gans 
extended this theory to ellipsoids,
30
 further theory is required to elucidate the optical 
response of nanoparticles with arbitrary shapes. Over the past two decades, new 
numerical methods have been introduced to model complex nanoparticles, including the 
discrete dipole approximation (DDA),
31, 32
 the T-matrix method,
33
 the multiple 
multipole method (MMP),
34
 the finite difference time domain method (FDTD)
35
 and the 
modified long wavelength approximation (MLWA).
36
  
In essence, the surface plasmon oscillation involves a displacement of the negative 
charges from the positive nuclei under the action of an incident electromagnetic field. 
This displacement of the negative charges gives rise to polarization charges at the 
particle surface and hence the restoring force of the system.
23
 The frequency and 
intensity of plasmon resonances are primarily determined by the surface polarization. 
Any change in the shape or geometry of the nanoparticle will change the surface 
polarization and therefore the resonance spectrum. For instance, within the quasistatic 
regime, an ellipsoid with three different axes presents three distinct dipole modes, 
differing from a sphere with only one dipole mode.
23
 Moreover, as the shape of the 
nanoparticle becomes less symmetric not only dipole modes with distinct frequencies 
but also higher multipole modes are induced. Wiley et al. demonstrated the optical 
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properties of different silver nanoparticles in electromagnetic fields using DDA 
calculations.
37
 The low-symmetry nanoparticles display redshifted resonance peaks 
compared to nanospheres, which is attributed to the corners of the structures where 
surface charges accumulate.
38, 39
 The charge distribution near the corners increases the 
surface polarization and therefore reduces the restoring force for electron oscillation, 
which is characterized by a redshift of the resonance peak and the appearance of high 
multipole modes (Figure 2.8).
37, 40
  
 
 
Figure 2.8 The DDA calculated UV-vis extinction (black), absorption (red) and 
scattering (blue) spectra of silver nanostructures. Adapted from reference.
37
 
Haes and coworkers demonstrated electric field enhancement contours around three 
differently shaped silver nanoparticles with the same volume.
41
 The electric field 
contours near the surfaces, especially at the corners of cubic and pyramidal 
nanostructures, are observed to be much more intense than those near spherical 
contours. The highly enhanced electric field is also observed near the sharply curved 
surface of a silver nanoellipsoid.
36
 In the case of triangular nanoplates, the maximum 
enhancement for the dipole resonances is observed to occur at the tips.
36, 42, 43
 Figure 2.9 
A shows a spectrum of a silver triangular nanoplate with 100 nm edge length and 16 nm 
thickness.
44
 The 770 nm peak is assigned to the in-plane dipole resonance, the 470 nm 
peak to the in-plane quadrupole resonance and the 340 nm peak to the out-of-plane 
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quadrupole resonance. A weak shoulder at 410 nm is assigned to the out-of-plane dipole 
resonance though it is only weakly visible. Figure 2.9 B shows the electric field 
enhancement contours near the surface of a silver triangular nanoplate as depicted in 
Figure 2.9 A.
36
 The maximum field for the dipole mode occurs at the nanoplate tips and 
is approximately 500 times the applied field, leading to enhanced sensitivity to local 
changes near the tips. This effect renders triangular nanoplates a more attractive 
candidate than spherical nanoparticles for optical sensing.  
 
 
Figure 2.9 (A) DDA simulation of the orientation averaged extinction efficiency 
spectrum of a silver triangular nanoplate in water (edge length = 100 nm, thickness = 16 
nm). (B) Electric field enhancement contours external to the silver triangular nanoplate 
for an in-plane dipole resonance at 770 nm. Adapted from references.
36,
 
44
 
2.5.4 Influence of dielectric environment: refractive index sensitivity 
The electron oscillations confined at the surface of nanoparticles are very sensitive to 
any change in the metal-dielectric interface. According to equation 2.4, it is apparent 
that the dielectric constant of the surrounding medium    determines the surface 
plasmon resonance of the nanoparticle. An increase in the dielectric constant, 
particularly the refractive index   (    
   ), of the surrounding medium results in a 
decrease in the restoring force for the electron oscillation, thus decreasing the plasmon 
oscillation frequency.
45
 In general, the plasmon resonances have been found to shift to 
longer wavelengths as the refractive index of the local medium is increased. More 
specifically, the LSPR peak wavelength (λmax) of the nanoparticles has been found to 
increase linearly with the local refractive index.
46-48
 The refractive index sensitivity of 
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the nanoparticle is defined as a ratio of the change in the LSPR λmax to the change in the 
local refractive index  , which is          (nm/RIU).
49, 50
 Refractive index 
sensitivities ranging from tens to hundreds of nanometers per refractive index unit have 
been observed within the visible spectral region which in cases rise to values greater 
than 1000 nm/RIU in the near infra-red spectral region for various nanoparticles such as 
nanospheres,
51, 52
 nanocubes,
51
 triangular nanoplates,
53, 54
 nanorods
51, 55
 and 
nanoshells.
45, 56
 
Miller and Lazarides postulated that the refractive index sensitivities of the 
nanoparticles are exclusively determined by the LSPR peak wavelengths and the 
dielectric properties of the material.
50
 They showed that the refractive index sensitivity 
linearly increases with the peak wavelength, regardless of the nanoparticle shape for 
wavelengths up to 800 nm. Lee and El-Sayed observed that the refractive index 
sensitivity of the nanorods is independent of the metal composition but primarily 
dependent on the aspect ratio (i.e. the ratio of the long axis to the short axis) of the 
structure.
55
 In addition, the sensitivity is found to linearly increase with the aspect ratio 
of the nanorods. Recently, Charles et al. have carried out a comprehensive refractive 
index sensitivity study for solution phase triangular silver nanoplates (TSNPs).
54
 It is 
observed that the refractive index sensitivities of TSNP sols increase linearly with 
LSPR peak wavelengths up to 800 nm and nonlinearly with the wavelengths in the near 
infrared region (Figure 2.10 A and B). A maximum refractive index sensitivity of 1096 
nm/RIU was obtained at an LSPR peak wavelength of 1093 nm. The refractive index 
sensitivity is experimentally and theoretically found to linearly increase with the aspect 
ratio (i.e. the ratio of the edge length to the thickness) of the structures (Figure 2.10 C). 
The aspect ratio of TSNPs is a key parameter in determining their refractive index 
sensitivities.
54
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Figure 2.10 (A) An example of the spectral shift observed for a TSNP ensemble 
exposed to various refractive indices. (B) Plotting of the LSPR λmax of the TSNP sols 
against the corresponding refractive index sensitivity. (C) The dependence of the 
refractive index sensitivity on aspect ratio of TSNP (experimental data = black, aspect 
ratio dependent approximation = red, DDA = green). Adapted from reference.
54
 
2.6 Metal-enhanced fluorescence  
When a fluorophore is placed in the vicinity of a metal nanoparticle, the optical 
properties of the fluorophore can be modified and both excitation and emission 
processes can be enhanced. Figure 2.11 shows the classical Jablonski diagram for the 
fluorescence process (left) and the modified form illustrating the metal-fluorophore 
interactions (right). As discussed above in section 2.5, locally enhanced electric fields 
are observed in the metal nanoparticles due to the collective oscillation of electrons on 
the metal surface. When a fluorophore is placed near to a metal nanoparticle, its 
absorption process is enhanced by the increased electric fields, resulting in a subsequent 
increase in the excitation rate and subsequently the emission intensity.
57
 Additionally, 
the excited-state fluorophore can couple to the surface plasmons of the nearby 
nanoparticle, generating far-field radiation at the emission wavelength. Through this 
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mechanism an increase in the emission is observed, accompanied by a decrease in the 
lifetime.
57
 
 
Figure 2.11 Jablonski diagram without (left) and with (right) metal-fluorophore 
interactions. The thicker arrows represent enhanced excitation and emission rates. 
Reproduced from reference.
58
 
In the case of a fluorophore in the vicinity of a metal nanoparticle, the radiative decay 
rate is increased and the quantum yield (  ) and lifetime (  ) are given by
12
   
 
    
    
         
 (2.5) 
 
 
    
 
          
 (2.6) 
where    and      are radiative and non-radiative decay rates induced by the metal 
nanoparticle, respectively. It is apparent that an increase in the metal-induced radiative 
decay rate    results in an increased quantum yield and decreased lifetime, an effect 
which is not observed in classical fluorescence in the absence of metal nanoparticles 
(equations 2.5 and 2.6). The decreased lifetime is expected to improve the photostability 
of the fluorophore as less time will be spent in the excited state per excitation/emission 
cycle. Therefore, fluorophores in the vicinity of metal nanoparticles, with increased 
quantum yield and decreased lifetime, can emit considerably more photons per second 
than those in the absence of metal nanoparticles.
59
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2.6.1 Key parameters for MEF 
Numerous theoretical and experimental studies have shown that MEF is highly sensitive 
to the optical properties of metal nanoparticles, the orientation of the fluorophores and 
the distance between the fluorophore and the nanoparticles.
60-62
 Calculations have 
shown that the maximum enhancement can be achieved when the dipole of the 
fluorophore is oriented perpendicular to the nearby nanoparticle surface and parallel to 
the dipole plasmon mode on the nanoparticle.
61, 62
 However, the optimization of the 
fluorophore-nanoparticle configuration can be quite complicated in practice. More 
practical approaches to achieving effective MEF involve choosing appropriate 
nanoparticles and varying the fluorophore-nanoparticle distance.  
As discussed in section 2.5.2, both absorption and scattering contribute to the extinction 
of a metal nanoparticle. The scattering component generating far-field radiation is 
believed to be the primary mechanism for enhanced fluorescence.
12
 In theory, the 
fluorescence will be enhanced when the scattering of the nanoparticle dominates the 
plasmon resonance. It is known that the relative contributions of absorption and 
scattering are determined by the material and the size of the nanoparticles.
29
 Among the 
numerous MEF studies, silver is preferred in the applications of MEF due to its greater 
scattering compared with gold. Yguerabide and Yguerabide observed that the scattering 
cross section of a 30 nm silver nanoparticle is 10 times larger than that of a gold 
nanoparticle of the same size.
21
 The size dependent scattering has been demonstrated in 
Figure 2.7 where the scattering cross section increases and dominates the extinction as 
the size of the silver nanoparticle increases from 22 nm to 100 nm. To obtain the 
enhanced fluorescence, the predicted diameters for silver and gold nanospheres are over 
40 and 80 nm, respectively.
29
 Moreover, non-spherical or aggregated particles have 
been observed to enhance fluorescence which is primarily associated with large 
scattering components dominating over absorption.
63, 64
  
In addition to the substantial scattering from the nanoparticle, the fluorescence of a 
nearby fluorophore is very sensitive to the spectral overlap between the scattering 
spectrum and the excitation and/or emission spectra of the fluorophore.
65, 66
 Both theory 
and experiment have shown that the fluorescence enhancement can be optimized by 
appropriately matching the spectra of the nanoparticle and the fluorophore.
65-69
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Furthermore, the distance between the fluorophores and the metal nanoparticles plays a 
key role in the fluorescence enhancement.
70-73
 Varying from system to system, MEF 
occurs when a fluorophore is placed within a distance of 3-50 nm from the surface of a 
metal nanoparticle,
74
 and the maximum enhancement is typically achieved at a distance 
between 3-10 nm.
70, 72
 When a fluorophore is directly coupled with a metal 
nanoparticle, its excited state can experience non-radiative decay through energy 
transfer from the fluorophore to the nanoparticle, leading to quenching.
60
 When the 
fluorophore is separated from the nanoparticle by an appropriate distance between 3-10 
nm, the non-radiative decay diminishes and the enhancement effect begins to dominate 
due to the increased excitation and emission rates. When the fluorophore-nanoparticle 
distance is larger than 10 nm, the enhancement effect reduces and eventually reaches 
unity.
75
     
2.7 LSPR biosensing – current state-of-the-art 
Nobel metal nanoparticles, especially gold and silver nanoparticles, have been 
extensively developed for biosensing such as the detection of molecular binding events 
on the basis of LSPR. In this section LSPR biosensing mainly for immunoassays in the 
biomedical area is discussed, based on different mechanisms including (i) refractive 
index sensitivity, (ii) colloidal aggregation, (iii) nanoparticle-enhanced SPR and (iv) 
MEF.  
2.7.1 LSPR biosensing based on refractive index sensitivity  
As discussed previously, the LSPR spectrum of noble metal nanoparticles is highly 
sensitive to changes in the dielectric environment. One approach to LSPR biosensing is 
the measurement of the LSPR spectral shift in response to the adsorption of analyte that 
results from a change in the local refractive index of the dielectric environment. The 
overall LSPR spectral shift is correlated with the analyte concentration, allowing for 
quantitative determination. To date, various LSPR biosensing systems have been 
designed using nanoparticles on solid phase surfaces and in liquid phase. Early work 
involved the use of gold and silver nanospheres immobilized on substrates. A biotin-
streptavidin assay was used to investigate the refractive index sensitivities of 
immobilized gold nanospheres with a range of diameters.
76
 The nanoparticles with 
optimal size exhibited a limit of detection (LOD) of 0.83 nM streptavidin. In assays 
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evaluating the antibody-antigen binding events with bovine or human serum albumin, 
an LOD of 10 nM was obtained using gold nanospheres.
77
 Along with the development 
of synthetic methods for diverse nanoparticles, non-spherical nanoparticles have 
attracted substantial attention due to their highly enhanced local electronic fields near 
the sharp curvatures of the surfaces. Haes and Van Duyne first reported a highly 
sensitive LSPR biosensor using surface-confined triangular Ag nanoparticles supported 
on a glass substrate.
9
 By functionalizing the triangular Ag nanoparticles with a specific 
antibody, they used this LSPR biosensing system to detect amyloid-β derived diffusible 
ligands (ADDLs), a biomarker for Alzheimer’s disease, with an LOD of 100 fM.9 The 
LSPR response of an individual gold nanorod sensor to exposure to prostate specific 
antigen (PSA) was measured by Truong et al. using a dark field microscope and a 
spectrograph.
78
 The LOD of such individual sensors was estimated to be as low as ~ 1 
aM, corresponding to an LSPR peak shift of ~ 4.2 nm.
78
 Yu and Irudayaraj 
demonstrated a solution-phase multiplex assay based on gold nanorods for the detection 
of three analytes including goat anti-human IgG1 Fab, rabbit anti-mouse IgG1 Fab and 
rabbit anti-sheep IgG (H+L).
79
 By combining three types of nanorods with distinct 
aspect ratios, different longitudinal LSPR peaks allowed for the simultaneous 
monitoring of three different analytes.
79
 The group further extended this sensing system 
to the simultaneous detection of bacterial pathogens, Escherichia coli and Salmonella 
typhimurium, using a dispersion of gold nanorods with two distinct aspect ratios.
80
  
2.7.2 LSPR biosensing based on colloidal aggregation  
The LSPR phenomenon results in enhanced electronic fields being confined within a 
region of only a few nanometers near the surface of the nanoparticles and which decay 
exponentially away from the surface.
81
 When multiple nanoparticles are placed in close 
vicinity of each other, the electronic fields of individual particles interact (i.e. near-field 
coupling) resulting in a redshift and a broadening of the LSPR wavelength.
82, 83
 In 1980, 
Leuvering et al. first reported a new immunoassay approach based on the aggregation of 
antibody-conjugated gold nanoparticles in the presence of analyte, which was associated 
with a color change of the solution.
84
 They further optimized the assay system for the 
detection of human chorionic gonadotrophin (hCG), a hormone produced during 
pregnancy.
85
 A rapid homogeneous immunoassay for human ferritin was demonstrated 
by Englebienne et al. using gold colloids and the LOD was determined to be 4.5 µg/L.
86
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Thanh and Rosenzweig developed an aggregation-based immunoassay for anti-protein 
A using gold nanoparticles coated with protein A.
87
 By adjusting the concentration of 
gold nanoparticles, pH and temperature, the aggregation immunoassay was optimized 
with an LOD of 1 µg/mL.
87
 Currently, most of the aggregation-based immunoassays are 
developed using spherical gold nanoparticles, non-spherical nanoparticles however can 
also be employed in this approach.
88, 89
 Hirsch et al. reported a rapid immunoassay 
based on the aggregation of antibody-conjugated gold nanoshells.
88
 Successful detection 
of rabbit IgG was achieved in saline, serum and diluted whole blood with LODs on the 
order of 100 pg/mL within 10-30 min.
88
 In contrast to the traditional spectroscopy 
measurement, dynamic light scattering (DLS) was used to analyze the aggregates of two 
types of gold nanoparticles for the detection of PSA.
89
 In this approach, gold 
nanospheres and nanorods were conjugated with two different antibodies capable of 
binding to PSA. Following the addition of analyte, the relative ratio of aggregates to 
individual particles was quantified by DLS measurement, which was correlated with the 
concentration of the analyte.
89
  
2.7.3 LSPR biosensing based on nanoparticle-enhanced SPR 
Since the mid-1980s, the SPR sensing technique has been developed and well-
established for detection and measurement of molecular interactions in real time. 
However, the conventional SPR sensing system has limited sensitivity to small 
molecules with low molecular weight such as hormones. To amplify the SPR signal and 
improve the sensitivity, noble metal nanoparticles have been incorporated with success 
in SPR sensors.
90-94
 The utilization of nanoparticles leads to enhanced SPR sensitivity 
through three main mechanisms: (i) an increase of the mass in every binding event, (ii) 
an increase in the refractive index of the analyte and (iii) coupling between the LSPR of 
nanoparticles and the SPR of the metal surface.
95
 Several groups have reported 
enhanced SPR signals due to gold nanospheres used in a sandwich assay format where 
the secondary antibody was conjugated with the nanoparticles.
90, 93, 94
 By using 
antibody-nanoparticle conjugates in a sandwich assay for detection of human matrix 
metalloproteinase (MMP)-2, an enhancement factor of 114 and an LOD of 0.5 pM was 
observed.
93
 In another sandwich assay for progesterone detection the antibody-
conjugated gold nanospheres resulted in an enhancement factor of 13 and an LOD of 
8.6 pg/mL.
94
 In addition to the spherical nanoparticles, various shapes of nanoparticles 
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have been studied for the enhancement of SPR.
95-97
 Law et al. reported a 23-fold 
enhancement in the sensitivity of SPR detection for rabbit IgG using antibody-
conjugated gold nanorods, with an LOD of ~ 40 pg/mL.
95
 In a recent study, three 
different shapes of gold nanoparticles including cubic cages, rods and quasi-spheres 
have been compared in terms of sensitivity enhancement of SPR detection for 
thrombin.
97
 The greatest enhancement was observed for quasi-spherical nanoparticles 
which resulted in the detection of thrombin concentrations as low as ~ 1 aM.  
2.7.4 LSPR biosensing based on MEF  
Fluorescence spectroscopy is one of the predominant tools used for biomedical 
research. Significant advances are being made in fluorescence techniques, which 
improve the sensitivity and LOD of biosensing systems. Over the last decade, noble 
metal nanoparticles have been incorporated into fluorescence-based assays, resulting in 
immunoassays with amplified fluorescence signals and increased sensitivities.
98-101
 The 
increased fluorescence intensity and improved performance of these assays is attributed 
to the phenomenon of MEF. MEF can arise from both enhanced excitation and emission 
processes. Nanoscale metals can interact with fluorophores through the presence of their 
local electromagnetic fields and through coupling of their plasmonic scattering modes to 
increase their fluorescence intensity.
29, 102, 103
 Herein, Table 2.1 summarizes the findings 
of selected reports from the recent literature in relation to the fluorescence-based assays 
enhanced by metal nanoparticles.  
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Table 2.1 Characteristics of MEF assays in the literature. 
Nanostructure 
Fluorophore & 
analyte 
Enhancement 
factor 
LOD Reference 
Silver nanosphere 
film (35 nm) 
6-(N-(7-nitrobenz-2-
oxa-1,3-diazol-4yl) 
amino) hexanoate 
(NBD), goat IgG 
20 N/A 
Sokolov et 
al. (1998)
104
 
Silver nanosphere 
film 
Fluorescein, rabbit IgG N/A 500 pM 
Lobmaier et 
al. (2001) 
105
 
Silver nanosphere 
film 
Fluorescein, insulin 4 250 nM 
Lochner et 
al. (2003)
106
 
Silver 
nanospheres in 
solution 
Cy3, streptavidin 3-5 N/A 
Aslan et al. 
(2004)
107
 
Silver island 
films (SIF) 
Rhodamine 
Red-X and Alexa 
Fluor-647, myoglobin 
10-15 for 100 
ng/mL myoglobin 
50 ng/mL 
Matveeva et 
al. (2005)
98
 
Gold nanosphere 
film (5 nm) 
Cy5, human B-type 
natriuretic peptide 
(BNP) and cardiac 
troponin I (cTnI) 
2.5 for BNP and 4 
for cTnI 
N/A 
Hong and 
Kang 
(2006)
108
 
SIF on gold/silver 
film 
Rhodamine-RedX, 
myoglobin 
50 for 1000 ng/mL 
myoglobin 
N/A 
Barnett et al. 
(2007)
100
 
Gold nanospheres 
(20 nm) 
Cy 5, mouse IgG N/A 1 pg/mL 
Hsieh et al. 
(2007)
109
 
SIF on gold film 
AlexaFluor 647, 
myoglobin 
50 for 100 ng/mL 
myoglobin 
N/A 
Matveeva et 
al. (2007)
110
 
Cap-shaped silver 
nanoparticles 
R-phycoerythrin, IL-6 50 N/A 
Yamaguchi 
et al. 
(2007)
111
 
Silver nanosphere 
film 
Cy 5, human IgG 11 - 37 
0.086 
ng/mL 
Nooney et al. 
(2010)
99
 
SIF DY 488, human TNF-α 10.4 50 pg/mL 
Szmacinski 
et al. 
(2010)
101
 
Silver-coated 
silica beads on 
substrate 
AlexaFluor 430, rabbit 
IgG 
8.5 N/A 
Deng et al. 
(2010)
112
 
SIF 
FITC, anthrax 
protective antigen 
20 – 30 0.1 pg/mL 
Dragan et al. 
(2010)
113
 
Silver 
nanospheres 
Cy 5, human IgG N/A 1 ng/mL 
Wei et al. 
(2012)
114
 
Silver bilayer 
nanosphere film 
FITC, human IgG 3.3 1 ng/mL 
Zhang et al. 
(2012)
115
 
Gold nanospheres 
Atto 633, UL-16 
binding protein 2 
N/A 
16-18 
pg/mL 
Chang et al. 
(2013)
116
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2.8 Conclusions   
In conclusion, this chapter has attempted to describe the principal elements of the work 
described in this thesis. A description of immunoassays has been given, distinguishing 
between homogeneous and heterogeneous assays, label-free and labeled assays, and 
direct and sandwich assays. The interaction of electromagnetic radiation with noble 
metal nanoparticles and the role of the surface plasmon has been described and the 
theory and has been outlined. As background to the work carried out in this thesis, four 
different approaches to LSPR biosensing have been described and key recent 
publications in these areas have been highlighted. Of the four approaches discussed, the 
first two, namely refractive index sensitivity-based and aggregation-based assays, were 
primarily carried out in solution-phase as reported in Chapters 4 and 5. Chapter 5 also 
includes a section on solid-phase SPR biosensing while Chapter 6 describes MEF-based 
immunoassays carried out on a solid-phase platform. 
 
  
  Chapter 2: Theory and background 
 
 34 
References  
1. A. D. MacNaught and A. R. Wilkinson, IUPAC Compendium of Chemical 
Terminology Gold Book. (Blackwell Science, 1997). 
2. N. S. Lipman, L. R. Jackson, L. J. Trudel and F. Weis-Garcia, ILAR journal 46 
(3), 258-267 (2005). 
3. R. Reverberi and L. Reverberi, Blood Transfusion 5 (4), 227-240 (2007). 
4. http://www.austincc.edu/apreview/EmphasisItems/Inflammatoryresponse.html. 
5. D. Wild, The immunoassay handbook. 15-50 (Elsevier Science & Technology 
Books, 2005). 
6. G. Wu, Assay Development: Fundamentals and Practices. (Wiley, 2010). 
7. N. Bojorge Ramírez, A. M. Salgado and B. Valdman, Brazilian Journal of 
Chemical Engineering 26, 227-249 (2009). 
8. W. M. Mullett, E. P. C. Lai and J. M. Yeung, Methods 22 (1), 77-91 (2000). 
9. A. J. Haes, L. Chang, W. L. Klein and R. P. Van Duyne, Journal of the 
American Chemical Society 127 (7), 2264-2271 (2005). 
10. K. M. Mayer, S. Lee, H. Liao, B. C. Rostro, A. Fuentes, P. T. Scully, C. L. Nehl 
and J. H. Hafner, ACS Nano 2 (4), 687-692 (2008). 
11. J. Cao, E. K. Galbraith, T. Sun and K. T. V. Grattan, Sensors and Actuators B: 
Chemical 169 (0), 360-367 (2012). 
12. J. R. Lakowicz, Principles of fluorescence spectroscopy. (Springer, 2006). 
13. S. J. Strickler and R. A. Berg, The Journal of Chemical Physics 37 (4), 814-822 
(1962). 
14. J. M. Brockman, B. P. Nelson and R. M. Corn, Annual Review of Physical 
Chemistry 51 (1), 41-63 (2000). 
15. R. P. Van Duyne, Science 306 (5698), 985-986 (2004). 
16. K. A. Willets and R. P. Van Duyne, Annual Review of Physical Chemistry 58 
(1), 267-297 (2007). 
17. S. Eustis and M. A. El-Sayed, ChemInform 37 (25) (2006). 
18. G. Mie, Annalen der Physik 330 (3), 377-445 (1908). 
19. Uwe Kreibig and M. Vollmer, Optical properties of metal clusters (Springer, 
Berlin, 1995). 
20. S. Link, Z. L. Wang and M. A. El-Sayed, The Journal of Physical Chemistry B 
103 (18), 3529-3533 (1999). 
  Chapter 2: Theory and background 
 
 35 
21. J. Yguerabide and E. E. Yguerabide, Analytical Biochemistry 262 (2), 137-156 
(1998). 
22. C. F. Bohren and D. R. Huffman, Absorption and scattering of light by small 
particles. (Wiley, 1983). 
23. U. Kreibig and M. Vollmer, Optical Properties of Metal Clusters. (Springer, 
1995). 
24. C. Noguez, The Journal of Physical Chemistry C 111 (10), 3806-3819 (2007). 
25. A. S. Kumbhar, M. K. Kinnan and G. Chumanov, Journal of the American 
Chemical Society 127 (36), 12444-12445 (2005). 
26. K. L. Shuford, M. A. Ratner and G. C. Schatz, The Journal of Chemical Physics 
123 (11), 114713 (2005). 
27. N. Felidj, J. Grand, G. Laurent, J. Aubard, G. Levi, A. Hohenau, N. Galler, F. R. 
Aussenegg and J. R. Krenn, The Journal of Chemical Physics 128 (9), 094702-
094705 (2008). 
28. M. Meier and A. Wokaun, Opt. Lett. 8 (11), 581-583 (1983). 
29. J. R. Lakowicz, Analytical Biochemistry 337 (2), 171-194 (2005). 
30. R. Gans, Annalen der Physik 342 (5), 881-900 (1912). 
31. W.-H. Yang, G. C. Schatz and R. P. Van Duyne, Journal of Chemical Physics 
103 (3), 869 (1995). 
32. K. L. Kelly, A. A. Lazarides and G. C. Schatz, Computing in Science & 
Engineering 3 (4), 67-73 (2001). 
33. N. Riefler and T. Wriedt, Progress In Electromagnetics Research Symposium 2 
(5), 450-454 (2006). 
34. E. Moreno, D. Erni, C. Hafner and R. Vahldieck, J. Opt. Soc. Am. A 19 (1), 
101-111 (2002). 
35. R. X. Bian, R. C. Dunn, X. S. Xie and P. T. Leung, Physical Review Letters 75 
(26), 4772 (1995). 
36. K. L. Kelly, E. Coronado, L. L. Zhao and G. C. Schatz, The Journal of Physical 
Chemistry B 107 (3), 668-677 (2003). 
37. B. J. Wiley, S. H. Im, Z.-Y. Li, J. McLellan, A. Siekkinen and Y. Xia, The 
Journal of Physical Chemistry B 110 (32), 15666-15675 (2006). 
38. J. Kottmann, ouml, P. rg, O. J. F. Martin, D. R. Smith and S. Schultz, Physical 
Review B 64 (23), 235402 (2001). 
  Chapter 2: Theory and background 
 
 36 
39. J. P. Kottmann, O. J. F. Martin, D. R. Smith and S. Schultz, Physical Review B 
64 (23), 235402 (2001). 
40. J. Aizpurua, G. W. Bryant, L. J. Richter, F. J. García de Abajo, B. K. Kelley and 
T. Mallouk, Physical Review B 71 (23), 235420 (2005). 
41. A. J. Haes, C. L. Haynes, A. D. McFarland, G. C. Schatz, R. P. Van Duyne and 
S. Zou, MRS Bulletin 30 (05), 368-375 (2005). 
42. E. Hao and G. C. Schatz, Electromagnetic fields around silver nanoparticles 
and dimers. (AIP, 2004). 
43. F. Guedje, K. , M. Giloan, M. Potara, M. N. Hounkonnou and S. Astilean, 
Physica Scripta 86 (5), 055702 (2012). 
44. R. Jin, Y. Cao, C. A. Mirkin, K. L. Kelly, G. C. Schatz and J. G. Zheng, Science 
294 (5548), 1901-1903 (2001). 
45. F. Tam, C. Moran and N. Halas, The Journal of Physical Chemistry B 108 (45), 
17290-17294 (2004). 
46. T. R. Jensen, M. L. Duval, K. L. Kelly, A. A. Lazarides, G. C. Schatz and R. P. 
Van Duyne, The Journal of Physical Chemistry B 103 (45), 9846-9853 (1999). 
47. A. D. McFarland and R. P. Van Duyne, Nano Letters 3 (8), 1057-1062 (2003). 
48. A. J. Haes, S. Zou, G. C. Schatz and R. P. Van Duyne, The Journal of Physical 
Chemistry B 108 (22), 6961-6968 (2004). 
49. M. D. Malinsky, K. L. Kelly, G. C. Schatz and R. P. Van Duyne, Journal of the 
American Chemical Society 123 (7), 1471-1482 (2001). 
50. M. M. Miller and A. A. Lazarides, The Journal of Physical Chemistry B 109 
(46), 21556-21565 (2005). 
51. H. Chen, X. Kou, Z. Yang, W. Ni and J. Wang, Langmuir 24 (10), 5233-5237 
(2008). 
52. P. Kvasnicka and J. Homola, Optical sensors based on spectroscopy of localized 
surface plasmons on metallic nanoparticles: Sensitivity considerations. (AVS, 
2008). 
53. C. Xue, Z. Li and Chad A. Mirkin, Small 1 (5), 513-516 (2005). 
54. D. E. Charles, D. Aherne, M. Gara, D. M. Ledwith, Y. K. Gun’ko, J. M. Kelly, 
W. J. Blau and M. E. Brennan-Fournet, ACS Nano 4 (1), 55-64 (2009). 
55. K.-S. Lee and M. A. El-Sayed, The Journal of Physical Chemistry B 110 (39), 
19220-19225 (2006). 
  Chapter 2: Theory and background 
 
 37 
56. P. K. Jain and M. A. El-Sayed, The Journal of Physical Chemistry C 111 (47), 
17451-17454 (2007). 
57. Y. Zhang, A. Dragan and C. D. Geddes, The Journal of Physical Chemistry C 
113 (28), 12095-12100 (2009). 
58. K. Ray, M. H. Chowdhury, J. Zhang, Y. Fu, H. Szmacinski, K. Nowaczyk and J. 
R. Lakowicz, in Optical Sensor Systems in Biotechnology, edited by G. Rao 
(Springer Berlin Heidelberg, 2010), Vol. 116, pp. 1-28. 
59. J. R. Lakowicz, K. Ray, M. Chowdhury, H. Szmacinski, Y. Fu, J. Zhang and K. 
Nowaczyk, Analyst 133 (10), 1308-1346 (2008). 
60. T. Ming, H. Chen, R. Jiang, Q. Li and J. Wang, The Journal of Physical 
Chemistry Letters 3 (2), 191-202 (2011). 
61. M. H. Chowdhury, S. K. Gray, J. Pond, C. D. Geddes, K. Aslan and J. R. 
Lakowicz, J. Opt. Soc. Am. B 24 (9), 2259-2267 (2007). 
62. T. Härtling, P. Reichenbach and L. M. Eng, Opt. Express 15 (20), 12806-12817 
(2007). 
63. K. Aslan, J. R. Lakowicz and C. D. Geddes, The Journal of Physical Chemistry 
B 109 (13), 6247-6251 (2005). 
64. H. Su, Y. Zhong, T. Ming, J. Wang and K. S. Wong, The Journal of Physical 
Chemistry C 116 (16), 9259-9264 (2012). 
65. Y. Chen, K. Munechika and D. S. Ginger, Nano Letters 7 (3), 690-696 (2007). 
66. S. Vukovic, S. Corni and B. Mennucci, The Journal of Physical Chemistry C 
113 (1), 121-133 (2009). 
67. M. Thomas, J. J. Greffet, R. Carminati and J. R. Arias-Gonzalez, Applied 
Physics Letters 85 (17), 3863-3865 (2004). 
68. P. Bharadwaj and L. Novotny, Opt. Express 15 (21), 14266-14274 (2007). 
69. F. Tam, G. P. Goodrich, B. R. Johnson and N. J. Halas, Nano Letters 7 (2), 496-
501 (2007). 
70. J. Malicka, I. Gryczynski, Z. Gryczynski and J. R. Lakowicz, Analytical 
Biochemistry 315 (1), 57-66 (2003). 
71. K. Ray, R. Badugu and J. R. Lakowicz, Chemistry of Materials 19 (24), 5902-
5909 (2007). 
72. R. I. Nooney, O. Stranik, C. McDonagh and B. D. MacCraith, Langmuir 24 
(19), 11261-11267 (2008). 
  Chapter 2: Theory and background 
 
 38 
73. K. Kang, J. Wang, J. Jasinski and S. Achilefu, Journal of Nanobiotechnology 9 
(1), 16 (2011). 
74. H. Szmacinski, D. S. Smith, M. A. Hanson, Y. Kostov, J. R. Lakowicz and G. 
Rao, Biotechnology and Bioengineering 100 (3), 448-457 (2008). 
75. W. Deng and E. M. Goldys, Langmuir 28 (27), 10152-10163 (2012). 
76. N. Nath and A. Chilkoti, Analytical Chemistry 76 (18), 5370-5378 (2004). 
77. K. Fujiwara, H. Watarai, H. Itoh, E. Nakahama and N. Ogawa, Anal Bioanal 
Chem 386 (3), 639-644 (2006). 
78. P. L. Truong, B. W. Kim and S. J. Sim, Lab on a Chip 12 (6), 1102-1109 (2012). 
79. C. Yu and J. Irudayaraj, Analytical Chemistry 79 (2), 572-579 (2007). 
80. C. Wang and J. Irudayaraj, Small 4 (12), 2204-2208 (2008). 
81. T. Jensen, L. Kelly, A. Lazarides and G. C. Schatz, Journal of Cluster Science 
10 (2), 295-317 (1999). 
82. K. H. Su, Q. H. Wei, X. Zhang, J. J. Mock, D. R. Smith and S. Schultz, Nano 
Letters 3 (8), 1087-1090 (2003). 
83. L. Gunnarsson, T. Rindzevicius, J. Prikulis, B. Kasemo, M. Käll, S. Zou and G. 
C. Schatz, The Journal of Physical Chemistry B 109 (3), 1079-1087 (2005). 
84. J. H. W. Leuvering, P. J. H. M. Thal, M. van der Waart and A. H. W. M. 
Schuurs, Journal of Immunoassay 1 (1), 77 - 91 (1980). 
85. J. H. W. Leuvering, P. J. H. M. Thal and A. H. W. M. Schuurs, Journal of 
Immunological Methods 62 (2), 175-184 (1983). 
86. P. Englebienne, A. Van Hoonacker and J. Valsamis, Clinical Chemistry 46 (12), 
2000-2003 (2000). 
87. N. T. K. Thanh and Z. Rosenzweig, Analytical Chemistry 74 (7), 1624-1628 
(2002). 
88. L. R. Hirsch, J. B. Jackson, A. Lee, N. J. Halas and J. L. West, Analytical 
Chemistry 75 (10), 2377-2381 (2003). 
89. X. Liu, Q. Dai, L. Austin, J. Coutts, G. Knowles, J. Zou, H. Chen and Q. Huo, 
Journal of the American Chemical Society 130 (9), 2780-2782 (2008). 
90. L. A. Lyon, M. D. Musick and M. J. Natan, Analytical Chemistry 70 (24), 5177-
5183 (1998). 
91. B. H. Schneider, E. L. Dickinson, M. D. Vach, J. V. Hoijer and L. V. Howard, 
Biosensors and Bioelectronics 15 (1–2), 13-22 (2000). 
  Chapter 2: Theory and background 
 
 39 
92. B. H. Schneider, E. L. Dickinson, M. D. Vach, J. V. Hoijer and L. V. Howard, 
Biosensors and Bioelectronics 15 (11–12), 597-604 (2000). 
93. U. Pieper-Fürst, U. Kleuser, W. F. M. Stöcklein, A. Warsinke and F. W. 
Scheller, Analytical Biochemistry 332 (1), 160-167 (2004). 
94. J. S. Mitchell, Y. Wu, C. J. Cook and L. Main, Analytical Biochemistry 343 (1), 
125-135 (2005). 
95. W.-C. Law, K.-T. Yong, A. Baev, R. Hu and P. N. Prasad, Opt. Express 17 (21), 
19041-19046 (2009). 
96. H. R. Sim, A. W. Wark and H. J. Lee, Analyst 135 (10), 2528-2532 (2010). 
97. M. J. Kwon, J. Lee, A. W. Wark and H. J. Lee, Analytical Chemistry 84 (3), 
1702-1707 (2012). 
98. E. G. Matveeva, Z. Gryczynski and J. R. Lakowicz, Journal of Immunological 
Methods 302 (1–2), 26-35 (2005). 
99. R. Nooney, A. Clifford, X. LeGuevel, O. Stranik, C. McDonagh and B. 
MacCraith, Anal Bioanal Chem 396 (3), 1127-1134 (2010). 
100. A. Barnett, E. G. Matveeva, I. Gryczynski, Z. Gryczynski and E. M. Goldys, 
Physica B: Condensed Matter 394 (2), 297-300 (2007). 
101. H. Szmacinski, Z. Murtaza and J. R. Lakowicz, The Journal of Physical 
Chemistry C 114 (16), 7236-7241 (2010). 
102. J. R. Lakowicz, Analytical Biochemistry 298 (1), 1-24 (2001). 
103. Y. Zhang, K. Aslan, M. J. R. Previte and C. D. Geddes, Applied Physics Letters 
90 (5), 053107/053101-053107/053103 (2007). 
104. K. Sokolov, G. Chumanov and T. M. Cotton, Analytical Chemistry 70 (18), 
3898-3905 (1998). 
105. C. Lobmaier, G. Hawa, M. Götzinger, M. Wirth, F. Pittner and F. Gabor, Journal 
of Molecular Recognition 14 (4), 215-222 (2001). 
106. N. Lochner, C. Lobmaier, M. Wirth, A. Leitner, F. Pittner and F. Gabor, 
European Journal of Pharmaceutics and Biopharmaceutics 56 (3), 469-477 
(2003). 
107. K. Aslan, J. Lakowicz, H. Szmacinski and C. Geddes, J Fluoresc 14 (6), 677-
679 (2004). 
108. B. Hong and K. A. Kang, Biosensors and Bioelectronics 21 (7), 1333-1338 
(2006). 
  Chapter 2: Theory and background 
 
 40 
109. B.-Y. Hsieh, Y.-F. Chang, M.-Y. Ng, W.-C. Liu, C.-H. Lin, H.-T. Wu and C. 
Chou, Analytical Chemistry 79 (9), 3487-3493 (2007). 
110. E. G. Matveeva, I. Gryczynski, A. Barnett, Z. Leonenko, J. R. Lakowicz and Z. 
Gryczynski, Analytical Biochemistry 363 (2), 239-245 (2007). 
111. T. Yamaguchi, T. Kaya and H. Takei, Analytical Biochemistry 364 (2), 171-179 
(2007). 
112. W. Deng, K. Drozdowicz-Tomsia, D. Jin and E. M. Goldys, presented at the 
Nanoscience and Nanotechnology (ICONN), 2010 International Conference on, 
2010 (unpublished). 
113. A. I. Dragan, M. T. Albrecht, R. Pavlovic, A. M. Keane-Myers and C. D. 
Geddes, Analytical Biochemistry 425 (1), 54-61 (2012). 
114. X. Wei, H. Li, Z. Li, M. Vuki, Y. Fan, W. Zhong and D. Xu, Anal Bioanal 
Chem 402 (3), 1057-1063 (2012). 
115. R. Zhang, Z. Wang, C. Song, J. Yang, A. Sadaf and Y. Cui, J Fluoresc 23 (1), 
71-77 (2012). 
116. Y.-F. Chang, J.-S. Yu, Y.-T. Chang, L.-C. Su, C.-C. Wu, Y.-S. Chang, C.-S. Lai 
and C. Chou, Biosensors and Bioelectronics 41 (0), 232-237 (2013). 
 
 
  Chapter 3: Instrumentation 
 
 41 
Chapter 3 
Instrumentation 
 
3.1 Introduction 
This chapter presents the theory behind the instrumentation and characterization 
techniques used for data collection within this thesis. The characterization techniques 
include ultraviolet-visible (UV-vis) spectroscopy, transmission electron microscopy 
(TEM), dynamic light scattering (DLS), surface plasmon resonance (SPR) 
spectroscopy, atomic force microscopy (AFM) and fluorescence spectroscopy. The 
background of each technique is given in the following sections.  
3.2 Ultraviolet-visible spectroscopy  
UV-vis spectroscopy is a broadly used tool for the characterization of noble metal 
nanoparticles as the optical properties of nanoparticles are sensitive to the size, shape 
and the concentration of the nanoparticles as well as the dielectric environment 
surrounding them. Noble metal nanoparticles will not only absorb light but also scatter 
it therefore meaning that the detected signal from the sample is representative of their 
extinction spectra, i.e. the sum of their absorption and scattering.  
UV-vis spectroscopy is based on absorbance. In spectroscopy, the absorbance   is 
defined as,
1
 
        
  
 
 (3.1) 
where    is the intensity of the incident light at a given wavelength,   is the intensity of 
the light after it passes through a sample (transmitted light intensity). To quantitatively 
determine the concentration of a sample, Beer-Lambert law is commonly used,
1
  
      
  
 
     (3.2) 
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where   is the molar extinction coefficient, c is the concentration of the absorbing 
sample and   is the path length through the sample. The schematic illustration of Beer-
Lambert law is given in Figure 3.1. According to equations 3.1 and 3.2, the Beer-
Lambert law implies a linear relationship between the absorbance and the concentration 
of an absorbing sample under constant conditions of the path length and the incident 
wavelength of the light. In this thesis the spectrophotometers used for characterization 
of UV-vis spectra include Ocean Optics USB4000, Varian Cary 50 and Tecan Infinite 
200.  
 
 
Figure 3.1 Schematic diagram illustrating Beer-Lambert law. 
3.3 Transmission electron microscopy 
TEM is a microscopy technique that images thin samples at a high resolution using a 
beam of electrons. It provides an approach to characterizing the morphology, 
dimensions and distribution of the nanoparticles. A simplified TEM setup is shown in 
Figure 3.2, depicting the major constituents in the vacuum system.
2
 The emission 
source which is otherwise known as the electron gun emits the electrons that travel 
down a column and are focused by the condenser lens into a very thin beam. The beam 
of electrons illuminates the specimen on the specimen holder. Depending on the density 
of the material present, some of the electrons are scattered and disappear from the 
beam. The transmitted electrons are focused into an image by the objective lens, 
followed by traveling through the projective lens to magnify the image. The image is 
detected by a phosphor screen or a charge coupled device (CCD).
2
 Contrast observed in 
the image is mostly attributed to differences in density. In this thesis the TEM used for 
characterizing the nanoparticles is an FEI Tecnai G
2
 20. All TEM experiments were 
carried out in University College Dublin (UCD).  
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Figure. 3.2 Schematic diagram of a simplified TEM system. Adapted from reference.
2
 
3.4 Dynamic light scattering 
DLS, also referred to as Photon Correlation Spectroscopy (PCS), is a technique that 
measures the size of particles suspended in liquids. Particles in suspensions undergo 
Brownian motion due to random collisions with the solvent molecules surrounding 
them. As a result of Brownian motion, particles diffuse through the solvent. The DLS 
system measures Brownian motion and relates it to the size of the particles by 
illuminating the particles with a laser beam and analyzing the time-dependent 
fluctuations in the intensity of scattered light from particles. The translational diffusion 
coefficient is determined by the analysis of intensity fluctuation using the 
autocorrelation function. The size of a particle is then calculated from the translational 
diffusion coefficient according to the Stokes-Einstein equation,
3
 
    
  
    
 (3.3) 
where    is the hydrodynamic diameter of the particle,   is the Boltzmann’s constant,   
is the absolute temperature,   is the viscosity of the solvent and   is the translational 
diffusion coefficient. The hydrodynamic diameter is the diameter of a sphere with the 
same diffusion coefficient as that of the measured particle in the suspension. It is 
apparent that small particles move quickly while larger particles move more slowly. In 
this thesis all DLS measurements were carried out with a Delsa Nano C. 
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3.5 Surface plasmon resonance spectroscopy 
SPR spectroscopy is widely used for detection of molecular interactions in real time by 
measuring a change in the SPR of a planar metal (typically gold and silver) surface as a 
result of a change in the refractive index near the surface. Figure 3.3 illustrates a typical 
SPR-based detection of molecular binding events. Under specific conditions (i.e. angle 
of incidence and wavelength), the incident p-polarized light excites plasmons in the 
gold film. As a result, a characteristic absorption of energy occurs and SPR is detected 
as a reduction in the intensity of the reflected light. The angle of incidence for SPR is 
highly sensitive to changes in the refractive index at the metal-dielectric interface.
4
 
Therefore, binding of an antigen (yellow circles) to the immobilized antibody (red ‘Y’ 
shapes) is detected as a shift in the angle of incidence required for SPR. Additionally, a 
plot of angle of incidence against time directly corresponds to magnitude and kinetics of 
antigen-antibody binding in real time. In this thesis, the SPR experiments were 
performed with a Biacore 3000.  
 
 
Figure 3.3 Schematic diagram illustrating SPR detection for antigen-antibody binding. 
Reproduced from Biacore.
5
  
The Biacore 3000 system is composed of three main components, including the SPR 
detection system, the sensor surface and the microfluidic system. The SPR detection 
system is described above. The sensor chip provides the physical conditions to generate 
the SPR signal. Gold surfaces with or without modification are used for the sensor 
chips. The biomolecular interactions being studied occur on the surface of the sensor 
chip. The microfluidic system is responsible for the precise delivery of sample and 
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buffer in a controlled fashion. The sensor surface forms one wall of a flow cell which is 
an integral part of the microfluidic system. A continuous flow of liquid is maintained 
over the sensor surface throughout the analysis, switching between buffer and sample.  
3.6 Atomic force microscopy 
AFM is a type of scanning probe microscopy that resolves features at the nanometer 
scale for either conductive or non-conductive samples. As shown in Figure 3.4, a 
typical AFM system consists of a cantilever with a sharp tip at its free end and a laser 
beam deflection system. By bringing the tip into the vicinity of a sample surface, forces 
acting between the tip and the sample surface cause the cantilever to bend. A laser spot 
is reflected from the back of the cantilever onto a position-sensitive photodetector. 
When the tip scans across the surface, the cantilever bends to accommodate changes in 
topography, resulting in changes in the position of the laser spot. The forces generally 
measured include Van der Waals, electrostatic, magnetic, capillary, Casimir and 
solvation forces. They are not measured directly but calculated by measuring the 
deflection of the cantilever.  
 
Figure 3.4 Schematic diagram illustrating a typical AFM set-up. Reproduced from 
Agilent.
6
  
  Chapter 3: Instrumentation 
 
 46 
The primary modes of AFM operation include contact mode, non-contact mode and 
tapping mode. Contact mode is performed with the tip in gentle contact with the surface 
of a sample. In this mode, the tip either scans at a constant height above the surface or 
scans with a constant force by keeping a constant deflection. In contrast to contact 
mode, non-contact mode is performed with the tip oscillated near the surface of a 
sample. The distance between the tip and the surface is on the order of tens to hundreds 
of Angstroms. In this mode, the cantilever is oscillated near its resonance frequency 
with an amplitude less than 10 nm. The detection scheme is based on analyzing changes 
in the resonance frequency or oscillation amplitude of the cantilever. Tapping mode is 
an approach that maps topography by intermittently contacting the surface with an 
oscillating tip. In this mode, the cantilever is driven to oscillate up and down at or near 
its resonance frequency with an amplitude greater than 10 nm. When the tip comes 
close to the surface, the oscillation amplitude reduces due to the forces acting between 
the tip and the sample. A feedback system monitors the changes in the amplitude and 
ensures that the amplitude is maintained constant during a scan. A topography image is 
obtained by monitoring the force required to keep the oscillation amplitude constant. 
The choice of operation modes depends on the sample and its environment. Tapping 
mode is usually used for imaging nanoparticles that are loosely bound to the substrate 
as it eliminates the lateral force applied by the tip that may damage the sample, which is 
common in contact mode.
7
 Compared with non-contact mode, tapping mode provides 
higher resolution. In this thesis, the AFM experiments were carried out in tapping mode 
using a Veeco BioScope II.  
3.7 Fluorescence spectroscopy 
Fluorescence spectroscopy is a tool that analyzes fluorescence from a sample. The 
detailed description of the absorption and fluorescence process of a fluorophore has 
been given in section 2.3. The instrument for measuring fluorescence is known as a 
spectrofluorometer or fluorescence spectrometer. A schematic representation of a 
typical spectrofluorometer is illustrated in Figure 3.5. The light source such as xenon 
lamp emits light over a broad spectrum typically ranging from 200 to 900 nm. The light 
passes through a monochromator that selects the desired narrow band of wavelengths. 
The transmitted light strikes the sample, causing fluorescence emission by fluorophores 
within the sample. The fluorescence is dispersed by a second monochromator and 
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collected by a detector which is usually a photomultiplier tube (PMT). The signal is 
amplified and finally presented in graphical form and stored digitally. In this thesis, all 
fluorescence measurements were performed with a Tecan Infinite 200 plate reader.  
 
 
Figure 3.5 Block diagram of a typical spectrofluorometer. 
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Chapter 4 
Triangular nanoplates for direct assays in 
solution 
 
4.1 Introduction 
As outlined in Chapter 1, this thesis work is in two sections, the earlier part, which was 
carried out in NUI Galway and which uses the Kelly particles for solution-based assays, 
and work carried out in BDI on both solution and solid-phase assays using various types 
of metal nanoparticles. This chapter focuses on the Galway work on solution-phase 
assays using the Kelly particles. The work here involves the utilization of solution-
phase triangular silver nanoplates (TSNPs) and their derivatives, gold-coated TSNPs 
(AuTSNPs), as LSPR refractive index sensors for biomedical assays. The size of the 
TSNPs can be readily controlled resulting in plasmon bands throughout the visible 
spectrum and the near infrared by using a seed-mediated synthetic procedure in aqueous 
solution (Figure 4.1).
1
 A comprehensive study has been carried out by Charles et al., 
demonstrating that these TSNP sols exhibit high ensemble refractive index sensitivities 
and can potentially act as efficient optical sensors for biomedical assays.
2
 The AuTSNP 
sols are synthesized in a straightforward fashion through epitaxial deposition of a gold 
layer at the edges of TSNPs. This effectively protects the TSNPs against etching by 
chloride and other anions.
3
 These AuTSNP sols are also found to exhibit high refractive 
index sensitivities and thus are promising candidates for biomedical sensing.  
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Figure 4.1 (A) Photograph of TSNP sols with a range of colors indicating various sizes; 
(B) The corresponding extinction spectra of the TSNP sols in image (A); and (C) TEM 
image of flat-lying TSNP from a representative sample. Adapted from reference.
1
 
4.2 Overview of the assays 
The LSPR-based biomedical assays in this work include two preliminary models, the 
first for the detection of human C-reactive protein (CRP) and the second for human 
cardiac troponin I (cTnI). Both assays are designed as one-step, solution-phase 
platforms for simple, highly sensitive and high-throughput biomedical sensing.  
As stated previously, the LSPR of the nanoplates are sensitive to the changes of local 
refractive index. The LSPR peak shifts as the local refractive index is changed. The 
utilization of the solution-phase triangular nanoplates in this study is directly based on 
this concept. In general, the triangular nanoplates are functionalized with a suitable 
biological receptor and then used to detect the target analyte which specifically binds to 
that receptor on the surface of the nanoplate. Consequently, the receptor-nanoplate 
conjugates experience a redshift in the LSPR peak when the analyte-receptor binding 
occurs inducing an increase in the refractive index of the nanoplates’ surrounding 
medium (Figure 4.2). This redshift can be detected by standard UV-vis spectroscopy 
using a conventional spectrophotometer and be used to quantify the concentration of the 
analyte.  
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Figure 4.2 Schematic illustrating a receptor functionalized triangular nanoplate sensing 
the analyte binding to its surface which is characterized by the absorption color 
changing from blue to purple.  
In this study, two preliminary model assays have been developed based on the 
aforementioned theory using solution-phase triangular nanoplates with high refractive 
index sensitivities. In one assay model, phosphocholine-functionalized triangular 
nanoplates are used to detect human CRP. In the other assay model, monoclonal anti-
troponin I antibody-functionalized triangular nanoplates are used to detect human cTnI.  
4.2.1 CRP 
Over eight decades ago, CRP was initially discovered by Tillett and Francis in the 
serum of patients with acute pneumococcal pneumonia.
4
 It was originally found to 
possess reactivity with pneumococcal C polysaccharide and was consequently named 
C-reactive protein.
4, 5
 CRP belongs to a protein family known as pentraxins which have 
been stably conserved during evolution.
6
 Each CRP molecule consists of five identical 
subunits that are attached non-covalently forming a cyclic pentamer with a total 
molecular weight ranging from 110 to 144 kDa.
7, 8
 One important characteristic of CRP 
is its high affinity for the ligands containing phosphocholine in the presence of calcium. 
A single molecule of phosphocholine is bound to each subunit of CRP via the choline 
group, cooperating with the two CRP-bound calcium ions via the phosphate group.
9
 
CRP is synthesized and secreted by hepatocytes in the liver as an acute-phase reactant 
in response to inflammation, infection or tissue injury.
10, 11
 The circulating 
concentration of CRP may elevate rapidly and significantly by 1,000 fold or more 
within 24 – 48 hours in the presence of various acute phase stimuli.12-15 The half-life of 
CRP in plasma is between 18 and 20 hours.
16
 It is able to remarkably reduce to the 
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normal level with the subsidence of symptoms. Therefore, CRP tests have been 
employed in clinical laboratories to evaluate inflammatory diseases and the response to 
therapies.
17
 
As a marker of inflammation, increased values of CRP have been found in the patients 
with atherosclerosis
18
 and cardiovascular disease including myocardial infarction,
19
 
myocardial ischemia and unstable angina.
20, 21
 Further studies have elucidated a strong 
correlation between the raised levels of CRP and the potential development, the severity 
and the prognosis of coronary heart disease.
22-26
 Currently, high-sensitivity CRP (hs-
CRP) assays, which refer to as the test of CRP using high sensitive method, are being 
utilized as a predictor to evaluate cardiovascular and stroke risk. According to the 
American Heart Association, an hs-CRP level of < 1 mg/L, 1 mg/L to 3 mg/L or > 3 
mg/L corresponds to a low, average or high risk of developing cardiovascular disease, 
respectively.
27
 Information of some manufactured hs-CRP methods is listed in Table 4.1.  
Table 4.1 Characteristics of some commercial hs-CRP assays 
Reagent 
manufacturer 
Reagent description Methodology 
Assay range 
(mg/L) 
LOD 
(mg/L) 
Denka Seiken 
CRP-Latex (II) × 2 
High 
Sensitive Application 
IT
a
 0.05–160 0.02 
Diagnostic Products 
Corporation 
hsCRP IL
b
 0.2–100 0.1 
Mitsubishi Kagaku 
Iatron 
PATHFAST hsCRP IL
b
 0.05–30 0.002 
Kamiya K-Assay CRP (I) IT
a
 0.1–20 0.03 
Olympus CRP (Latex) Sensitive 
Application 
IT
a
 0.5–20 0.08 
Roche Tina-quant CRP 
(Latex) HS 
IT
a
 0.1−20 0.03 
Sekisui Nanopia CRP IT
a
 0.1–420 0.1 
Siemens Cardiophase hsCRP IT
a
 0.16−10 0.02 
Wako CRP-HS II LT IT
a
 1–350 0.1 
a
 IT, immunoturbidimetric; 
b
 IL, immunoluminometric 
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4.2.2 cTnI 
cTnI is a protein subunit of the cardiac troponin complex, which regulates the 
contraction of cardiac muscle by inhibiting the ATPase activity of actomyosin.
28
 Human 
cTnI, with a molecular weight of around 24 kDa, consists of 210 amino acid residues.
29, 
30
 Cardiac TnI is reported to express exclusively in heart muscle, and therefore it is 
considered as a highly cardiac-specific protein.
31
 
During the myocardial injury process, the troponin complex is degraded and cTnI is 
then released into the bloodstream both in free form and complexed with the other 
subunits (troponin C and cardiac troponin T).
32, 33
 In the case of patients with acute 
myocardial infarction (AMI), cTnI elevates within 6 hours, peaks within 8 to16 hours 
and remains detectable up to 9 days after the onset of chest pain.
34
 The release kinetics 
makes cTnI an excellent biomarker for detection of AMI. Furthermore, the 
measurement of serum cTnI is reported to be superior to the conventional measurement 
of creatinine kinase (CK) and its myocardial isoenzyme (CKMB) in terms of specificity 
and selectivity for the identification of cardiac injury.
35, 36
 Recently, many studies 
demonstrate that the measurement of cTnI can be used as not only a diagnostic but also 
a prognostic tool for acute coronary syndromes.
34, 35, 37-39
 Moreover, cTnI has been 
accepted as the gold standard in the diagnosis of myocardial infarction (MI).
40
 The 2007 
joint European Society of Cardiology, American College of Cardiology Foundation, 
American Heart Association, and World Heart Federation expert consensus document 
recommends that the cutoff values for cTnI should be determined for each assay at the 
99th percentile of a normal reference population with ≤10% coefficient of variation (CV) 
in each labarotory.
41
 Table 4.2 shows information of some commercial cTnI assays.  
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Table 4.2 Characteristics of some commercial cTnI assays  
Reagent 
manufacturer 
Reagent description Methodology 
Assay range 
(µg/L) 
LOD 
(µg/L) 
99
th
 % 
(µg/L) 
Abbott 
ARCHITECT STAT 
Troponin-I 
IL
a
 0.02 – 50 ≤ 0.01 0.04 
bioMérieux 
VIDAS Troponin I 
Ultra 
IL
a
 0.01 − 30 0.01 0.01 
Mitsubishi PATHFAST cTnI IL
a
 0.02 – 50 0.02 0.02 
Ortho 
VITROS Troponin I 
ES 
IL
a
 0.012 – 80 0.012 0.034 
Roche Troponin I STAT IL
a
 0.16−2.5×104 0.16 0.16 
Siemens 
ADVIA Centaur TnI-
Ultra 
IL
a
 0.008 − 50 0.008 0.04 
Tosoh 
AIA-PACK cTnI 
2nd-Gen 
IL
a
 0.02 – 120 0.02 0.02 
a
 IL, immunoluminometric 
 
4.3 Experimental methods 
4.3.1 Materials  
Silver nitrate (AgNO3, ≥ 99.9%), trisodium citrate (TSC), poly(sodium 4-
styrenesulfonate) (PSS), sodium borohydride (NaBH4), L-ascorbic acid (AA), 
tetrachloroauric (III) acid (HAuCl4, ≥ 99.9%), cytidine 5’-diphosphocholine (PC), 
sodium phosphate dibasic (Na2HPO4), sodium phosphate monobasic (NaH2PO4), 
sucrose and CRP were purchased from Sigma-Aldrich and were used as received. 
Human cTnI and monoclonal anti-TnI antibody were purchased from Fitzgerald 
Industries International (USA). All glassware used in the synthesis of nanoparticles was 
first rinsed with concentrated nitric acid (65%) and then rinsed thoroughly with 
Millipore water and finally water from Sigma-Aldrich before use. All the consumables 
were obtained from Fisher Scientific. Water purchased from Sigma-Aldrich was used 
throughout.  
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4.3.2 Synthesis of TSNPs  
The TSNP sols were synthesized according to the method of Aherne et al. using a seed-
mediated reduction of Ag
+
 in aqueous solution as previously described.
1
 Typically, the 
silver seeds were prepared by combining water (4.5 mL), aqueous TSC (0.5 mL, 25 
mM), aqueous PSS (0.25 mL, 500 mg/L; 1,000 kDa) and aqueous NaBH4 (0.3 mL, 10 
mM), followed by addition of aqueous AgNO3 (5 mL, 0.5 mL) at a rate of 2 mL/min 
while stirring continuously. The nanoplates were grown from the synthesized seeds by 
adding aqueous AgNO3 (3 mL, 0.5 mM) at a rate of 1 mL/min to the combination of 
water (5 mL), aqueous AA (75 μL, 10 mM) and various quantities of seed solution 
while stirring vigorously. After synthesis, aqueous TSC (0.5 mL, 25 mM) was added to 
stabilize the nanoparticles. 
4.3.3 Synthesis of AuTSNPs 
Silver seeds and TSNP sols were prepared via the method stated in section 4.3.2. 
AuTSNP sols were then synthesized according to the method of Aherne et al.
3
 by 
adding AA (150 μL, 10 mM) to one aliquot of the as-prepared TSNP corresponding to 3 
mL of added AgNO3 solution, followed by addition of an appropriate volume of 
HAuCl4 (0.5 mM) at a rate of 0.2 mL/min while stirring vigorously. The volume of 
HAuCl4 added is observed to correlate to the size of the TSNPs and the location of their 
LSPR peak wavelength. Figure 4.3 shows the relationship between the volume of 
HAuCl4 to add and the LSPR peak wavelength of TSNP sols. For instance, the volumes 
of HAuCl4 to add for the TSNP sols with maximum wavelengths at 600 nm and 700 nm 
are 170 µL and 79 µL, respectively. This graph was used as a reference for the 
preparation of AuTSNP sols from TSNP sols.  
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Figure 4.3 Relationship between the volume of HAuCl4 needed to gold coat TSNP 
sample and the plasmon peak wavelength of TSNP sols. Data supplied by Dr. Damian 
Aherne, TCD. 
4.3.4 CRP assay 
The synthesized TSNP and AuTSNP sols were functionalized with PC to prepare the 
sensors. Typically, PC (0.5 mL, 0.1 M) was added to an aliquot of TSNP or AuTSNP 
sol (9.5 mL). The PC-TSNP and PC-AuTSNP sols were then incubated overnight at 4 ℃ 
in the dark. Before the assay performance, the unbound PC molecules were removed 
through centrifugation for 20 min at 15,616 × g and 4 ℃. The supernatant was discarded 
and the pellet was resuspended in water. The centrifugation procedure was repeated and 
the pellet was resuspended to 10% of the initial volume in water. In a typical assay, an 
aliquot of PC-TSNP or PC-AuTSNP (10 μL) was added to the combination of 
phosphate buffer (270 μL, 10 mM, pH 7.4), CaCl2 (10 μL, 1 mM) and CRP (10 μL) at 
various concentrations in phosphate buffer (10 mM, pH 7.4). The concentration of CRP 
detected in the assay ranged between 3.3×10
-3
 and 3.34 mg/L. The incubation time for 
the assay was 30 min. All assays were carried out in disposable UV micro cuvettes and 
characterized using a fiber optic spectrophotometer (Ocean Optics USB4000). The data 
obtained from the complete assay were fitted with the four-parameter logistic curve 
model, 
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     (4.1) 
where    and    are the lower and upper asymptotes for the binding assay, respectively. 
The inflection point is given by the variable    and the slope of the tangent in this point 
is given by the parameter  . The curve-fitting model used is based on an analytical 
expression, and this logistic function is used as a mathematical model to describe a 
sigmoid curve progression.  
4.3.5 cTnI assay 
To remove sodium azide and saline buffer contained in the anti-troponin I (aTnI) 
antibody stock solution, the antibody (300 μL, 0.2 mg/mL) was dialyzed against 
phosphate buffer (300 mL, 100 mM, pH 8.0) for 2 hours. The buffer was changed once 
and 2 more hours were allowed for the dialysis. The TSNP and AuTSNP sols were 
functionalized with aTnI by adding an aliquot of dialyzed aTnI (80 μL, 0.2 mg/mL) to 
an aliquot of TSNP or AuTSNP sol (10 mL). The aTnI-TSNP and aTnI-AuTSNP sols 
were then incubated overnight at 4 ℃. Before the assay performance, the unbound 
antibody was removed by centrifugation at 9240 × g and 4 ℃ for 20 min. The 
supernatant was discarded and the pellet was resuspended in water. The centrifugation 
procedure was repeated and the pellet was resuspended to the original volume in water. 
In a typical assay, an aliquot of aTnI-TSNP or aTnI-AuTSNP (10 μL) was added to the 
combination of phosphate buffer (280 μL, 10mM, pH 8.0) and cTnI (10 μL) at various 
concentrations in phosphate buffer (10 mM, pH 8.0). The concentration of cTnI used in 
the experiment was ranged from 0.15 to 333 µg/L. The incubation time for the assay 
was 30 min. The assays were carried out in disposable UV micro cuvettes and 
characterized using the fiber optic spectrophotometer. The data collected for the 
complete assay were fitted with the four-parameter logistic model as above.  
4.3.6 Refractive index sensitivity measurement  
In order to investigate the refractive index sensitivity of the nanoplates, sucrose 
solutions of various concentrations were prepared by dissolving a range of quantities of 
sucrose (≥ 99.5%) in water. All the solutions were used at room temperature. Table 4.3 
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shows the preparation of the sucrose solutions and the corresponding refractive indices 
in refractive index units (RIU) as generally known using the Brix scale.
42
 
Table 4.3 Sucrose solutions of various concentrations and the corresponding Brix scale 
refractive indices  
Sucrose (mg) 
Water 
(mL) 
Concentration of sucrose 
(%) 
Brix scale refractive index 
(RIU) 
0 10 0 1.3333 
1 9 10 1.3479 
2 8 20 1.3639 
3 7 30 1.3811 
4 6 40 1.3997 
5 5 50 1.4200 
 
The refractive index sensitivities of sols including bare TSNP, bare AuTSNP, PC-TSNP, 
PC-AuTSNP, aTnI-TSNP and aTnI-AuTSNP were measured using the sucrose method. 
The extinction spectra of the sols suspended in various sucrose solutions were acquired 
using the optic fiber spectrophotometer. In a typical measurement, 50 μL of a nanoplate 
sol was added to 350 μL of a certain sucrose solution in a disposable UV micro cuvette.  
As the nanoplates are originally suspended in water before they are mixed with the 
sucrose solutions, the refractive indices of the sucrose-sol mixtures need to be adjusted 
according to the Lorentz-Lorenz equation,
43, 44
  
 
   
   
   
   
   
  
   
  
   
   
  
   
  
   
 (4.2) 
where     is the refractive index of the sucrose-sol mixture,    and    are the refractive 
indices of nanostructure sol (1.3333) and sucrose solution respectively,    and    are 
the volume fractions of the two components. The calculated refractive indices of the 
sucrose-sol mixtures based on the preparation described above in this section are shown 
in Table 4.4.  
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Table 4.4 Refractive indices of the sucrose-sol mixtures used for refractive index 
sensitivity measurements. 
Sucrose concentration 
(%) 
      
Refractive index 
(RIU) 
10 0.125 0.875 1.3461 
20 0.125 0.875 1.3600 
30 0.125 0.875 1.3750 
40 0.125 0.875 1.3912 
50 0.125 0.875 1.4089 
 
4.4 Results and discussion  
4.4.1 Synthesis of TSNPs and AuTSNPs 
In this work, the synthesis of TSNPs is based on a two-step seed-mediated method that 
produces TSNPs in a rapid and reproducible fashion under very mild conditions (room 
temperature and water as solvent, see section 4.3.2 for details).
1
 The first step involves 
seed preparation by reducing AgNO3 with NaBH4 in the presence of PSS. NaBH4, as a 
strong reducing agent, is used to rapidly reduce the Ag
+
, forming a large quantity of 
monodisperse silver seed particles. PSS has been observed to play an important role in 
producing monodisperse nanoplates when growing the nanoplates from the seeds. 
Though the role of PSS has not been completely understood, it is considered to have a 
face selectivity and play a shape-directing role during the growth step.
1
 The second step 
involves the growth of silver seeds into TSNPs through the reduction of Ag
+
 with AA in 
the presence of silver seed particles. AA is a mild reducing agent that requires the 
facilitation of seed particles to reduce the Ag
+
, forming silver atoms which are 
deposited on the seed particles.  
Silver nanoparticles tend to chemically degrade due to a catalytic oxidation (etching) of 
the surface in the presence of halides and other anions.
45-47
 Cl
-
 has been reported to 
selectively etch the tips and side faces of the silver nanoprism,
48
 inducing changes in the 
nanoprism’s geometry (e.g. truncation of apices and reduction of aspect ratio) and thus 
blueshifting the LSPR wavelength. Therefore, to improve the stability of TSNPs, gold 
as a more stable metal was used to coat the nanoplates. Typically, a thin layer of gold 
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was selectively deposited on the edges of the nanoplates through galvanic replacement 
reaction.
3
 Galvanic replacement involves a process by which a metal is deposited as a 
result of the consumption of another metal with a lower reduction potential. This 
reaction has been successfully used for preparing bimetallic nanoparticles of various 
shapes.
49, 50
 Figure 4.4 A shows UV-vis spectra of a typical TSNP sol and the AuTSNP 
sol prepared from it. The gold coating results in an 18 nm redshift in the LSPR peak 
from 609 nm to 627 nm and a slight broadening of the band. The success of gold 
coating was determined by placing the AuTSNP sol in 10 mM NaCl for 5 min. As 
shown in Figure 4.4 B, no shift in the LSPR peak is observed for the AuTSNP sample 
whereas the LSPR peak of TSNP sol blueshifts to 397 nm in the presence of Cl
-
. This 
indicates that the unprotected TSNPs are etched backed to the silver seed particles as 
397 nm is close to the position of the LSPR for small silver nanoparticles.
51
  
 
Figure 4.4 (A) UV-vis spectra of a TSNP sol and the AuTSNP sol derived from it; (B) 
UV-vis spectra of the same sols placed in 10 mM NaCl for 5 min. 
4.4.2 CRP assay 
4.4.2.1 PC-functionalized nanoplates 
PC was used to functionalize the nanoplates including TSNPs and AuTSNPs according 
to the method described in section 4.3.4. It is postulated that a monolayer of PC is 
formed on the nanoplate surface by spontaneous adsorption of the molecule to the 
metallic surface. The interaction between TSNP and the PC molecule may involve the 
carbonyl group (C=O), amino group (-NH2) and N1 atom of the cytosine ring, while the 
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AuTSNP is more likely to interact with carbonyl group (C=O), amino group (-NH2) and 
N3 atom of the cytosine ring (Figure 4.5).
52-55
 Moreover, the phosphate and choline 
groups form a high-affinity binding site for CRP.  
 
Figure 4.5 Chemical structure of cytidine 5’-diphosphocholine (PC). 
Figure 4.6 shows representative UV-vis spectra of TSNP (A) and AuTSNP (B) sols and 
their corresponding PC-functionalized samples. Upon PC functionalization, TSNP and 
AuTSNP are found to typically exhibit 7 and 9 nm redshifts in their peak wavelengths, 
respectively. The redshift in the extinction spectrum is attributed to the adsorption of PC 
onto the surface of the nanoplate which thereby increases the local refractive index. The 
magnitude of the redshift is determined by the refractive index sensitivity of the 
nanoplates as well as the density of PC molecules adsorbed to the surface (i.e. surface 
coverage). Either high refractive index sensitivity or high surface coverage may result in 
a large redshift of the plasmon peak.  
 
Figure 4.6 (A) Extinction spectra of TSNP sol and its corresponding PC-functionalized 
sample with LSPR λmax located at 567 nm and 574 nm, respectively; (B) Extinction 
spectra of AuTSNP sol and its corresponding PC-functionalized sample with LSPR λmax 
located at 611 nm and 620 nm, respectively. 
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4.4.2.2 Refractive index sensitivities of the nanoplates 
Refractive index sensitivities of the bare TSNP, PC-TSNP, bare AuTSNP and PC-
AuTSNP samples before and after centrifugation were determined using the sucrose 
testing method described in section 4.3.6. This sucrose test provides a simple, 
reproducible method for the refractive index sensitivity analysis of the nanoplates 
without causing any destruction and destabilization. It ensures that any shift observed 
can be ascribed to the variation in the refractive index of the surrounding medium. 
Therefore, this method is a highly valuable approach for estimating the performance 
efficiency of the nanoplates as biosensors. Figure 4.7 shows the typical extinction 
spectra of TSNPs suspended in sucrose solutions of various concentrations 
corresponding to different refractive indices. The LSPR peak wavelength is observed to 
redshift as the sucrose concentration is increased, which indeed is also observed for PC-
TSNP, bare AuTSNP and PC-AuTSNP sols. Additionally, centrifugation is a necessary 
preparation step to remove the excess PC molecules before carrying out the CRP assay. 
Therefore, the effect of centrifugation on the refractive index sensitivities of the 
nanoplates was investigated.  
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Figure. 4.7 Example of extinction spectra of TSNPs suspended in a range of sucrose 
solutions.  
Figures 4.8 A and B show the refractive index sensitivities of the TSNP and PC-TSNP 
sols presented in Figure 4.6 A before and after centrifugation. Before centrifugation a 
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small reduction in the refractive index sensitivity is observed when TSNPs are 
functionalized with PC molecules (Figure 4.8 A). This observation is in agreement with 
a previous study of Ag nanoparticles modified with alkanethiol self-assembled 
monolayers (SAMs).
56
 The measured reduction in the sensitivity of the nanoplates may 
be attributed to the coating of PC. When the LSPR is excited, the enhanced electric 
fields decay over the length scale of ~ 50 nm.
57
 Therefore, the highest sensing 
capabilities are in the near surface vicinity of the nanoparticle where the electric fields 
are strongest. The PC coating may act as a barrier impeding sucrose molecules 
permeating to the surface of the nanoplate and hence shifts the sensing area further 
away from the surface where the electric fields are less strong. After centrifugation both 
samples showed decreased refractive index sensitivities when compared to their 
corresponding values before centrifugation (Figure 4.8 B). The sensitivity of bare 
TSNPs is reduced by ~ 23% while the sensitivity of PC-TSNPs is reduced by ~ 14%. 
Upon examination of the extinction spectra for all the samples suspended in water 
(Figure 4.8 C and D), different magnitudes of blueshift are found when TSNPs and PC-
TSNPs are centrifuged, suggesting a reduction in size, i.e. aspect ratio, of the nanoplates. 
The centrifugation-induced blushift in the LSPR wavelength of the TSNPs has been 
previously reported by Zeng et al.
58
 who also observed the truncation of sharp tips for 
the centrifuged triangular nanoplates. Moreover, the LSPR peak of the PC-TSNP 
sample shows less blueshift than that of the bare TSNP sample after centrifugation 
(Figure 4.8 C and D), suggesting that the PC coating may protect the TSNP structure to 
some extent and reduce the prevalence of truncation.  
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Figure 4.8 (A) Refractive index sensitivities of TSNP and PC-TSNP before 
centrifugation, (B) Refractive index sensitivities of TSNP and PC-TSNP after 
centrifugation, (C) Extinction spectra of TSNP before (black curve, λmax = 567 nm) and 
after (red curve, λmax = 556 nm) centrifugation and (D) Extinction spectra of PC-TSNP 
before (black curve, λmax = 574 nm) and after (red curve, λmax = 572 nm) centrifugation. 
Figures 4.9 A and B show the refractive index sensitivities of the AuTSNP and PC-
AuTSNP sols presented in Figure 4.6 B before and after centrifugation. Before 
centrifugation the sensitivity of AuTSNP is decreased when the sample is functionalized 
with PC (Figure 4.9 A), which is consistent with the observation for the as-prepared 
TSNP sample presented in Figure 4.8 A. However, significantly the sensitivities of 
AuTSNPs and PC-AuTSNPs are found to remain almost unchanged after centrifugation 
(Figure 4.9 B), which is distinct from the observation for TSNPs and PC-TSNPs (Figure 
4.8 B). By analyzing the extinction spectra of the AuTSNP and PC-AuTSNP samples 
suspended in water (Figure 4.9 C and D), no blueshift is observed for both samples after 
centrifugation. This is an important result suggesting that no significant change in the 
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aspect ratio of the nanoplates occurs and that this may be attributed to the protection 
from the gold coating on the edges of these nanoplates.  
 
Figure 4.9 (A) Refractive index sensitivities of AuTSNP and PC-AuTSNP before 
centrifugation, (B) Refractive index sensitivities of AuTSNP and PC-AuTSNP after 
centrifugation, (C) Extinction spectra of AuTSNP before (black curve) and after (red 
curve) centrifugation and (D) Extinction spectra of PC-AuTSNP before (black curve) 
and after (red curve) centrifugation. 
The sensitivities of all the samples before and after centrifugation were compared to the 
Miller line (Figure 4.10). The Miller line is a theoretical upper bound to sensitivities of 
arbitrary nanoparticles to the changes of local refractive index.
59
 It is apparent that the 
sensitivities of all as-prepared and centrifuged samples exceed the maximum values 
predicted by the theory of Miller et al. (Figure 4.10). In addition, PC-AuTSNPs may 
present higher sensitivity and stability than PC-TSNP due to the gold coating. These 
results imply that the PC-AuTSNP sols have the potential to serve as robust and highly 
sensitive biosensors for detection of CRP.  
                                            Chapter 4: Triangular nanoplates for direct assays in solution 
 
  66 
 
Figure 4.10 Comparison of experimental sensitivities of as-prepared (A) and 
centrifuged (B) sols to the Miller line. 
4.4.2.3 CRP detection 
CRP assays were carried out using PC-TSNP and PC-AuTSNP sols via a direct-binding 
method as described in section 4.3.4. In a typical assay the final concentration of the 
sensors was estimated to be ~ 2 × 10
12
 particles per liter. Upon exposing to the CRP 
dilutions ranging from 3.3×10
-3
 to 3.34 mg/L, different magnitudes of shift in LSPR 
wavelength were observed for PC-TSNP and PC-AuTSNP sols. The LSPR peak shifts 
were plotted against the concentrations of CRP as shown in Figure 4.11. For the assay 
using PC-TSNP (Figure 4.11 red plotting), minute blueshifts are observed when the 
CRP concentration is below 0.017 mg/L. This can be attributed to the etching of the 
nanoplates by Clˉ ions from CaCl2 solution. CaCl2 is used in this assay because PC-
CRP binding is Ca
2+
 dependent. Above 0.017 mg/L of CRP, the LSPR peak is observed 
to redshift and experiences an increased redshift as the concentration of the analyte is 
increased. For the assay using PC-AuTSNP (Figure 4.11 black plotting), no blueshifting 
is found with a redshift of 0.28 nm in the LSPR peak observed for the lowest 
concentration of CRP (3.3×10
-3
 mg/L). The redshift increases with CRP concentration. 
Below 0.67 mg/L of CRP, both PC-TSNP and PC-AuTSNP sensors present similar 
responses to the analyte. Significantly, when the concentration of CRP is above 0.67 
mg/L, the PC-AuTSNP sensor presents a greater redshift than the PC-TSNP in response 
to the analyte. At the highest analyte concentration (3.34 mg/L), both sensors approach 
saturation. 
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Figure 4.11 LSPR peak shift as a function of the CRP concentration for PC-TSNP (red) 
and PC-AuTSNP (black).  
Clearly, the assay data in Figure 4.11 has the expected shape and demonstrates an 
improved response for the AuTSNP sample compared to the TSNP sample. This assay 
is a preliminary study for the detection of CRP and improvements are needed. First of 
all, blocking of the free sites on the nanoplate surface is needed to prevent non-specific 
binding. Secondly, a control assay using a protein other than CRP (e.g. IgG) is needed 
for comparison purposes. Furthermore, the assay needs to be repeated for a number of 
times to evaluate the LOD and precision. However, there are limitations present due to 
the subsequent restrictions imposed on the use of these Kelly particles, it was not 
feasible to make the required improvements as discussed above. This work on solution-
phase assays using alternative AuTSNPs will be continued in the next chapter.  
4.4.3 cTnI assay 
4.4.3.1 aTnI-functionalized nanoplates  
aTnI antibody was used to functionalize the nanoplates including both TSNPs and 
AuTSNPs, by following the procedure outlined in section 4.3.5. The spontaneous 
adsorption of antibody molecules to the surface of metallic nanoparticles in aqueous 
solution is complex and dependent on the structure of the protein molecules, ionic 
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strength, pH and temperature.
60
 In general, the antibody molecules when bound to 
metallic nanoparticles are assumed to retain their bioactivity.
61
 The potential 
interactions between the antibody and the nanoplates include (i) the electrostatic 
attraction between the positively charged amino acid groups of the antibody and the 
negatively charged colloids, (ii) the hydrophobic interaction between the hydrophobic 
pockets of the antibody and the metal surface, and (iii) semi-covalent binding of the 
metal to free sulfhydryl groups of the antibody, if present.
62
 Figure 4.12 shows 
examples of LSPR peak shifts for TSNP and AuTSNP sols before and after aTnI 
functionalization. The adsorption of antibody to the nanoplates typically induced a 17 
nm redshift for the TSNP sol and a 15 nm redshift for the AuTSNP sol.  
 
Figure 4.12 (A) Extinction spectra of TSNP sol and its corresponding aTnI-
functionalized sample with LSPR λmax located at 609 nm and 626 nm, respectively; (B) 
Extinction spectra of AuTSNP sol and its corresponding aTnI-functionalized sample 
with LSPR λmax located at 627 nm and 642 nm, respectively. 
4.4.3.2 Refractive index sensitivity analysis 
Refractive index sensitivities of bare TSNP, aTnI-TSNP, bare AuTSNP and anti-TnI-
AuTSNP samples before and after centrifugation were determined using the sucrose 
testing method described earlier. The refractive index sensitivities of TSNP and aTnI-
TSNP sols before centrifugation are shown in Figure 4.13 A. The sensitivity of the 
TSNP sample slightly decreased upon functionalization of the nanoplates with the 
antibody, which is in agreement with the observation for the PC-functionalized TSNP 
                                            Chapter 4: Triangular nanoplates for direct assays in solution 
 
  69 
sol. After centrifugation, both TSNP and aTnI-TSNP sols show decreased sensitivities 
(Figure 4.13 B). The sensitivity of the bare TSNP sample is reduced by ~ 14% while the 
sensitivity of aTnI-TSNP sample is reduced by ~ 5%. When examining the extinction 
spectra of the two sols before and after centrifugation (Figure 4.13 C and D), it is 
apparent that the LSPR peaks for both TSNP and aTnI-TSNP samples experience 
different magnitudes of blueshift after centrifugation. As stated previously, the blueshift 
in the LSPR peak indicates the reduced aspect ratio of the nanoplates which results in a 
decreased sensitivity to changes of the local dielectric environment. In addition, the 
plasmon band of aTnI-TSNP sol became broadened after centrifugation (Figure 4.13 D), 
suggesting that coupling and/or aggregation of the nanoplates may have occurred.  
 
Figure 4.13 (A) Refractive index sensitivities of TSNP and aTnI-TSNP sols before 
centrifugation; (B) Refractive index sensitivities of TSNP and aTnI-TSNP sols after 
centrifugation; (C) Extinction spectra of TSNPs suspended in water, showing a peak 
shift from 609 nm (black) to 596 nm (red) upon centrifugation; (D) Extinction spectra 
of aTnI-TSNPs suspended in water, showing a peak shift from 626 nm (black) to 623 
nm (red) upon centrifugation. 
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Figure 4.14 A shows the refractive index sensitivities of the as-prepared AuTSNP and 
aTnI-AuTSNP sols. Similar to the case of CRP, the adsorption of antibody to the metal 
surface reduces the sensitivity of the nanoplate. After centrifugation, the sensitivity of 
AuTSNPs remains unchanged while the aTnI-AuTSNP sol exhibits a slightly increased 
sensitivity (Figure 4.14 B). Upon analyzing the extinction spectra for both samples, no 
shift is observed in the LSPR peak for AuTSNP and aTnI-AuTSNP after centrifugation 
(Figure 4.14 C and D). This is attributed to the protection of the gold coating on the 
edges of TSNP. Similar to the aTnI-TSNP sample, the plasmon band of aTnI-AuTSNPs 
is broadened after centrifugation, indicating the coupling and/or aggregation of the 
nanoplates.  
 
Figure 4.14 (A) Refractive index sensitivities of AuTSNP and aTnI-AuTSNP sols 
before centrifugation; (B) Refractive index sensitivities of AuTSNP and aTnI-AuTSNP 
sols after centrifugation; (C) Extinction spectra of AuTSNPs suspended in water (D) 
Extinction spectra of aTnI-TSNPs suspended in water. 
Figure 4.15 displays the refractive index sensitivities observed for all the sols in 
comparison to the Miller line. Most of the sols give sensitivities above the optimum 
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values predicted by the theory of Miller et al., while the sensitivities of aTnI-AuTSNPs 
are slightly below the predicted trend. This would therefore suggest that aTnI-TSNP and 
aTnI-AuTSNP sols have the potential to serve as highly sensitive sensors for the 
detection of cTnI.  
 
Figure 4.15 Comparison of experimental sensitivities of as-prepared (A) and 
centrifuged (B) sols to the Miller line. 
4.4.3.3 cTnI detection 
The aTnI-TSNP and aTnI-AuTSNP sols were used for the cTnI assays by following the 
protocol described in section 4.3.5. In a typical assay the final concentration of the 
sensors was estimated to be 2 × 10
11
 particles per liter. The shifts of the LSPR peak in 
response to cTnI were plotted against the concentrations of the analyte ranged between 
0.15 and 333 µg/L, as shown in Figure 4.16. For the assay using aTnI-TSNPs (Figure 
4.16 red plotting), blueshifts in LSPR λmax are observed for the concentrations of cTnI 
below 4.1 µg/L, indicating that certain etching of the nanoplates may have taken place. 
When the concentration of cTnI increases to 4.1 µg/L, a redshift of 0.3 nm in the LSPR 
peak is observed. The redshift continues to increase with the concentration of cTnI up to 
333 µg/L. For the assay using aTnI-AuTSNP (Figure 4.16 black plotting), the LSPR 
peak starts to redshift when cTnI increases to 4.1 µg/L. Additionally, aTnI-AuTSNP sol 
generally presents a greater redshift than aTnI-TSNP sol in response to different 
concentrations of cTnI as was found in the case of the CRP assay. At the highest cTnI 
concentration, both sensors appear not to reach saturation.  
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Figure 4.16 LSPR peak shift as a function of the concentration of human cTnI for aTnI-
TSNP (red) and aTnI-AuTSNP (black). 
Similar to the CRP assay, this assay is a preliminary study on the cTnI detection and 
improvements are required, including the blocking step, control assay and replication. 
However, it was impossible to make the improvements due to the restriction on the use 
of these nanoparticles. While the CRP work is continued in subsequent chapters, 
unfortunately it was necessary to discontinue the cTnI work, partly due to high costs of 
the antibodies and also due to the change in direct of the project work.  
4.5 Conclusions 
In this work, solution-phase TSNPs and AuTSNPs with high refractive index 
sensitivities have been used as LSPR sensors for one-step, wash-free detection of CRP 
and cTnI via a direct binding assay format. Though these two assays need to be 
optimized, the triangular nanoplates have shown excellent potential for efficient 
biosensing. Particularly, AuTSNPs have shown advantages over TSNPs with respect to 
stability and sensitivity, which can be further employed in biosensing in physiological 
environments. 
In the case of CRP assays, TSNPs and AuTSNPs were functionalized with PC 
molecules. The refractive index sensitivities of TSNPs, PC-TSNPs, AuTSNPs and PC-
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AuTSNPs were examined before and after centrifugation. Centrifugation, as a necessary 
process to remove the excess PC from the sols, was found to affect the refractive index 
sensitivities of the nanoplates. The sensitivities of as-prepared TSNPs and AuTSNPs 
were observed to decrease upon PC functionalization, indicating the PC molecules 
adsorbed on the nanoplate surface may dampen the attenuation of the environmental 
sensitivity. After centrifugation, the sensitivities of both TSNPs and PC-TSNPs reduced 
whereas those of AuTSNPs and PC-AuTSNPs remained unchanged or slightly 
increased. It is postulated that centrifugation-induced truncation may contribute to the 
reduction in the sensitivities of TSNP and PC-TSNP sols. Additionally, gold coating is 
considered to protect the silver nanoplates against truncation. Sensitivities of the 
samples exceeded the Miller line regardless of centrifugation, suggesting that PC-
TSNPs and PC-AuTSNPs can act as efficient sensors for CRP detection. For the assays 
using the two sensors, PC-AuTSNPs showed larger LSPR response of the analyte 
concentration range than PC-TSNPs. Furthermore, a redshift in the LSPR peak of the 
AuTSNPs was observed for lower analyte concentrations when CRP was as low as 
3.3×10
-3
 mg/L. 
In the case of the cTnI assay, aTnI was used to functionalize TSNP and AuTSNP sols. 
Both as-prepared TSNP and AuTSNP sols exhibited reduced refractive index 
sensitivities upon aTnI functionalization. After centrifugation, the refractive index 
sensitivities of TSNP and aTnI-TSNP sols decreased whereas those of AuTSNP and 
aTnI-AuTSNP sols maintained the same or slightly increased. All observations are 
consistent with those obtained for the bare and PC-functionalized nanoplates. When 
comparing with the Miller line, aTnI-TSNPs and aTnI-AuTSNPs showed high 
sensitivities even after centrifugation, suggesting their potential efficiency for the 
detection of cTnI. For the assays using these two sensors, in both cases the LSPR peaks 
commenced redshifting when cTnI was 4.1 µg/L.  
Both CRP and cTnI assays are preliminary work for biosensing application using 
triangular nanoplates. Improvements are needed for these two assays, including the 
blocking of the free sites on the nanoplate surface, the control assay and appropriate 
replication. In addition, increased performance should be achievable through 
optimization of the CRP and cTnI assays by controlling several parameters such as the 
quantity of sensors used, pH, temperature and incubation time. Unfortunately, the work 
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on the Kelly particles had to be discontinued at this point, due to intellectual property 
restrictions on the use of the particles, which was outside of my control. Consequently, 
no improvements were carried out for the CRP and cTnI assays. As indicated above, the 
CRP assay work will be continued in the next chapter albeit using different AuTSNPs 
while solid-phase MEF-based CRP assays will be reported in Chapter 6. It was 
necessary to discontinue the cTnI assay work.   
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Chapter 5  
Nanoparticles for development of sensitive assays 
 
5.1 Introduction  
This chapter focuses on the development of immunoassays using nanoparticles for 
biosensing applications, including LSPR refractive index sensitivity-based assays, 
aggregation-based assays and nanoparticle-enhanced SPR assays. The LSPR refractive 
index sensitivity-based assay involves the detection of human CRP using antibody-
conjugated AuTSNP sols. This part of the work continues on from that of Chapter 4 
except the AuTSNPs used are synthesized using a different method from that used for 
the Kelly particles. For reasons explained later, aggregation-based assays and 
nanoparticle-enhanced SPR assays, both for human IgG, were also investigated.  
5.2 Overview of assays 
Three different types of assays were used in this section of the work, (i) LSPR refractive 
index sensitivity-based assay, following on from Chapter 4, using the AuTSNPs, (ii) 
aggregation-based assay using spherical gold particles (AuNPs) and (iii) nanoparticle-
enhanced SPR assay using the AuTSNPs. 
5.2.1 Refractive index sensitivity-based assay  
Instead of PC which was used in Chapter 4, two types of monoclonal anti-human CRP 
(aCRP) antibodies C2 and C6 are used to functionalize the AuTSNPs, forming C2-
AuTSNP and C6-AuTSNP conjugates. These two antibodies specifically bind to 
different epitopes of the CRP molecule, and hence C2-AuTSNP and C6-AuTSNP 
conjugates can be used individually or cooperatively for the detection of CRP. The 
mechanism for the assay based on LSPR refractive index sensitivity has been discussed 
in Chapter 4 (Figure 4.2). In this chapter, C2-AuTSNP and C6-AuTSNP conjugates 
were individually used for CRP assays. Additionally, a 1:1 mixture of these two sensors 
was used for CRP detection. Due to the pentameric structure of the CRP molecule and 
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the fact that one antibody can bind to one CRP monomer, it is possible that more than 
one sensor binds to a CRP molecule forming aggregates. All assays were characterized 
with a UV-vis spectrophotometer and DLS. 
5.2.2 Aggregation-based assay 
The aggregation-based assay involves the detection of human IgG in aqueous solution 
using antibody-conjugated spherical gold nanoparticles (AuNPs) (Figure 5.1). It was 
decided to use IgG here for this model assay instead of CRP for cost reasons, coupled 
with the fact that the main focus was to compare the relative performance of this 
commonly used assay format with that of the LSPR refractive index sensitivity 
approach. Polyclonal anti-human IgG (H+L) antibody (aIgG) was used to functionalize 
13 nm AuNPs, forming aIgG-AuNP conjugates. The antibody reacts with both heavy 
and light chains of a human IgG molecule at different epitopes. Therefore, it is easy to 
cause aggregation of the AuNPs when the analyte is added to the aIgG-AuNP solution. 
The aIgG-AuNP sol is red in color with an LSPR wavelength peaked at 525 nm. The 
aggregation of the AuNPs results in a redshift of the LSPR peak due to the electric 
dipole-dipole interaction and coupling between the plasmons of the adjacent particles in 
the aggregates.
1
 In addition, the LSPR wavelength region between 580 and 800 nm 
experiences substantial changes in the extinction intensity during aggregation, which 
can be monitored for the aggregation progress.
1-4
 In this experiment, the largest change 
in LSPR extinction at longer wavelength occurred at 600 nm. Therefore, the 
aggregation rate of aIgG-AuNPs in the presence of various IgG concentrations was 
monitored by measuring the extinction of the sol at 600 nm. In addition, the aggregation 
process was characterized using TEM and the size of the aggregates formed in the assay 
was measured using DLS. 
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Figure 5.1 Schematic illustration of aggregation-based assay for human IgG detection 
using AuNPs. 
 
5.2.3 Nanoparticle-enhanced SPR assay 
This assay design incorporates AuTSNPs in an SPR assay for real-time detection of 
human IgG. As shown in Figure 5.2, the assay is performed on the gold surface of a 
commercial sensor chip. Protein A is immobilized on the gold surface to capture human 
IgG via a specific interaction with the Fc region of the antibody. The aIgG-AuTSNP 
conjugates are used to bind to the analyte at specific epitopes. A control assay using free 
aIgG is performed under the same conditions for comparison purposes. The utilization 
of AuTSNPs results in significantly improved SPR response due to three main factors: 
(i) an increase in the refractive index of the analyte, (ii) the plasmon resonant coupling 
between the nanoplates and the gold film, and (iii) an increase in the surface mass.
5
 All 
experiments were carried out using a Biacore 3000 system which was described in 
Chapter 3. 
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Figure 5.2 Schematic illustration of AuTSNP-enhanced SPR detection of human IgG. 
 
5.3 Experimental methods 
5.3.1 Materials  
AgNO3 (≥ 99.9%), TSC, NaBH4, AA, hydrogen peroxide (H2O2, 30 wt. %), HAuCl4 (≥ 
99.9%), sodium chloride (NaCl), boric acid (H3BO3), sodium tetraborate decahydrate ( 
Na2B4O7∙10H2O), Na2HPO4, NaH2PO4, phosphate buffered saline (PBS, pH 7.4), 
sucrose, nitric acid (HNO3, 69%), sulfuric acid (H2SO4, 95-98%) and polyclonal anti-
human IgG (Fab specific) antibody were purchased from Sigma-Aldrich and were used 
as received unless mentioned otherwise. Human CRP was purchased from Millipore 
(USA). Monoclonal mouse anti-human CRP antibodies C2 and C6 were purchased from 
HyTest (Finland). Protein A was purchased from Fisher Scientific (USA). Human IgG 
was purchased from SeraCare (USA). Bovine serum albumin (BSA) and polyclonal 
goat anti-human IgG (H+L) antibody were purchased from Jackson ImmunoResearch 
(USA). Gold sensor chips (SIA kit Au) were purchased from GE Healthcare (Sweden). 
All glassware used in the synthesis of nanoparticles was first rinsed with concentrated 
HNO3 (69%) and then rinsed thoroughly with Millipore water before use. All the 
consumables were obtained from Fisher Scientific. Millipore water was used 
throughout.  
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5.3.2 Refractive index sensitivity-based CRP assay using AuTSNP 
5.3.2.1 Synthesis of AuTSNP 
The TSNP sol was synthesized using the method of Zhang et al. instead of the method 
of Aherne et al. used in Chapter 4.
6
 In a typical experiment, aqueous AgNO3 (0.05M, 50 
µL), TSC (75 mM, 0.5 mL) and H2O2 (30 wt. %, 60 µL) solutions were added to 24.14 
mL of water with vigorous agitation at room temperature in air, followed by rapid 
addition of NaBH4 (100 mM, 0.25 mL) to the mixture. Within 10 min, the solution 
turned from light yellow to dark yellow and finally blue. The size of the nanoplates can 
be varied by adjusting the concentration of added NaBH4.  
The AuTSNP sol was prepared by adopting a previously reported method.
7
 Typically, 
AA (10 mM, 50 µL) was added to 5 mL of as-prepared TSNP sol with rigorous 
agitation, followed by the gradual addition of HAuCl4 (0.5 mM, 100 µL). The success 
of the Au coating was determined by exposing the nanoplates to 10 mM NaCl. UV-vis 
spectra were taken after 5 min incubation to monitor the stability of the sample.  
5.3.2.2 aCRP-AuTSNP conjugation 
Monoclonal mouse anti-human CRP antibodies (aCRPs) C2 and C6 were used to 
functionalize the nanoplates. Before adding antibody to the sol, the as-prepared 
AuTSNP sol was centrifuged at 20℃ and 16,100 × g for 15 min. The supernatant was 
removed and the pellet was resuspended in 0.01M borate buffer (BB, pH 8.5). In order 
to determine the quantity of antibody to be added to an aliquot of AuTSNP sol, different 
concentrations of antibody ranging from 2.5 to 10 µg/mL were used to functionalize 
aliquots of the sol. Following 2h incubation, the sols were incubated in 0.05 M NaCl for 
2 h and then were characterized with a Cary 50 UV-vis spectrophotometer.  
In order to prepare the aCRP-AuTSNP conjugates for CRP assay, antibodies C2 and C6 
were used to functionalize two aliquots of AuTSNP sol, respectively. The final 
concentration of C2 or C6 in the sol was 10 µg/mL. After 2 h incubation with gentle 
shaking, BSA (final concentration 5 µg/mL) was added and the sols were incubated for 
another hour. The antibody-functionalized AuTSNP sols were then stored at 4 ℃ before 
use.  
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Prior to the assay performance, the unbound antibody was removed by centrifuging the 
sol for 20 min at 4 ℃ and 9240 × g. The supernatant was discarded and the pellet was 
resuspended in BB (0.01 M, pH 8.5) containing 10 µg/mL BSA. The centrifugation 
procedure was repeated and the pellet was resuspended to one third of the initial volume 
in BB (0.01 M, pH 8.5) containing 10 µg/mL BSA.  
5.3.2.3 CRP detection 
C2-AuTSNPs, C6-AuTSNPs and a 1:1 mixture of these two sensors were used for CRP 
detection. In a typical assay using individual aCRP-AuTSNP conjugates (C2-AuTSNPs 
or C6-AuTSNPs), 10 µL of CRP at various concentrations was added to the 
combination of 50 µL of aCRP-AuTSNP (C2-AuTSNP or C6-AuTSNP) sol and 40 µL 
of phosphate buffer (PB, 0.01M, pH 7.2) containing 10 µg/mL BSA. In a typical assay 
using the 1:1 mixture of both conjugates, 10 µL of CRP at various concentrations was 
added to the combination of 25 µL of C2-AuTSNP sol, 25 µL of C6-AuTSNPs sol and 
40 µL of phosphate buffer (PB, 0.01M, pH 7.2) containing 10 µg/mL BSA. The 
concentrations of CRP used in those two types of assay ranged from 0.86 to 110 mg/L. 
Human IgG (110 mg/L) was used as negative control. All assays were performed in 
triplicate on a 96-well microplate (Greiner Bio-One) at room temperature. Separately, 
the assays were monitored for 2 h using a plate reader (Tecan, USA) as discussed later. 
The LOD of the assay was calculated from the mean signal of the lowest concentration 
of CRP producing a signal higher than the zero calibrator plus three standard deviations 
(SDs). The assays with 90 min incubation were also characterized using Delsa Nano C 
(Beckman Coulter, USA) for particle size analysis.  
5.3.2.4 Refractive index sensitivity measurement 
The refractive index sensitivities of the bare AuTSNP, C2-AuTSNP and C6-AuTSNP 
sols before and after centrifugation were measured using the sucrose method described 
in section 4.3.6.  
5.3.2.5 TEM  
TEM of AuTSNPs was performed with a Tecnai G
2
 20 twin microscope (FEI, USA), 
operating at an acceleration voltage of 200 kV. To prepare the TEM sample, an aliquot 
of AuTSNP sol was centrifuged for 15 min at 16,100 × g. The supernatant was removed 
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and the pellet was resuspended to 10% of the initial volume. A 10 µL aliquot of 
concentrated sol was dropped on a 300 mesh copper grid coated with Formvar/carbon 
(Agar Scientific, UK) and dried in air for one hour. The excess solution was wicked 
away and the sample was further dried overnight prior to imaging. The size analysis of 
the nanoplates was performed using ImageJ. 
5.3.3 Aggregation-based IgG assay using AuNP 
5.3.3.1 Synthesis of AuNP 
Spherical AuNPs were synthesized by TSC reduction of HAuCl4.
8, 9
 Aqueous TSC 
(38.8 mM, 25 mL) was added to an aqueous solution of HAuCl4 (1 mM, 250 mL) when 
it was brought to the boil with vigorous stirring. The mixture was refluxed for 20 min 
during which time the solution turned from pale yellow to deep red. After the solution 
was cooled to room temperature, it was filtered through a 0.2 µm Isopore membrane 
filter (Millipore). The resulting Au colloid was stored at 4℃ in the dark before use. 
5.3.3.2 aIgG-AuNP conjugation 
AuNPs were functionalized with polyclonal goat anti-human IgG (H+L) (aIgG) via 
spontaneous adsorption. Before functionalization, an aliquot of AuNP sol was 
centrifuged for 12 min at 16,100 × g. The supernatant was removed and the pellet was 
resuspended to the original volume in BB (0.01 M, pH 8.5). To determine the quantity 
of aIgG to be added, different concentrations of aIgG ranging from 5 to 25 µg/mL were 
used to functionalize aliquots of the AuNP sol. Following 2 h incubation, the sols were 
incubated in 0.05 M NaCl for 2 h and then were characterized with the UV-vis 
spectrophotometer.  
To prepare the aIgG-AuTSNP conjugates for IgG assay, aIgG (20 µg/mL) was used to 
functionalize an aliquot of AuTSNP sol. After 2 h incubation with gentle shaking, BSA 
(final concentration 0.1%) was added and the sol was incubated for another hour. The 
aIgG-AuTSNP sol was then stored at 4 ℃ before use. 
Prior to the assay performance, the unbound antibody was removed by centrifugation 
for 12 min at 4 ℃ and 15,616 × g. The supernatant was discarded and the pellet was 
resuspended in PB (0.01 M, pH 7.2) containing 0.1% BSA. The centrifugation 
                                            Chapter 5: Nanoparticles for development of sensitive assays 
 
 86 
procedure was repeated and the pellet was resuspended to half of the initial volume in 
PB (0.01 M, pH 7.2) containing 0.1% BSA. 
5.3.3.3 IgG detection 
In a typical assay, 10 µL of CRP at various concentrations was added to the 
combination of 50 µL of aIgG-AuNP sol and 40 µL of PB (0.01 M, pH 7.2) containing 
0.1% BSA. The concentrations of IgG used in this assay ranged from 0.78 to 400 mg/L. 
Anti-human IgG (Fab specific) antibody (200 mg/L) was used as negative control. All 
assays were performed in triplicate on a 96-well microplate (Greiner Bio-One) at room 
temperature. As previously, the assays were monitored for 2 h using a plate reader 
(Tecan, USA). In addition, the assays incubated for 90 min were characterized using 
Delsa Nano C (Beckman Coulter, USA) for particle size analysis. 
5.3.3.4 TEM 
The AuNPs were characterized with a Tecnai G
2
 20 twin microscope (FEI, USA) 
operated at 200 kV. The TEM sample was prepared using the method described in 
section 5.3.2.5. The IgG assay incubated for various durations was characterized with 
TEM. Typically, a 10 µL aliquot of the assay sample was dropped on a 300 mesh 
copper grid coated with Formvar/carbon (Agar Scientific, UK) and dried in air for one 
hour. The excess solution was wicked away and the sample was further dried overnight 
prior to imaging. 
5.3.4 AuTSNP-enhanced SPR detection of human IgG 
5.3.4.1 aIgG-AuTSNP conjugation 
Polyclonal anti-human IgG (H+L) antibody (aIgG) was used to functionalize the 
AuTSNP sol that was prepared with the method stated in section 5.3.2.1. Typically, an 
aliquot of AuTSNP sol was functionalized with 10 µg/mL of aIgG and blocked with 5 
µg/mL of BSA using the method described in section 5.3.2.2. The aIgG-AuTSNP sol 
was stored at 4 ℃ before use. 
Before the assay performance, the unbound aIgG was removed from the sol by 
centrifugation for 20 min at 4 ℃ and 9240 × g. The supernatant was discarded and the 
pellet was resuspended in BB (0.01 M, pH 8.5) containing 10 µg/mL of BSA. The 
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centrifugation was repeated and the pellet was resuspended to the original volume in 
PBS (0.01 M, pH 7.4) containing 10 µg/mL of BSA. 
5.3.4.2 IgG assay using AuTSNP-enhanced SPR 
In a typical experiment, a gold chip (SIA kit Au) was cleaned with acid piranha (a 3:1 
mixture of concentrated H2SO4 and 30% H2O2) for 2 min. Next, the chip was rinsed 
thoroughly with water and assembled onto the holder. The IgG assay performed on the 
Au chip was monitored by Biacore 3000. PBS (0.01M, pH 7.4) was used throughout. 
The volume of each reagent was 100 µL with a flow rate of 10 µL/min. Four flow cells 
were used for a set of assay. Flow cells 2 and 4 were assigned to the control and 
AuTSNP-enhanced assay, respectively. Flow cells 1 and 3 were assigned to the 
corresponding reference cells of flow cells 2 and 4. For the AuTSNP-enhanced assay, 
protein A (50 µg/mL), BSA (1%), human IgG at various concentration and aIgG-
AuTSNP were sequentially injected to flow cell 4. The same reagents except protein A 
were injected to the corresponding reference cell (i.e. flow cell 3). For the control assay, 
protein A (50 µg/mL), BSA (1%), human IgG at various concentration and aIgG (1 
µg/mL) were sequentially injected to the flow cell 2. The same reagents except protein 
A were injected to the corresponding reference cell (i.e. flow cell 1). The concentrations 
of human IgG ranged from 0.001 to 10 µg/mL.  
5.4 Results and discussion 
5.4.1 Refractive index sensitivity-based CRP assay using AuTSNP 
5.4.1.1 Synthesis and characterizations of AuTSNP 
As discussed at the beginning of this chapter, it was necessary to adopt a different 
particle synthesis approach for the remaining work on solution assays. The method 
reported by Zhang et al. for the preparation of TSNPs was chosen.
6
 The method of 
Zhang et al. involves the reduction of AgNO3 with NaBH4 in the presence of H2O2 and 
TSC. NaBH4 is a strong reducing agent that reduces Ag
+
 to form Ag nanoparticles and 
TSC acts as a stabilizer to keep the particles from aggregating. H2O2 plays a critical role 
in determining the shape evolution into triangular nanoplates. To improve the stability 
of the silver nanoplates against etching, a thin layer of gold was coated on the edges of 
the nanoplates by adopting the method reported by Aherne et al.for the Kelly particles.
7
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Figure 5.3 A shows an example of a TSNP sol and the corresponding AuTSNP sol 
derived from it. The gold coating induces a small redshift and a slight broadening of the 
LSPR wavelength, similar to that described in Chapter 4. The success of the gold 
coating was monitored by placing an aliquot of AuTSNP sol in 10 mM NaCl solution 
for 5 min. Figure 5.3.B illustrates the effect of 10 mM NaCl on the TSNPs and 
AuTSNPs after 5 min. The TSNPs are etched back to small silver particles as indicated 
by the LSPR blueshifting to 395 nm which is the characteristic LSPR wavelength for 
small spherical silver particles.
10
 In contrast, the AuTSNP sol shows high stability with 
no change in the LSPR wavelength in 10 mM NaCl, indicating successful and complete 
gold coating, again similar to the behavior of the Kelly particles.  
 
Figure 5.3 (A) UV-vis spectra of TSNPs (black) and AuTSNPs (red) suspended in 
water; (B) UV-vis spectra of the same samples after 5 min in 10 mM NaCl. 
A representative set of alternative AuTSNPs was compared with a set of AuTSNPs 
prepared using the method of Aherne et al.. The two sets of AuTSNPs have a LSPR 
peak located at 695 nm as shown in Figure 5.4. Apparently, the alternative AuTSNPs 
exhibit much broader plasmon band than the nanoplates prepared using the method of 
Aherne et al., indicating the former have greater size distribution and inhomogeneity 
within the sol. Both samples were characterized with TEM as shown in Figure 5.5. The 
mean edge length for the nanoplates prepared using the method of Aherne et al. and the 
alternative nanoplates is 41 ± 9 nm and 30 ± 8 nm, respectively. The nanoplates 
prepared using the method of Aherne et al. (CV = 22%) are more homogeneous than the 
altenative nanoplates (CV = 27%). According to the AFM measurement stated in 
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Chapter 6, the thickness of the alternative nanoplates is ~ 7 nm which is similar to that 
of the nanoplates prepared using the method of Aherne et al..
11
 This therefore results in 
aspect ratio being ~ 4.3 for the alternative nanoplates and ~ 5.9 for the nanoplates 
prepared using the method of Aherne et al.. In both samples, most of the nanoplates are 
triangular with varying degrees of tip truncation while a few nanoframes are observed 
due to the galvanic replacement of the silver by the gold.
7
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Figure 5.4 UV-vis spectra of representative AuTSNP samples prepared using the 
method of Aherne et al. (black) and the method of Zhang et al. (red). 
 
Figure 5.5 TEM images of AuTSNP samples prepared using the method of Aherne et 
al. (A) and the method of Zhang et al. (B). 
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5.4.1.2 aCRP-AuTSNP conjugation 
The addition of electrolyte such as NaCl to the colloidal suspension induces aggregation 
of the nanoparticles due to the screening of the repulsive electrostatic interactions 
between the particles. As shown in Figure 5.6, the concentration of NaCl causing 
AuTSNP aggregation is ~ 0.03 M, after 1 h incubation. When the concentration of NaCl 
increases to 1 M, the LSPR spectrum of the AuTSNP is undetectable, suggesting the 
nanoplates aggregate and completely fall out of the solution. These observations 
provide an estimation of the nanoplates’ stability and an indication of the appropriate 
ionic strength for the antibody-AuTSNP conjugation.  
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Figure 5.6 UV-vis spectra of AuTSNPs suspended in different concentrations of NaCl 
for 1 h.  
As discussed earlier in section 5.2.1, two types of aCRP antibodies, C2 and C6, were 
used to functionalize the nanoplates, which specifically bind to different epitopes of a 
CRP molecule. The antibody-AuTSNP conjugates are formed by spontaneous 
adsorption of the protein on the surface of the nanoplates with the interactions involving 
electrostatic, hydrophobic and Van der Waals forces.
12
 The AuTSNPs become more 
stable and less aggregation-prone when they are conjugated with antibody. To 
determine the quantity of antibody (C2 or C6) required for the stabilization of the 
nanoplates, various concentrations of antibody were added to aliquots of the AuTSNP 
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sol. The LSPR spectra of the resulting sols were collected after they were incubated in 
0.05 M NaCl for 2 h, which is illustrated in Figure 5.7. Bare AuTSNPs which are 
incubated in NaCl solution completely aggregate and no LSPR wavelength is 
detectable. This observation is different from the UV-vis spectrum observed for the bare 
AuTSNPs incubated in 0.05 M NaCl for 1 h as shown in Figure 5.6 because further 
aggregation occurred during longer incubation period. For both C2 and C6 antibody 
functionalization, no aggregation is observed when the concentration of antibody is 
increased to 5 and 10 µg/mL. To ensure that all nanoplates are conjugated with the 
antibody and the conjugates are sufficiently stable, 10 µg/mL of antibody (C2 or C6) 
was used for the conjugation.  
 
Figure 5.7 UV-vis spectra of C2-AuTSNPs (A) and C6-AuTSNPs (B) conjugates 
incubated in 0.05 M NaCl for 2 h. The concentrations of C2 or C6 used for the 
conjugation are given in the legend.  
5.4.1.3 Refractive index sensitivity analysis 
The refractive index sensitivities of bare AuTSNP, C2-AuTSNP and C6-AuTSNP sols 
before and after centrifugation were determined using the sucrose method as described 
in section 4.3.6. The refractive index sensitivities of the samples before centrifugation 
are shown in Figure 5.8 A. The adsorption of antibody on the surface of nanoplates 
results in decreased refractive index sensitivities, which is in agreement with the 
observations for PC and aTnI functionalized nanoplates in Chapter 4. After 
centrifugation, the sensitivity of AuTSNP sol remains the same while the sensitivities of 
C2-AuTSNP and C6-AuTSNP sols slightly increase (Figure 5.8 B). When examining 
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the UV-vis spectra of the samples, no significant shift is observed for all samples after 
centrifugation (Figure 5.8 C and D), similar to observations for the PC and aTnI 
functionalized AuTSNPs in Chapter 4. The refractive index sensitivities measured in the 
experiment were compared with the theoretical values predicted by Miller et al.,
13
 as 
illustrated in Figure 5.8 E and F. All samples exhibit sensitivities below the optimum 
values calculated by Miller’s theory, regardless of centrifugation. This suggests that the 
alternative sol is less sensitive than the one prepared using the method of Aherne et al. 
described in Chapter 4. This can be due to the discrepancies between the two sols in 
terms of aspect ratio and spectral width under the same condition of maximum LSPR 
wavelength. As shown earlier in section 5.4.1.1, the nanoplates prepared using the 
method of Aherne et al. exhibit greater aspect ratio and narrower plasmon band than 
those prepared using the method of Zhang et al.. Since large aspect ratios and narrow 
plasmon bands are considered to contribute to high sensitivity.
11, 14-16
 The nanoplates 
prepared using the method of Aherne et al. are expected to be more sensitive than the 
alternative nanoplates. 
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Figure 5.8 (A) Refractive index sensitivities of AuTSNP, C2-AuTSNP and C6-
AuTSNP sols before centrifugation; (B) Refractive index sensitivities of the same 
samples after centrifugation; (C) UV-vis spectra of the samples before centrifugation, 
the LSPR peak for AuTSNP, C2-AuTSNP and C6-AuTSNP is 624 nm, 649 nm and 651 
nm, respectively; (D) UV-vis spectra of the samples after centrifugation, no significant 
shift is observed for the LSPR peaks; (E) Comparison between the Miller line and 
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measured sensitivities of as-prepared samples; (F) Comparison between the Miller line 
and measured sensitivities of centrifuged samples. 
5.4.1.4 CRP assay  
Two individual sets of aCRP-AuTSNP conjugates including C2-AuTSNPs and C6-
AuTSNPs and a 1:1 mixture of the two conjugates were used for the detection of CRP. 
All assays were monitored for 2 h to investigate the effect of incubation time on the 
LSPR shift. Figure 5.9 A shows the LSPR peak for the three sols in the presence of 110 
mg/L CRP over 2 h. All sols present a similar trend in the peak shift over time where 
the LSPR peak continues to shift to longer wavelengths during the 2 h incubation. This 
indicates that the antibody-antigen binding can take more than 2 h to reach equilibrium. 
In contrast, no significant change is observed for the LSPR peaks of the three sols in the 
presence of 110 mg/L human IgG which was used as a negative control (Figure 5.9 B). 
This suggests that no non-specific binding occurred during the assay.  
 
Figure 5.9 LSPR peak of the C2-AuTSNPs (black), C6-AuTSNPs (red) and the mixture 
of both (blue) in the presence of 110 mg/L CRP (A) and 110 mg/L human IgG (B) over 
time. (n = 3) 
Response curves were constructed by measuring the LSPR wavelength shifts after 
exposure of the three sols to concentrations of CRP between 0.86 and 110 mg/L for 90 
min (Figure 5.10 A). The LSPR shifts observed for the assay using mixed sensors are 
generally greater than the shifts observed for the assay using either C2-AuTSNPs or C6-
AuTSNPs. The LODs for the assays using C2-AuTSNPs, C6-AuTSNPs and the mixture 
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of both were calculated to be 1.53, 1.62 and 1.29 mg/L, respectively. At the highest 
concentration of analyte (110 mg/L), all assays appear not to reach saturation. 
Compared with the commercial hs-CRP assays listed in Table 4.1, the assays using 
AuTSNPs present much higher LODs. The commercial assays are either based on 
immunoturbidimetric or immunoluminometric methods. These assays are well-
developed and optimized, resulting in much lower LODs than the refractive index 
sensitivity-based assay. However, the refractive index sensitivity-based assay is a more 
straightforward method that requires no separation steps when compared with the 
commercial assays based on immunoluminometric method.  
The assays incubated for 90 min were characterized using DLS for particle size analysis 
(Figure 5.10 B). The hydrodynamic diameter of aCRP-AuTSNPs (either C2-AuTSNPs 
or C6-AuTSNPs) is measured to be 35 ± 6 nm. On exposure to increasing 
concentrations of CRP, the sizes of the conjugates increase. Typically, in the presence 
of 110 mg/L CRP the sizes of the conjugates in direct binding and sandwich assays are 
measured to be 250 ± 48 nm and 431 ± 69 nm, respectively. This indicates that small 
aggregates are formed on exposure of aCRP-AuTSNPs to high concentrations of 
analyte.  
 
Figure 5.10 (A) Shift in the LSPR peak for C2-AuTSNPs (black), C6-AuTSNPs (red) 
and the mixture of both as a function of CRP concentration after 90 min incubation; (B) 
Change in hydrodynamic diameter for the same samples as the concentration of CRP 
increases. (n = 3) 
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It is assumed that better assay performance could be achieved if the Kelly particles were 
used in the same assays. This assumption is mainly based on the comparison of the 
refractive index sensitivities observed for Kelly and alternative particles. The Kelly 
particles generally exhibit sensitivities above or near the Miller line whereas the 
alternative particles have sensitivities below the Miller line.  
5.4.2 Aggregation-based IgG assay using AuNPs 
The decision to switch from refractive index sensitivity-based CRP assay using 
AuTSNPs to aggregation-based assay using spherical AgNPs was taken as a result of 
difficulties encountered with maintaining stability of the antibody-functionalized 
AuTSNPs. The AuTSNPs were found to aggregate and fall out of the solution after 1 
week when conjugated to antibody. While the refractive index sensitivity-based assays 
have potential for high sensitivity as indicated in the previous chapter for the Kelly 
particles, it was decided to evaluate the potential performance achievable with the 
commonly developed aggregation-based assay approach using a simpler nanoparticle 
model, namely a spherical AuNP. 
5.4.2.1 aIgG-AuNP conjugation 
The AuNPs used for the aggregation-based assay are spherical with a mean diameter of 
13 ± 1 nm (Figure 5.11) and it was decided to use human IgG instead of human CRP. 
Similar to AuTSNPs, the addition of NaCl can reduce the stability of the nanoparticles 
in suspension and cause aggregation. As shown in Figure 5.12 A, AuNPs aggregate and 
completely fall out of the solution when the concentration of NaCl is above 0.04 M. To 
determine the quantity of antibody to be added, aliquots of AuNP sol were 
functionalized with various concentrations of aIgG ranging from 5 to 25 µg/mL. The 
conjugates were then placed in 0.05 M of NaCl solution and incubated for 2 h. Particles 
incubated in aCRP show increased stability towards increasing ionic strength in the 
surrounding solution. As shown in Figure 5.12 B, no aggregation is observed for the 
AuNPs incubated in the solutions containing aIgG ranging between 15 and 25 µg/mL. 
To make sure the antibody concentation is sufficient but not excessive for conjugation, 
20 µg/mL of aIgG was used, since high overloads of protein can cause subsequent 
leaching of bound material.
17
 Upon adding aIgG to the AuNP sol, the LSPR peak 
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redshifted from 519 nm to 525 nm due to the adsorption of the protein increasing the 
local refractive index of the nanoparticles. 
 
 
Figure 5.11 TEM images of as-prepared AuNPs 
 
Figure 5.12 (A) UV-vis spectra of AuNPs suspended in different concentrations of 
NaCl solutions for 2 h. (B) UV-vis spectra of aIgG-AuNP conjugates incubated in 0.05 
M NaCl solution for 2 h. The quantities of aIgG used for conjugation are given in the 
legend.  
The addition of human IgG to aIgG-AuNP results in aggregation within 30 min. The 
UV-vis spectra of solutions containing aIgG-AuNPs and 200 mg/L of IgG at different 
times during the assay are shown in Figure 5.13 A. The concentration of AuNPs used 
for the assay was estimated to be 4.3 × 10
12
 particles/mL (Appendix A). The spectrum 
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in black is a typical spectrum of aIgG-AuNP sol presenting an LSPR peak at 525 nm. 
After 30 min incubation, the LSPR peak redshifts to 535 nm accompanied by a decrease 
in the extinction intensity at the maximum wavelength and an increase in extinction 
intensity at longer wavelengths. Similar observations have been reported by other 
groups.
2, 3, 18
 The redshift is attributed to the antibody-antigen binding event that 
increases the local refractive index of the AuNPs and substantially decreases the 
interparticle distance.
2, 3
 The changes in the intensity of the LSPR wavelength result 
from the formation of AuNP aggregates and their subsequent precipitation.
18
 Though 
the decrease in the intensity of the LSPR peak has been measured and correlated to the 
analyte concentration,
19, 20
 it is found that measuring the change in extinction intensity 
at longer wavelengths rather than at the maximum wavelength improved the 
sensitivity.
21
 Moreover, measuring the intensity of the LSPR peak maximum to monitor 
the aggregation of the particles led to a long assay time of about 8 h since the intensity 
of the plasmon band decreases only when large aggregates are formed.
22
 In this 
experiment, the largest change in extinction during the aggregation of aIgG-AuNP is 
found to be at 600 nm. Figure 5.13 B shows the extinction intensity at 600 nm for the 
aIgG-AuNPs incubated with 0 mg/L of IgG, 200 mg/L of aIgG (Fab) and 200 mg/L of 
IgG over time. It is apparent that no significant change in the extinction intensity at 600 
nm for the samples containing 0 mg/L of IgG and 200 mg/L of aIgG (Fab). In the 
presence of 200 mg/L IgG, the extinction intensity at 600 nm starts to increase within 
30 min, peaks at t = 90 min and decreases at t = 120 min. Therefore, all assays were 
incubated for 90 min to obtain the maximum change in the extinction intensity at 600 
nm.  
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Figure 5.13 (A) UV-vis spectra of aIgG-AuNP conjugates in the presence of 200 mg/L 
IgG over time; (B) Extinction at 600 nm for aIgG-AuNP conjugates in the presence of 0 
mg/L IgG (black), 200 mg/L aIgG(Fab) (red) and 200 mg/L IgG (blue) over time. (n = 
3) 
A response curve was constructed by plotting the change in extinction intensity at 600 
nm against human IgG concentrations ranged from 0.78 to 400 mg/L (Figure 5.14 A). 
The LOD was determined to be 1.59 mg/L of IgG, which shows a greater sensitivity 
than a similar assay reported by Cao et al. who used less concentrated antibody-AuNP 
conjugates for IgG detection.
23
 The aggregation rate depends mostly on the collision 
frequency of the particles, which is directly related to the density of AuNPs in the 
analyte solution. As expected, the extinction change is larger at a higher concentration 
of AuNPs. Though the fitted assay curve is not a complete sigmoid curve, it indicates 
the working range of the assay is approximately two orders of magnitude. When 
compared with a commercial human IgG assay, the LOD of this aggregation-based 
assay is much higher than that of Abcam’s ELISA kit which has an LOD of 0.15 µg/L. 
This is due to the fact that the commercial assay has been well-developed and optimized 
whereas improvements are required for the aggregation-based assay. The required 
improvements involve the optimization of AuNP concentration, pH and temperature.  
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Figure 5.14 (A) Extinction change at 600 nm against the concentration of human IgG (n 
= 3); (B) Hydrodynamic diameter of the aIgG-AuNP conjugates as the concentration of 
human IgG increases. All assays were incubated for 90 min.  
The sizes of the aIgG-AuNP conjugates used for the assay were characterized with 
DLS. As shown in Figure 5.14 B, the size of the conjugates increases with IgG 
concentration. The mean size of aIgG-AuNP conjugates is measured to be 28 ± 8 nm. 
Upon exposing to 400 mg/L of IgG, the mean size of the conjugates increases to 1115 ± 
187 nm, suggesting that a high degree of aggregation has occurred. An example of the 
aggregation progress over time is given in Figure 5.15. Figure 5.15 A shows the TEM 
image of aIgG-AuNP conjugates prior to the addition of IgG. Following the addition of 
200 mg/L IgG, increased density of nanoparticles is observed at t = 30 min, in 
accompany with the formation of islands of small aggregates (Figure 5.15 B). At t = 90 
min, abundant nanoparticles are assembled forming a microscale structure (Figure 5.15 
C). 
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Figure 5.15 TEM images during the aggregation process of the AuNPs in the presence 
of 200 mg/L IgG at (A) t = 0 min, (B) t = 30 min and (C) t = 90 min. 
In this work, both refractive index sensitivity-based assay and aggregation-based assay 
belong to the colorimetric detection. To date, spherical AuNPs have been the most 
commonly used particles for the aggregation-based assays in relation to plasmonic 
sensing. However, only a narrow color change of the sol is observed when AuNPs are 
used for the colorimetric detection. On the contrary, the spectral wavelength of 
AuTSNPs can be tuned through the entire visible spectrum, rendering them more 
possibility as a colorimetric sensor. In addition to the refractive index sensitivity-based 
assays using nanoparticle ensembles, single nanoparticle sensing has been developed for 
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the assays.
24, 25
 Therefore, refractive index sensitivity-based assays exhibit more 
potential than aggregation-based assays.  
 
5.4.3 AuTSNP-enhanced SPR detection of human IgG 
As discussed in Chapter 2, there is a growing interest in the potential of plasmonic 
nanoparticles to enhance conventional label-free SPR assays. This section acts as a 
bridge between the purely solution-based assays reported in Chapter 4 and the earlier 
part of this Chapter and the final results chapter which deals with solid-phase MEF 
assays. This section also provides the opportunity to explore the use of the alternative 
AuTSNPs for another assay approach, given that their performance was not very 
satisfactory when used in refractive index sensitivity-based assays. 
In order to carry out this assay, an aliquot of AuTSNP sol was functionalized with 10 
µg/mL of polyclonal anti-human IgG (aIgG), followed by the addition of BSA (5 
µg/mL) to block the free sites on the nanoplate surface. As shown in Figure 5.16, the 
LSPR peak redshifts from 632 nm to 658 nm due to the spontaneous adsorption of 
protein molecules to the nanoplate surface. To evaluate the effect of AuTSNPs on SPR-
based biosensing, an immunoassay was carried out using human IgG model. In a typical 
assay, protein A was first immobilized on the gold surface of a sensor chip, followed by 
a blocking step with BSA. Various concentrations of human IgG were injected and 
captured by protein A. Next, the aIgG-AuTSNP sol was injected and bound to the 
protein A/IgG layer on the gold surface. The concentration of aIgG-AuTSNP conjugates 
was estimated to be 3 × 10
11
 particles/mL. A control experiment was performed by 
simply introducing free aIgG (1 µg/ml) to the SPR system under the same experimental 
conditions. The concentration of free aIgG used in the control assay was determined by 
assuming that a monolayer of antibody remained after removing the unbound aIgG from 
aIgG-AuTSNP sol via centrifugation, which was ~ 1 µg/mL (Appendix B).  
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Figure 5.16 UV-vis spectra of AuTSNP and aIgG-AuTSNP sols. 
An example of the obtained SPR response curves is given in Figure 5.17, showing the 
binding of free aIgG (black) and aIgG-AuTSNPs (red) to IgG immobilized on the gold 
chip. The concentration of IgG injected to the sensing system is 10 µg/mL. The binding 
response measured in response units (RU) is increased by ~ 11-fold when using aIgG-
AuTSNP. Figure 5.18 shows the plottings of SPR response against IgG concentration 
for AuTSNP-enhanced (A) and control (B) assays. When no IgG is injected to the SPR 
system, binding responses of 3.4 RU and 145.9 RU are observed for the control and 
AuTSNP-enhanced assay, respectively. This indicates that non-specific binding has 
occurred. It is presumed that a higher concentration of BSA or a longer flow time could 
be used to minimize the non-specific binding. In general, the binding responses of the 
assay using aIgG-AuTSNPs are much higher than those of the control assay. The 
mechanism behind the nanoparticle-enhanced SPR detection is still under investigation. 
Three possible factors have been suggested, including (i) an increase in the surface 
mass, (ii) an increase in the refractive index of the analyte, and (iii) coupling between 
the LSPR of the nanoparticles and the propagating SPR of the gold film.
5, 26, 27
 
Nevertheless, AuTSNPs provide a potential approach to efficiently enhancing SPR-
based biosensing.   
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Figure 5.17 SPR responses of the binding of aIgG (black) and aIgG-AuTSNPs (red) 
onto the protein A/IgG layers formed on the gold surface. The concentration of IgG 
used to bind protein A is 10 µg/mL.  
 
Figure 5.18 SPR responses at different IgG concentrations using (A) aIgG-AuTSNP 
and (B) free aIgG. 
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5.5 Conclusions  
In this chapter, homogenous assays were developed using different nanoparticles. The 
first set of assays involves LSPR refractive index sensitivity based CRP assay using 
AuTSNPs. AuTSNPs were derived from TSNPs that were prepared with a different 
method from the one in Chapter 4. The refractive index sensitivities of as-prepared 
AuTSNPs and aCRP-AuTSNPs before and after centrifugation were determined using 
sucrose method. The refractive index sensitivity of AuTSNP decreased after antibody 
functionalization. As-prepared AuTSNPs exhibited no change in the refractive index 
sensitivity after centrifugation while a slight increase was observed for aCRP-AuTSNPs 
after centrifugation. The measured sensitivities of all samples were below the optimum 
values predicted by Miller et al., indicating the AuTSNPs prepared using H2O2 and 
NaBH4 do not exhibit sensitivities as high as the ones prepared using the seed-mediated 
method in Chapter 4. The lowest LOD (1.29 mg/L) was observed for the assay using a 
1:1 mixture of two sensors (C2-AuTSNP and C6-AuTSNP). However, this LOD is 
much higher than those of the commercial hs-CRP assays as listed in Table 4.1. These 
commercial assays have been well-developed and optimized whereas improvements are 
needed for the refractive index sensitivity-based assay by optimizing the AuTSNP 
concentration, pH and temperature. Additionally, the triangular nanoplates with high 
refractive index sensitivities are required for the optimization of the assay. All assays 
were characterized using DLS for size analysis. It is found that the size of aCRP-
AuTSNPs increases with CRP concentration, suggesting that larger aggregates are 
formed as more analytes are added.  
The second set of assay involves aggregation-based IgG assay using spherical AuNPs. 
AuNPs were conjugated with aIgG. The extinction of aIgG-AuNP conjugates at 600 nm 
was measured when exposing to various concentrations of IgG. The LOD of the assay 
was 1.59 mg/L, which is lower than that of a similar assay reported by Cao et al..
23
 The 
assay was characterized with DLS and TEM. The third assay set involves nanoparticle-
enhanced SPR detection of human IgG using AuTSNPs. The SPR responses observed 
for the assay using aIgG-AuTSNPs were much greater than those for assay using free 
aIgG. However, non-specific binding was noted and optimization is needed to minimize 
it. Though more study needs to be carried out for the AuTSNP-enhanced SPR assay, 
nanoparticles indeed show great potential to enhance the SPR detection. For instance, 
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the sensitivity of an SPR biosensor for the detection of IgG was improved by 23-fold 
when gold nanorods were integrated in the detection system.
5
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Chapter 6 
Metal-enhanced fluorescence (MEF) -based 
immunoassays 
 
6.1 Introduction 
This chapter focuses on the investigation and development of fluorescence-based 
immunoassays enhanced by noble metal nanoparticles. In this work, two distinct types 
of nanoparticles including large spherical silver nanoparticles (AgNPs) and AuTSNPs 
have been investigated to further understand the underlying parameters required for 
optimal MEF. The enhancement effect of different dyes Cy5 and [Ru(bpy)2(pic)]
2+
 were 
also investigated. Silver nanoparticles can be prone to oxidation and restructuring, 
therefore gold coating of the large AgNPs was performed and the effect of the gold-
coated AgNPs on the fluorescence of Cy5 was examined. An initial MEF assay was 
carried out using a human IgG model system. The assay format was further used to 
develop a fluorescence-based immunoassay for the detection of CRP.  
6.2 Background and overview of the MEF assay  
Recently noble metal nanoparticles have been incorporated into fluorescence-based 
assays, resulting in immunoassays with amplified fluorescence signals and increased 
sensitivities.
1-4
 The increased fluorescence intensity and improved performance of these 
assays can be attributed to the phenomenon of MEF. MEF can arise from both enhanced 
excitation and emission processes. Nanoscale metals can interact with fluorophores 
through the presence of their local electromagnetic fields and through coupling of their 
plasmonic scattering modes to increase their fluorescence intensity.
5-7
 The factors 
influencing fluorescence enhancement are complex and include parameters such as the 
spectral location of the nanostructure plasmon resonance, the intensity of its spectral 
scattering and absorption components, electric field enhancement, the overlap with the 
fluorophore excitation and emission spectra, the distance between the metal particle and 
the dye and the intrinsic quantum efficiency of the fluorophore.  
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The relative contributions of the factors above differ across several studies in the 
literature. A significantly greater influence on MEF from plasmonic scattering 
components over electric field contributions has been reported by many authors. 
8, 9
 
Zhang et al. confirmed that the wavelength dependence of MEF for the solvent sensitive 
dye, Prodan, correlated more strongly with the scattering component of the extinction 
with a poor correlation observed with the wavelength dependence of the electric field.
10
 
Controlling and optimizing the relative contributions of these often competitive 
properties provides a significant challenge to harnessing the potential of MEF. 
Furthermore, strategies towards the fabrication of substrates, which overcome the 
negative effects of ensemble averaging and provide statistically representative 
ultrabright fluorescence signals are required, particularly for biological assay 
applications. Towards this goal, planar substrates with highly ordered 100-nm gold 
triangular nanoprism patterns have been demonstrated by Pompa et al. to produce a 33-
fold enhancement for CdSe/ZnS semiconductor nanocrystals.
11
  
In this work, a model immunoassay involving polyclonal anti-human IgG antibodies 
and human IgG was firstly used to investigate the enhancement effect of noble metal 
nanoparticles on the fluorescence-based assay. Following that, the MEF assay format 
was extended to the detection of human CRP. Both MEF immunoassays were 
performed in a sandwich format on the nanoparticle-modified substrates. A schematic 
diagram of the MEF assay setup is shown in Figure 6.1. The nanoparticle-modified 
substrate was prepared by depositing the nanoparticles onto a polyelectrolyte (PEL)-
coated substrate.
12
 A sandwich immunoassay was carried out on the modified substrate, 
where the analyte (i.e. IgG or CRP) was sandwiched between the capture antibody and 
the fluorophore-labeled antibody (i.e. detection antibody). The fluorescence signal of 
the immunoassay was amplified due to the phenomenon of MEF by using the 
nanoparticle-modified substrate. Consequently, the sensitivity and LOD of the assay 
was improved when compared to the control assay without nanoparticles. 
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Figure 6.1 Schematic diagram of MEF immunoassay. 
6.3 Experimental methods 
6.3.1 Materials  
AgNO3 (≥ 99.9%), TSC, NaBH4, H2O2 (30 wt. %), aniline (≥99.5%), AA, HAuCl4 (≥ 
99.9%), NaCl, sodium bicarbonate (NaHCO3), sodium carbonate (Na2CO3), 
poly(ethyleneimine) (PEI, average Mw ~ 750,000), poly(allylamine) hydrochloride 
(PAH, average Mw ~ 58,000), poly (sodium 4-styrene sulfonate) (PSS, average Mw ~ 
70,000), hydrochloric acid (HCl, 37%), sodium hydroxide (NaOH), PBS, 2-(N-
Morpholino)ethanesulfonic acid (MES), Tween 20, potassium cyanide (KCN) and N,N-
dimethylformamide (DMF, ≥99.8%) were purchased from Sigma-Aldrich and were 
used as received. 
Goat anti-human IgG polyclonal antibody (Fab specific) and human IgG were 
purchased from Sigma-Aldrich. Alexa Fluor 647 labeled goat anti-human IgG 
polyclonal antibody (H+L) was purchased from Invitrogen. The dye-to-protein molar 
ratio was 5. Mouse anti-human CRP monoclonal antibody C2 was purchased from 
HyTest (Turku, Finland). Human CRP was purchased from Millipore (California, USA). 
DY647-labeled mouse anti-human CRP monoclonal antibody C6 was purchased from 
Exbio Praha (Vestec, Czech Republic). The dye-to-protein molar ratio was 4.5. Bovine 
serum albumin (IgG-free) was purchased from Jackson ImmunoResearch (Pennsylvania, 
USA). Cy5 mono NHS ester was purchased from GE Healthcare (Buckinghamshire, 
UK). DY647 NHS ester was purchased from Dyomics (Jena, Germany). 
[Ru(bpy)2(pic)]
2+
 was obtained from the group of Prof. Tia Keyes in School of 
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Chemical Sciences. Black 96-well microtiter plates with clear bottom were purchased 
from Greiner Bio-one (Solingen, Germany). Nunc Maxisorp 96-well microtiter plates 
were purchased from Fisher Scientific (Roskilde, Denmark). Water purified by a Milli-
Q Academic system (Millipore, USA) to a resistivity of 18.2 MΩ cm-1 was used 
throughout. 
6.3.2 Synthesis of nanoparticles 
6.3.2.1 Synthesis of AuTSNPs 
AuTSNPs were prepared using the method described in section 5.3.2.1.  
6.3.2.2 Synthesis of spherical silver nanoparticles  
Large spherical silver nanoparticles (AgNPs) were prepared by the reduction of AgNO3 
with TSC in the presence of aniline.
13
 Typically, AgNO3 (0.02 M, 4 mL) and aniline 
(7.3 µL) were added to 108 mL of water with vigorous stirring. The solution was heated 
to reflux and TSC (1 wt. %, 8 mL) was added. The stirring was stopped after 10 seconds 
and the solution was refluxed for 30 min during which the solution color changed from 
clear to milky grey. The obtained AgNP suspension was doubly concentrated by 5 min 
centrifugation at 15,616 × g and re-dispersion in water. The final suspension was kept at 
4 ℃ before use.  
6.3.2.3 Synthesis of gold-coated AgNPs 
In a typical synthesis, a batch of AgNPs was prepared using the method stated in section 
6.3.2.2 without the concentration process. The colloid was then split into four aliquots 
of identical volume, with each aliquot containing 1.6 × 10
-5
 mol of AgNO3. AA (10 mM, 
1.6 mL) was added to one aliquot with vigorous stirring, followed by gradually adding 
the appropriate volume of HAuCl4 solution (0.5 mM) corresponding to the desired 
Au/Ag ratio. The obtained samples were then doubly concentrated by centrifugation as 
described above in section 6.3.2.2. The final colloids were kept at 4 ℃ before use.  
6.3.3 Synthesis of dye-PAH conjugates 
Different NHS ester-activated fluorescence dyes including Cy5, DY647 and 
[Ru(bpy)2(pic)]
2+
 were used in this work. The conjugation of each dye with PAH was 
                              Chapter 6: Metal-enhanced fluorescence (MEF)-based immunoassays 
 
 113 
carried out using the same procedure. The dye-to-PAH ratio was maintained at 1 to 40. 
Taking Cy5 as an example, the Cy5-PAH conjugate was synthesized by mixing Cy5-
NHS ester (1.5 mg) dissolved in DMF (50 µL) and PAH (4.76 mg) dissolved in 
NaHCO3/Na2CO3 buffer (4.7 mL, 0.1 M, pH 8.5) for four hours. The free dye was 
removed by filtration using a Vivaspin 6 centrifugal column with a 10,000 MWCO. The 
conjugate solution was stored at 4 ℃ before use.  
6.3.4 Layer-by-layer assembly of PEL multilayer films 
Black 96- well microtiter plates with transparent polystyrene bottoms were used as an 
experimental assay platform. To immobilize AgNPs onto the substrate, five layers of 
PEL were firstly constructed using the layer-by-layer (LbL) deposition technique.
12
 Five 
is the minimum number of preliminary PEL layers required to ensure the complete 
coverage of PEL on the substrate. PEI, PAH and PSS solutions at 2 mg/mL were 
prepared by dissolving individual PEL in an aqueous solution containing 0.5 M NaCl. 
All PEL solutions were adjusted to pH 7 using NaOH or HCl. Prior to PEL modification, 
a plate was oxygen plasma-treated for 5 min under vacuum in a Harrick PDC-200 
plasma chamber. PEL layers were deposited onto the plate substrate by incubating 150 
µL aliquots of PEL solutions in individual wells for 15 minutes, followed by three 
washes with water. The deposition sequence of PEL layers was PEI/PSS/PAH/PSS 
/PAH with the uppermost layer providing a positively-charged surface for subsequent 
assembly of a nanoparticle film.  
6.3.5 Assembly of nanoparticle film 
150 µL aliquots of nanoparticle solution were added to the PEL-modified wells of the 
microtiter plate. The plate was sealed with Parafilm and incubated overnight at room 
temperature in the dark. After three washes with water, extinction spectra of the 
nanoparticle films were obtained with 150 µL of water in each well.  
6.3.6 Assembly of PEL multilayer spacers and deposition of dye-PAH 
conjugate 
To create different thicknesses of spacers between the nanoparticle film and 
fluorescence dye, a series of (PAH/PSS)n bilayers were assembled by alternately 
depositing PAH and PSS onto the nanoparticle film using the same approach as 
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described in section 6.3.4. The number of bilayers (n) ranged from 0 to 7. After 
constructing PEL multilayer spacers, 150 µL aliquots of dye-PAH conjugate solution 
were added to the wells with an incubation time of 15 minutes, followed by thorough 
washes with water. A set of control wells was prepared by directly depositing dye-PAH 
conjugate onto the PEL-modified substrate in the absence of nanoparticles.  
6.3.7 IgG assay
2
 
The MEF human IgG immunoassay was carried out in a sandwich assay format with 
four replicates. In a typical experiment, a Greiner 96-well microtiter plate with a 
transparent polystyrene bottom was coated with AgNPs, and a Nunc Maxisorp 96-well 
black microtiter plate was used for the control assay without AgNPs. In the case of the 
plasmon-enhanced immunoassay, AgNPs were firstly deposited onto the PEL-modified 
wells of the Greiner plate using the method described in section 6.3.5. Goat anti-human 
IgG polyclonal antibody (Fab specific) (5 µg/mL, 100µL) was then added to each well 
and the plate was incubated for 1 hour at 37 ℃. For the control assay without AgNPs, 
the plate was incubated overnight at 4 ℃ after adding capture antibody (5 µg/mL, 
100µL) to each well. The two plates were washed three times with PBS and three times 
with PBS solution containing 0.05 (v/v) % Tween 20 (PBST) before blocking each well 
with 300 µL of 1 (w/v) % BSA in PBS for 1 hour at 37 ℃. The wash cycle was repeated. 
Next, 100 µL aliquots of human IgG in 0.1 (w/v) % BSA ranged from 0.1 to 10
5
 µg/L 
were added to appropriate wells and the plates were incubated for 1 hour at 37 ℃. 
Following the wash cycle, 100 µL aliquots of Alexa Fluor 647-labeled polyclonal anti-
human IgG (H+L) (0.025 mg/mL) were added to each well and the plates were 
incubated for 1 hour at 37 ℃ in the dark. The plates were then washed one more time 
and 100 µL aliquots of PBS were added to each well before the measurements. 
6.3.8 CRP assay 
Solid phase sandwich assays based on MEF were carried out for the detection of human 
CRP. A series of CRP dilutions ranging from 1.5 × 10
-4
 to 10 mg/L were assayed in 
four replicates. Typically, a Greiner 96-well microtiter plate with transparent 
polystyrene substrate was coated with AgNPs, and a Nunc Maxisorp 96-well black 
microtiter plate was used for the control assay in the absence of AgNPs. In the case of 
the MEF immunoassay, AgNPs were firstly deposited onto the PEL-modified wells of 
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the Greiner plate using the method described in section 6.3.5. Mouse anti-human CRP 
monoclonal antibody C2 (5 µg/mL, 100µL) was added to each well and the plate was 
incubated for 1 hour at 37 ℃. In the case of control assay without AgNPs, the plate was 
incubated overnight at 4 ℃ after adding capture antibody (5 µg/mL, 100µL) to each 
well. The plates were washed three times with PBS and three times with PBST before 
blocking each well with 300 µL of 1 (w/v) % BSA in PBS for 1 hour at 37 ℃. The wash 
cycle was repeated. Next, 100 µL aliquots of human CRP in 0.1 (w/v) % BSA ranged 
from 1.5 × 10
-4
 to 10 mg/L were added to appropriate wells and the plates were 
incubated for 1 hour at 37 ℃. Following the wash cycle, 100 µL aliquots of DY647-
labeled mouse monoclonal anti-human CRP C6 (0.02 mg/mL) were added to each well 
and the plates were incubated for 1 hour at 37 ℃ in the dark. The plates were then 
washed one more time and 100 µL aliquots of PBS were added to each well before the 
measurements. 
6.3.9 KCN test 
Following the measurements of the CRP assay plate with AgNPs, 10 µL aliquots of 
PBS were removed from one replicate of the assay. Aliquots of KCN (1 M, 10 µL) were 
then added to each well in this replicate. After 45 min incubation, the wells were 
measured using the plate reader. 
6.3.10 Characterization techniques 
6.3.10.1 UV-vis and fluorescence spectroscopy 
Ultraviolet-visible (UV-vis) extinction measurements were collected using either a Cary 
50 (Varian) or a microplate reader (Tecan Infinite 200). All fluorescence measurements 
were collected using the Tecan plate reader.  
6.3.10.2 TEM 
TEM of the nanoparticles was performed with a Tecnai G
2
 20 twin microscope (FEI, 
USA), operating at an acceleration voltage of 200 kV. Typically, an aliquot of the as-
prepared nanoparticle sample was three-fold concentrated by 5 min centrifugation at 
16,100 × g and room temperature. A 10 µL drop of concentrated sample in water was 
placed onto a 300 mesh copper grid coated with Formvar/carbon (Agar Scientific, UK) 
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and dried in air for one hour. The excess solution was wicked away and the sample was 
further dried overnight prior to imaging. ImageJ was used for measuring the dimensions 
of nanoparticles. 
6.3.10.3 AFM 
AFM was performed to analyze the surface profile of the nanoparticle-coated substrates 
using a Veeco BioScope II. In a typical sample preparation, a glass slide (Menzel-
Gläser, Germany) was firstly cleaned by sequential sonication for 30 min in 1(v/v) % 
detergent, water and absolute ethanol. The glass slide was dried with nitrogen gas and 
oxygen plasma treated for 5 min. It was sequentially immersed in PEL solutions 
(PEI/PSS/PAH/PSS/PAH) with an incubation time of 15 minutes. The glass slide was 
washed with water and dried using a slide centrifuge between immersions. A 1cm × 1 
cm gene frame (Thermo Scientific ABgene) was adhered to the PEL-coated glass slide 
and a 150 µL aliquot of nanoparticle solution was added to the substrate. Following an 
overnight incubation at room temperature in the dark, the nanoparticle solution and the 
frame were removed. The slide was washed with water and dried thoroughly with 
nitrogen gas before the analysis. The AFM measurements were performed in tapping 
mode using silicon probes (NanoWorld AG). The obtained images were analyzed using 
ImageJ software.  
6.4 Results and discussion 
6.4.1 Nanoparticle deposition and characterization 
Two distinct nanoparticle systems were selected, large spherical AgNPs and AuTSNPs, 
to investigate and compare their ability to enhance the fluorescence of Cy5, and to 
illustrate the relative enhancement obtained as a function of the nanoparticle extinction 
contributions, namely the absorption and scattering components of the nanoparticles.  
In this work, AgNP and AuTSNP sols were individually used to coat the substrates. 
Nanoparticle-coated substrates were conveniently prepared by depositing the 
nanoparticles on PEL-modified polystyrene substrates (Figure 6.2).
2
 PELs are polymers 
with ionized groups. In aqueous solutions such as water, these groups dissociate, 
leading to charged polymers. The PEL multilayer film is assembled onto the substrate 
through the alternate adsorption of cationic (PEI and PAH) and anionic (PSS) polymers 
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from solution. This sequential self-assembly method is known as layer-by-layer (LbL) 
deposition technique. As the film is assembled layer by layer, the use of PELs allows 
control over the layer thicknesses at the nanometer scale. Two possible interactions are 
involved in the adsorption of the nanoparticles to the substrate. One is the electrostatic 
interaction between the negatively charged nanoparticles and the positively charged 
PAH layer, the other is via semi-covalent bonding between the metal and the amine 
group in PAH. 
 
 
Figure 6.2 Schematic for the stepwise preparation of the nanoparticle-coated substrates. 
 
The UV-Vis spectra of the two nanoparticle samples before and after deposition are 
shown in Figure 6.3. The AgNP sol displayed a plasmon band at 435 nm and a shoulder 
at 630 nm. The LSPR band at 435 nm corresponds to the quadrupole peak and the 
shoulder corresponds to the dipole peak of the AgNP sol. Following deposition the 
plasmon band was observed to shift to 455 nm. The AuTSNP sol exhibited a plasmon 
band at 695 nm which was broadened and redshifted to 800 nm upon immobilizing the 
nanoplates on the substrate. This shift in the LSPR band can be attributed to the change 
in refractive index and could also possibly be due in part to near field coupling.
14
 The 
LSPR of high aspect ratio TSNPs has been shown to be very sensitive to changes in 
refractive index due to the strong localized electromagnetic field at the particles surface 
and can account for the large shift observed.
15, 16
 A similar behavior has been observed 
by Jensen et al. using a DDA calculation and experiment, whereby they found that the 
extinction maxima of silver truncated tetrahedrons and silver oblate ellipsoids shifted to 
longer wavelengths after immobilization on a substrate.
17
 In our work, a standard 
deviation of 1% and 3% was observed for the extinction maxima of the AgNP films and 
the AuTSNP films respectively (Figure 6.3), confirming the high reproducibility of the 
nanoparticle deposition. 
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Figure 6.3 Normalized UV-Vis spectra of the AgNP (black) and AuTSNP (red) in 
suspension (dashed lines) and the corresponding samples immobilized on the substrates 
(solid lines). 
 
The TEM images of the synthesized AgNP and AuTSNP samples are shown in Figure 
6.4. The majority (88 %) of AgNPs featured a roughly faceted spherical structure with 
an average diameter of 146 ± 21 nm while rod-like structures account for 12 % of the 
nanoparticle sample (Figure 6.4 A). The AuTSNPs with an average edge length of 30 ± 
8 nm showed a high degree of geometric uniformity (Figure 6.4 B). Figure 6.5 A and B 
show the AFM images of the AgNP and AuTSNP samples deposited on the substrate, 
respectively. The AuTSNPs were noted to be immobilized onto the substrate via their 
flat surfaces (Figure 6.5 B). The average height was estimated to be 129 ± 23 nm for the 
AgNPs and 7 ± 1 nm for the AuTSNPs sample. It was estimated that the surface 
coverage for AgNPs and AuTSNPs was 43% and 81%, respectively.  
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Figure 6.4 TEM images of (A) AgNPs and (B) AuTSNPs. 
 
 
Figure 6.5 AFM images of (A) AgNPs and (B) AuTSNPs deposited on the PEL 
modified substrate. 
6.4.2 Distance dependence of MEF 
The prepared nanoparticle films were used to investigate the phenomenon of MEF using 
Cy5 dye. MEF has been shown to have a distance dependence and this was probed by 
assembling PAH/PSS bilayers over the nanoparticle films. As illustrated in Figure 6.6, 
various numbers of bilayers can be deposited on the nanoparticle films to create 
different distances between the metal and the dye. Each PAH/PSS bilayer has been 
shown to correspond to an average thickness of 3 nm by ellipsometry.
12
 The top graph 
in Figure 6.7 shows the normalized extinction bands of the AgNP (red) and AuTSNP 
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(black) films while the bottom graph shows the excitation and emission spectra of Cy5. 
Clearly, the optical properties of the Cy5 dye are compatible with both nanoparticle 
systems with their broad plasmon bands. 
 
 
Figure 6.6 Schematic diagram illustrating controlled assembly of PEL layers. 
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Figure 6.7 Normalized UV-Vis spectra of AgNP (red) and AuTSNP (black) 
immobilized on the PEL-modified substrate and the excitation (blue dashed line) and 
emission (blue solid line) of Cy5-PAH conjugate. 
The relative enhancement, Ren, of fluorescence was calculated using the following 
equation,  
 
      
                
               
  (6.1) 
where            is the fluorescence of the dye-PAH in the vicinity of the 
nanoparticles,     is the background fluorescence of the nanoparticles,          is the 
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fluorescence of the dye-PAH conjugate alone and      is the background fluorescence 
of the five PEL layers. A 23-fold relative enhancement of fluorescence for Cy5 in the 
vicinity of AgNPs was obtained (Figure 6.8 black line) whereas no enhancement was 
observed for the fluorescence of the dye in the vicinity of AuTSNPs (Figure 6.8 red 
line). For the Cy5-AgNP system, the lowest enhancement was 10-fold when no PEL 
layers were placed between the nanoparticles and the dye. The highest enhancement of 
23-fold was observed when the thickness of PEL layers was increased to 9 nm. On 
increasing the thickness of PEL layers to 21 nm, the relative enhancement of the 
fluorescence slightly dropped to 20-fold. Therefore, the highest enhancement was 
observed when the distance between the AgNPs and Cy5 molecules was around 9 nm, 
which is in agreement with previous reports of 3 nm to 50 nm for different systems.
18
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Figure 6.8 Relative enhancement of Cy5 as a function of PEL thickness. Different 
layers of PEL were placed between the nanostructures and the dye. AgNPs (black) and 
AuTSNPs (red). 
There are a number of reports in the literature of TSNPs showing MEF.
19, 20
 The TSNPs 
showing MEF generally have thicknesses of 12-15 nm whereas the AuTSNPs used in 
this study are ~ 7 nm thick. It has previously been shown that due to the platelet 
nature/geometry of similar high aspect ratio TSNPs that their extinction is dominated by 
absorption processes and that they have a low scattering contribution with a localized 
electromagnetic field at the particle surface,
16
 which is distinct from reports on thicker 
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TSNPs prepared by a photo-mediated method.
21
 The large volume of the AgNPs results 
in a high scattering contribution to their extinction and thus the observed fluorescence 
enhancement can be primarily attributed to the scattering component of the nanoparticle 
extinction. Xu et al. have also shown large AgNPs to be better substrates for MEF than 
TSNPs using a ruthenium dye.
22
 They attributed the larger enhancement to the coupling 
of the AgNP plasmon with the excitation band of the dye without considering the 
extinction properties of the particles. In our case both our particle systems overlap with 
the dye spectrum and thus we attribute the difference in enhancement observed to be 
due to the relative scattering contribution of the nanoparticles.  
6.4.3 MEF of the Ru complex using AgNPs 
Studies have shown that MEF is influenced by the spectral overlap between 
fluorophores and the plasmon band of the metal nanoparticles.
19, 22-24
 As discussed 
previously, the optimum enhancement can be achieved when the LSPR band coincides 
with the excitation/emission wavelength of the fluorophore. Herein, a Ru complex was 
used to evaluate the effect of spectral overlap on the fluorescence enhancement by large 
AgNPs. A distance dependence experiment was carried out using PEL multilayers as 
spacers between the AgNP films and the Ru complex conjugated with PAH. Figure 6.9 
A shows the LSPR wavelength of AgNP film and the excitation and emission 
wavelength of the Ru complex. The excitation wavelength of the Ru complex is ~ 465 
nm which overlaps the plasmon resonance of the nanoparticles. As shown in Figure 6.9 
B, the optimized thickness of the PEL multilayers is observed to be ~ 9 nm which is in 
agreement with the value obtained for Cy5. The optimum enhancement of ~ 50-fold is 
much higher than the value measured for Cy5. This significant improvement of the 
enhancement factor is probably attributed to the better matched spectra of the Ru-AgNP 
system compared with the Cy5-AgNP system (Figure 6.7). In addition, the Ru complex 
exhibits a lower quantum yield (~ 0.067)
25
 than Cy5 (~ 0.27).
26
 Since greater 
enhancements have been observed for fluorophores with lower quantum yields,
5
 
fluorescence enhancement of the Ru complex is expected to be more significant than 
that of Cy5. 
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Figure 6.9 (A) Normalized UV-Vis spectra of AgNP (black) immobilized on the PEL-
modified substrate and the excitation (blue dashed line) and emission (blue solid line) of 
Ru-PAH conjugate; (B) Relative enhancement of Ru as a function of PEL thickness.  
6.4.4 MEF study using gold coated AgNPs 
Silver nanoparticles are prone to oxidation and restructuring with time. 
27
 In Chapters 4 
and 5 we have shown that triangular-shaped nanoparticles undergo an etching process 
by anions like Cl
-
.
28, 29
 The use of nanoparticles, in future applications, is reliant on the 
properties of the nanoparticle being maintained over an extended time period, and thus 
the long-term stability of the particle is key. To improve the stability of the AgNPs used 
for the preparation of the enhancement substrates, coating the nanoparticles with a less 
reactive noble metal, i.e. gold, has been performed. In this work, the gold coating of 
AgNPs was based on a galvanic replacement reaction previously demonstrated as a 
means for the efficient saline protection of highly non-isometric TSNP.
30
 To investigate 
the effectiveness of gold coating for improving the stability of the AgNPs, a series of 
samples was prepared with various quantities of added gold. As shown in Figure 6.10 A, 
increasing the quantity of gold leads to a redshift, a broadening and a decrease in the 
UV-vis spectra. The continuous redshift of the AgNP plasmon band, originally at ~ 435 
nm, confirms the formation of gold-coated AgNPs. Additionally, this redshift is in 
agreement with the bimetallic Au/Ag nanoparticles reports on increasing Au molar 
fraction, where the extinction maximum shifts from the wavelength of pure AgNPs to 
that of pure AuNPs as the Au fraction increases.
31-33
 The distance dependence study of 
MEF was carried out using the different gold-coated AgNP samples and Cy5. Figure 
6.10 B shows the distance dependence of MEF for all samples. As the Au/Ag ratio 
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increases, the maximum enhancement of Cy5 decreases. In addition, the distance 
corresponding to the maximum enhancement increases from 9 nm (sample A) to 12 nm 
(samples B, C and D).  
 
Figure 6.10 (A) UV-vis spectra of AgNPs (black) and three samples of AgNPs coated 
with increasing quantities of gold. The molar ratio of gold to silver for each sample is 
shown in the legend. (B) Relative enhancement of Cy5 as a function of PEL thickness 
using the four samples shown in (A). 
The nanoparticles were characterized with TEM for size measurements. The 
nanoparticle-modified substrates were analyzed with AFM for determination of surface 
coverage. The TEM and AFM images for all samples are shown in Figure 6.11 and 6.12, 
respectively. The measurements are summarized in Table 6.1. As more Au is added to 
the Ag colloid, no significant change in the nanoparticle size is observed. Upon 
examining the TEM images, the surface of the nanoparticle samples C and D was 
covered by increasing numbers of small clusters which are assumed to be the gold 
particles formed during the reaction. According to the AFM images, the surface 
coverage of the nanoparticles deposited on the substrate is decreased as an increasing 
amount of gold is added to the Ag colloid. The decrease in surface coverage is 
considered to be the main factor resulting in the decrease of the fluorescence 
enhancement as observed in Figure 6.10 B. In order to achieve the appropriate 
comparison between AgNPs and gold-coated AgNPs, the surface coverage of the gold-
coated AgNP samples should be similar to that of the AgNP samples. This can be 
achieved by increasing the concentrations of the gold-coated AgNP samples. From 
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these experiments, it is clear that, although the gold-coated AgNPs are likely to have 
less reactivity and improved long-term stability, they are not as good a choice for the 
MEF assay system due to the reduced enhancement and surface coverage. Consequently, 
the assays which follow were carried out using the spherical AgNPs. 
Table 6.1 Characterization of samples A-D.  
Sample Mean diameter (nm) Surface coverage (%) 
A (AgNPs) 146 ± 21 43 
B (Au:Ag = 0.013:1) 146 ± 25 38 
C (Au:Ag = 0.04:1) 145 ± 32 32 
D (Au:Ag = 0.1:1) 139 ± 36 21 
 
 
 
Figure 6.11 TEM images of samples A-D presented in Figure 6.10 A. The scale bar is 
100 nm.  
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Figure 6.12 AFM images of samples A-D presented in Figure 6.10 A. 
6.4.5 IgG assay based on MEF 
Previous work has shown that nanoparticle platforms can be used to enhance the 
performance of immunoassays.
2, 34, 35
 Initial work of the MEF assay was performed by 
adapting a previously reported model assay for the detection of human IgG on the 
nanoparticle-modified plate.
2
 For comparison purposes, a control assay was performed 
on a conventional Nunc Maxisorp plate without AgNP modification. The detection 
antibody was labeled with Alexa Fluor 647 which has a similar spectrum to Cy5.  
The fluorescence intensity of the assay signal was normalized according to the 
equation,
36
 
 
      
     
    
  (6.2) 
where     is the signal-to-noise ratio,   is the fluorescence intensity of the signal,   is 
the fluorescence intensity of the background and    is the standard deviation (SD) of 
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the background intensity. The S/N ratio as a function of human IgG concentration is 
shown in Figure 6.13. 
 
Figure 6.13 (A) Fluorescence immunoassay for the detection of human IgG using 
AgNPs. (B) A control assay in the absence of AgNPs. (n = 4) 
As shown in Figure 6.13, the response for the MEF assay is compared to that for a 
control assay in the absence of AgNPs. At the highest IgG concentration (10
5
 µg/L), the 
signal was enhanced by ~ 13 times. The background intensity of the enhanced assay 
(100 ± 9) was approximately four times higher than that of the control assay (23 ± 4), 
which was due to scattering of the nanoparticles. The LODs of AgNP-enhanced assay 
and the control assay were estimated to be 0.52 and 4.6 µg/L, respectively. This 
improvement of ~ 9-fold in LOD is much lower than that reported by Nooney et al.
2
 
who observed ~ 66-fold improvement in LOD. Such discrepancies can be attributed to 
the different nanoparticles used. One limitation of the method used for fabricating the 
AgNPs is the lack of batch-to-batch reproducibility. The improvement in LOD for the 
enhanced assay is mainly due to the MEF phenomenon which amplifies the 
fluorescence signal of the assay thereby allowing the system to sense lower 
concentrations of analyte. Upon analyzing the data obtained for both assays, the CV of 
the background intensity was found to be ~ 9 % for the enhanced assay and ~ 19% for 
the control assay. The reduction in this CV value for the enhanced assay resulted from 
the reproducible deposition of AgNPs on the substrate, which also contributes to the 
improvement of the LOD.  
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The relative enhancement of fluorescence for the immunoassay derived from the AgNPs 
in the vicinity of the dye molecules was calculated using the following equation:
2
  
 
      
               
           
  (6.3) 
where          is the fluorescence signal of the AgNP-enhanced assay,      is the 
background signal in the presence of AgNPs,        is the fluorescence signal of the 
control assay without AgNPs and    is the background signal of the control assay. The 
relative enhancement of the immunoassay is plotted against human IgG concentration as 
demonstrated in Figure 6.14. At the lowest concentration of IgG (0.1 µg/L), the relative 
enhancement was ~ 10 and this increased to ~ 28 at the highest IgG concentration (10
5
 
µg/L). A similar trend has been observed previously for a MEF assay.
2
 According to the 
dimensions of IgG reported previously,
37
 the estimated distance between the AgNP film 
and the fluorophore is within 11.4 – 42.6 nm, which is in the distance range that has 
been reported for MEF.
18
 The variation of enhancement with the concentration of 
analyte will be discussed in the next section as the similar trend has been observed for 
the CRP assay using the MEF platform.  
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Figure 6.14 The change in relative enhancement of an AgNP-enhanced immunoassay 
with change in human IgG concentration. 
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6.4.6 CRP assay based on MEF 
Since enhancement was observed for the model assay described in the previous section, 
the MEF assay format was extended to the application of human CRP detection. In this 
sandwich assay system, the detection antibody molecules were labeled with DY-647, 
which has a similar spectrum and properties to Cy5 and Alexa Fluor 647 as shown in 
Figure 6.15. A control assay was performed on a conventional Nunc Maxisorp plate 
without AgNP modification.  
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Figure 6.15 Excitation (dashed lines) and emission (solid lines) spectra of Cy5 (black), 
Alexa Fluor 647 (red) and DY647 (blue).  
The fluorescence response as a function of human CRP concentration is shown in 
Figure 6.16. Compared to the control assay, a significant increase in the fluorescence 
signal was observed for the AgNP-enhanced assay. At the highest CRP level (10 mg/L), 
the signal was enhanced by 60 fold. The background intensity of the enhanced assay (76 
± 1.7) was roughly five times higher than that of the control assay (15 ± 4.6). This 
increase in the background intensity was also observed for the IgG assay, which is 
attributed to the scattering of nanoparticles. The LODs for the AgNP-enhanced assay 
and the control assay were 0.24 µg/L and 4.5 µg/L, respectively. This LOD compares 
well with that reported by Luo et al.
38
 who obtained an LOD of 0.06 µg/L for their 
fluorescence-based CRP assay using quantum dot labels.
38
 Luo et al. found that they 
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had to adopt a two-step detection to overcome the instability of their quantum dot-
labeled antibody, whereas the MEF-based assay requires a single detection step. It was 
found that the CV of the background intensity was 2.3% for the enhanced assay and 29 % 
for the control assay. The reduction in this CV value was similar to the trend observed 
for the IgG assay, suggesting that the AgNP-modified substrate provides a more 
homogeneous platform for the assay performance, which is a key factor in the 
production of reproducible assays. When comparing with the homogenous CRP assays 
performed using AuTSNP sol as described in Chapter 5, the MEF assay shows a 
significantly lower LOD than the solution-phase assays which have LODs ranged from 
1.29 to 1.62 mg/L.  
 
Figure 6.16 (A) Fluorescence immunoassay for the detection of human CRP using 
AgNPs. (B) A control assay in the absence of AgNPs. The insets show the 
corresponding assays for the detection of human CRP at low concentration. (n = 4)  
 
The relative enhancement of the immunoassay is plotted against human CRP 
concentration as demonstrated in Figure 6.17 A. The relative enhancement was 2-fold at 
the lowest analyte level (1.5 × 10
-4
 mg/L) and increased to 22-fold at the highest CRP 
level (10 mg/L), showing a similar trend to the one observed for the IgG assay. For 
comparison purpose, a distance dependence experiment was carried out using DY647-
PAH and the same batch of nanoparticles. As shown in Figure 6.17 B, the optimum 
enhancement (~ 31-fold) was observed when the distance between the dye and AgNPs 
was 6 nm, differing from the results obtained for the Cy5-AgNP system. The 
discrepancy between these two systems can be explained by the variation of 
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nanoparticles from batch to batch and the different dyes used for the study. Estimating 
the dimensions of an antibody molecule as 14.2 × 8.5 × 3.8 nm and a pentameric CRP 
molecule as 10.2 × 3.6 nm,
37, 39
 the average distance between the fluorophores and the 
AgNP surface in this assay is within 10.8 - 38.6 nm. The increase in relative 
enhancement with increasing concentrations of CRP is likely to be due to a change in 
the protein orientation with higher loading. Since no attempt has been made in this 
assay platform to align the protein vertically, comparing the relative enhancement of 31 
obtained for a separation distance of 6 nm using the PEL spacer layers (Figure 6.17 B) 
and 22 for the highest concentration of CRP (Figure 6.16) it can be suggested that the 
antibody is lying flat on the silver surface. Furthermore, the preferred orientation mode 
for an antibody spontaneously adsorbed to negatively charged surface has been reported 
to be flat-on by another group.
37, 40
 
 
Figure 6.17 (A) The change in relative enhancement of the MEF immunoassay with 
change in human CRP concentration; (B) Relative enhancement of DY647 as a function 
of PEL thickness. 
Initially, two hypotheses were proposed to explain the enhancement of the fluorescence 
immunoassay: (i) the coupling of the fluorophore excitation/emission with the 
plasmonic scattering components of the AgNPs and (ii) an increased surface area for the 
AgNP-modified plate that could bind more capture antibodies than the control plate, 
resulting in a higher fluorescence signal. To examine the second hypothesis, a KCN test 
was carried out on the AgNP-enhanced assay system. The addition of KCN (0.1 M) to 
the AgNP-modified wells induced the dissolution of the nanoparticles, releasing the 
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antibody-antigen complexes into the solution. Schneider and Decher previously showed 
that dissolving the Au cores of fluorescent core-shell nanoparticles by KCN made 
significant changes in the fluorescence.
41
 Figure 6.18 shows the extinction spectra of the 
AgNP film before and after addition of KCN. 
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Figure 6.18 UV-Vis spectra of the AgNP film before (black) and after addition of 0.1 
M KCN. 
After addition of KCN, the extinction spectrum of the AgNP film was monitored. The 
LSPR band disappeared within 45 min confirming dissolution of the AgNPs. The 
fluorescence signal of the CRP assay was collected and the data was then compared 
with the enhanced assay and the control assay as shown in Figure 6.19. Upon dissolving 
the nanoparticles, the fluorescence signal of the assay with AgNPs dropped to a 
comparable level to that observed for the control assay. This indicates that the enhanced 
fluorescence signal is not as a result of the increased surface area but is directly as a 
result of the MEF effect. 
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Figure 6.19 Fluorescence signal of the immunoassay enhanced with AgNPs before 
(black) and after (blue) dissolving the nanostructures in 0.1 M KCN. The data is 
compared with the control assay without AgNPs (red). 
 
6.5 Conclusions 
In this work, the effects of large AgNP and AuTSNP films on the enhancement of 
fluorescence were investigated. The AgNP film was observed to enhance the 
fluorescence of Cy5 by 23-fold whereas no enhancement was found for the AuTSNPs. 
This enhancement is attributed to the large scattering component of the AgNP sample. It 
is believed that this work further supports the emerging radiating plasmon model for 
MEF.
6
 The radiating plasmon model suggests that the excited fluorophore interacts with 
the nearby metal nanoparticle, generating far-field radiation at the emission wavelength. 
According to this model, the relative scattering contribution of the nanoparticle 
extinction determines the MEF. A nanoparticle with its extinction dominated by 
scattering is believed to enhance fluorescence.  
A Ru complex was used to examine the effect of spectral overlap on the fluorescence 
enhancement. Comparing to the Cy5-AgNP system, higher enhancement was observed 
for the Ru-AgNP system. This can be due to the better matched spectra between the Ru 
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complex and the nanoparticles as well as the lower quantum yield of the dye which is a 
better candidate for the radiative decay engineering processe as discussed by Lacowicz.
5
 
To improve the long-term stability of the AgNP platform, gold coating of the particles 
was performed. The effects of gold-coated AgNP samples on the fluorescence 
enhancement were investigated. Decreasing enhancements were observed for the 
samples with increasing Au/Ag ratios, which was mainly attributed to surface coverage. 
To obtain the appropriate comparison between the nanoparticle samples, the surface 
coverage of gold-coated AgNPs should be similar to that of AgNPs by increasing the 
concentrations of the coated particles. This will be part of the future work.  
The large AgNPs were initially used in a model assay for the detection of human IgG 
and a significant increase in the fluorescence signal was observed. The LOD of the 
assay was improved by ~ 9-fold when compared with the assay in the absence of 
nanoparticles. The relative enhancement was found to increase with the analyte 
concentration. The same MEF assay format was further used to enhance a CRP 
sandwich immunoassay and the LOD of the assay was improved by 19-fold. Similar to 
the enhanced IgG assay, the relative enhancement was observed to increase with the 
CRP concentration. The increases in fluorescence signals and improvements in the 
LODs for both immunoassays are primarily due to the interactions of the fluorophores 
with the plasmonic scattering components of the AgNPs. Notably the MEF-based CRP 
assay compares well with the best reports to date,
38
 requiring only a single detection 
step. In addition, the LOD of the MEF-based CRP assay is much lower than those of the 
commercial assays as listed in Table 4.1. Though clinically relevant range for CRP 
assay is high, the MEF-based platform can be used for other cases requiring high 
sensitivities such as cTnI assay. Additionally, low-cost optics can be used for the read-
out of MEF-based assays due to their significantly enhanced signal, which has the 
advantage of developing diagnostic systems for low resource environments. This work 
demonstrates the potential of MEF for enhancing the performance of immunoassays, 
with the AgNP substrates providing a reproducible and sensitive detection platform. In 
the next chapter, an evaluation is carried out on the results obtained for all the different 
assay formats performed in this thesis work. 
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Chapter 7  
Conclusions and future work 
 
7.1 Conclusions  
The aim of the work was to experimentally investigate the biosensing applications of 
noble metal nanoparticles in terms of various assays.  
Initial work was carried out at NUIG during the first year of my PhD program, which 
involved homogeneous, refractive index sensitivity-based assays for detecting human 
CRP and cTnI using triangular nanoplates including TSNPs and AuTSNPs. The 
synthetic methods of these nanoplates were developed in Prof. John Kelly’s group in 
the chemistry department in TCD. The nanoplates were conjugated with PC molecules 
and aTnI antibody to form biosensors for the corresponding CRP and cTnI detection. 
The refractive index sensitivities of the bare nanoplates and biosensors before and after 
centrifugation were examined using a sucrose method. All samples showed sensitivities 
near or above the optimum values predicted by the theory of Miller et al. regardless of 
centrifugation, suggesting that the PC and aTnI-conjugated nanoplates can serve as 
efficient sensors for the corresponding CRP and cTnI detection. Additionally, gold 
coating of the TSNPs was considered to protect the morphology of the nanoplates and 
thus maintain their sensitivities. In the case of the CRP assays, PC-AuTSNPs showed a 
higher sensitivity and greater LSPR response than PC-TSNPs. The lowest 
concentrations of analyte that were detected by PC-TSNPs and PC-AuTSNPs were 
0.017 mg/L and 3.3×10
-3
 mg/L of CRP, respectively. When the analyte increased to 
3.34 mg/L, both sensors approached saturation. In the case of cTnI assays, both aTnI-
TSNPs and aTnI-AuTSNPs started to show a redshift in their LSPR peaks when cTnI 
was 4.1 µg/L. Similar to the case of the CRP assays, aTnI-AuTSNPs generally 
presented a greater LSPR response than aTnI-TSNPs. At the highest concentration of 
cTnI (333 µg/L), no saturation was observed for both sensors. Unfortunately, the work 
was discontinued due to IP restrictions on the use of the Kelly particles in DCU, and it 
was infeasible to implement a set of replicates to estimate an LOD and a working range 
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for each assay. Furthermore, optimization of the sensors and the assays was impossible 
for the same reason. Nevertheless, the AuTSNPs showed promise as robust and highly 
sensitive sensors for biosensing applications.  
Following the work conducted in the first year, the homogeneous CRP assays were 
carried on with alternative nanoplates that were synthesized using a different method. In 
this case the AuTSNPs were conjugated with aCRP monoclonal antibodies C2 and C6. 
The refractive index sensitivities of the bare nanoplates and biosensors were estimated 
using the sucrose method. Unlike the Kelly particles, the alternative nanoplates 
presented sensitivities below the Miller line, indicating that these particles may not be 
as sensitive as the Kelly particles. C2-AuTSNPs, C6-AuTSNPs and a 1:1 mixture of 
these two sensors were individually used for the CRP assays, the corresponding LODs 
for which were 1.53, 1.62 and 1.29 mg/L. However, instability of the sensors was 
observed after they were prepared for a few days. It was decided to evaluate the 
potential performance achievable with a commonly developed aggregation-based assay 
approach using spherical AuNPs. In this case, the AuNPs were conjugated with 
polyclonal aIgG, forming biosensors for human IgG detection. Upon adding the analyte, 
the AuNPs aggregated and an increase in the extinction intensity at 600 nm was 
observed. The LOD for this assay was determined to be 1.59 mg/L, which was lower 
than a similar assay reported previously.
1
  
To explore the potential application of the alternative AuTSNPs for biosensing 
approaches, the nanoplates were incorporated into an SPR system for detection of 
human IgG. In this biosensing system AuTSNPs acted as an enhancer to amplify the 
SPR response to the antigen-antibody binding event, thus improving the sensitivity of 
the SPR detection. Compared to a control assay, the assay using AuTSNP-conjugated 
aIgG presented a significantly increased binding response. However, non-specific 
binding was observed for the assays which can be minimized by optimizing the 
blocking step. Currently, the mechanism behind nanoparticle-enhanced SPR is not fully 
understood. Possible mechanisms include (i) increased surface mass, (ii) increased 
refractive index of the analyte and (iii) the plasmon resonant coupling between the 
nanoparticles and the gold film.
2
 Though more work needs to be carried out to further 
investigate the assay, this preliminary experiment has shown great potential for 
enhanced sensitivity of SPR detection incorporating AuTSNPs.  
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The last section of the work involved the MEF-based assays using noble metal 
nanoparticles. Initially, the effect of AuTSNPs on the enhancement of fluorescence was 
evaluated and compared with that of large spherical AgNPs. A distance dependence of 
the fluorescence enhancement was observed for AgNPs whereas no enhancement was 
observed for AuTSNPs. This is attributed to the large scattering component of the 
AgNP extinction. Since large AgNPs showed an enhancement effect on the 
fluorescence, the following experiments were performed using these particles. The 
effect of spectral overlap on the MEF was examined using a Ru dye which was 
compared with Cy5. Due to the better matched spectra between the Ru dye and 
nanoparticles, a much higher enhancement was obtained for Ru-AgNP system. 
Additionally, gold coating of the nanoparticles was performed to improve the long term 
stability of the AgNPs. The enhancement effects of the gold-coated AgNPs on the 
fluorescence were estimated. Decreasing enhancements were noted for the particles 
with increasing Au/Ag ratios, which was mainly due to the decreases in the surface 
coverage. The AgNP-coated substrates were used for enhanced assays for the detection 
of human IgG and CRP. A remarkable increase in the fluorescence signal was observed 
for the enhanced assays. The LODs of the IgG and CRP assays were improved by ~ 9-
fold and 19-fold, respectively. These effects were primarily attributed to the coupling of 
the fluorescence to the scattering component of the nanoparticle LSPR extinction. This 
work signifies that MEF provides a promising approach for improving the assay 
performance.  
A comparison of all the assays carried out in this thesis is shown in Table 7.1. With 
respect to the assays for the detection of CRP, the lowest LOD (0.24 µg/L) is observed 
for the MEF-based assay, which is much lower than the values for the commercial hs-
CRP assays as listed in Table 4.1. However, as a conventional heterogeneous sandwich 
assay, washing steps are required and the assay time is very long. Though the refractive 
index sensitivity-based assay is a more straightforward method, its LOD is much higher 
than the values of the commercial assays. The solution-phase refractive index 
sensitivity-based and aggregation-based assays are usually used for colorimetric 
detection. In general, they are better choices for point-of-care devices and for low 
resource environments due to their simplicity and low cost. The MEF platform provides 
an efficient approach for the enhancement of fluorescence-based assay to detect 
analytes that require a low LOD, such as cTnI. SPR biosensing offers rapid detection 
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and the study of various biomolecules such as proteins and nucleic acids in real time. 
Incorporation of nanoparticles into this sensing system can increase measurement 
sensitivities, particularly with respect to small molecule detection. 
Table 7.1 Comparison of the assays performed in this thesis 
 
Refractive 
index 
sensitivity-
base assay 
(Kelly 
particles) 
Refractive 
index 
sensitivity-
base assay 
(alternative 
AuTSNPs) 
Aggregation-
based assay 
(AuNPs) 
AuTSNP-
enhanced 
SPR 
assay 
MEF-based 
assay 
(AgNPs) 
Assay time  30 min 90 min  90 min  10 min 120 min 
Analyte volume 10 µL 10 µL 10 µL 100 µL 100 µL 
LOD N/A 
1.29 mg/L of 
CRP 
1.59 mg/L of 
IgG 
N/A 
0.52 µg/L of 
IgG, 0.24 
µg/L of CRP 
Measurement LSPR λmax LSPR λmax LSPR λ600nm 
SPR 
response 
Fluorescence  
Instrumentation 
UV-vis 
spectrometer 
UV-vis 
spectrometer 
UV-vis 
spectrometer 
Biacore 
3000 
Fluorescence 
spectrometer 
Washing steps No No No Yes Yes 
Cost Low  Low  Low  High  High  
 
7.2 Future work 
The next stage of the work will involve a further investigation of the nanoparticle-
enhanced SPR detection using nanoparticles of various shapes and sizes. In addition to 
the AuTSNPs, other nanoparticles such as nanospheres and nanorods can be 
incorporated into the SPR sensing system. Particularly, an LOD of 1 aM was reported 
for an SPR detection enhanced by nanorods.
3
 Furthermore, the effect of the nanoparticle 
size on the enhanced SPR detection needs to be evaluated.  
With respect to the MEF-based assay, further investigation of MEF using gold-coated 
AgNPs is needed. To improve the reproducibility of the AgNP-coated substrates, a 
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method for preparing more homogeneous nanoparticles is required. Additionally, 
shaped nanoparticles such as nanorods could be used for the evaluation of the MEF.
4, 5
 
For the development of assays, a few parameters are required for optimization including 
the concentration of antibody or antibody-nanoparticle conjugates, pH and ionic 
strength of the assay buffer, incubation temperature and duration. Sufficient blocking is 
also needed to prevent non-specific binding. To verify the specificity of the antibody-
antigen reaction, negative controls need to be included when carrying out the assays. 
Multiple replicates need to be carried out within the same day and on different days to 
estimate the precision of the assay. Statistically, LOD, limit of quantitation (LOQ) and 
the working range of the assay can be estimated according to a set of assay with 
multiple replicates. 
Currently, the field of biosensing with noble metal nanoparticles is a fast growing area 
in biomedical sciences. The unique optical properties of the nanoparticles provide 
numerous exciting prospects for highly sensitive detection of biomolecules. While a lot 
of achievements have been obtained in this field, more significant progress will be 
made in the next few years.  
  
  Chapter 7: Conclusions and future work 
 
143 
 
References  
1. Q. Cao, H. Yuan and R. Cai, J. Wuhan Univ. Technol.-Mat. Sci. Edit. 24 (5), 
772-775 (2008). 
2. L. He, M. D. Musick, S. R. Nicewarner, F. G. Salinas, S. J. Benkovic, M. J. 
Natan and C. D. Keating, Journal of the American Chemical Society 122 (38), 
9071-9077 (2000). 
3. H. R. Sim, A. W. Wark and H. J. Lee, Analyst 135 (10), 2528-2532 (2010). 
4. K. Aslan, Z. Leonenko, J. R. Lakowicz and C. D. Geddes, The Journal of 
Physical Chemistry B 109 (8), 3157-3162 (2005). 
5. A. M. Gabudean, M. Focsan and S. Astilean, The Journal of Physical Chemistry 
C 116 (22), 12240-12249 (2012). 
 
 
144 
 
List of publications and presentations  
Peer-reviewed publications: 
Zhang Y., Keegan G., McDonagh C. and Brennan-Fournet M. (2013). Highly sensitive 
C-reactive protein (CRP) assay using metal-enhanced fluorescence (MEF). Manuscript 
submitted. 
Oral presentations:  
Zhang Y., Voisin M., Ledwith D. and Brennan-Fournet M. (2010). One-step highly 
sensitive human cardiac troponin I diagnostic method using plasmonic silver nanoplate 
sensors. Oral presentation delivered at Inspire Bionano Postgraduate research 
workshop, UCD, Ireland 
Poster presentations: 
1. Zhang Y., Voisin M., Ledwith D. and Brennan-Fournet M. (2010). Solution phase 
triangular silver nanoplates for highly sensitive surface plasmon resonance sensing of 
C-reactive protein. Poster presentation delivered at Inspire Bionano Postgraduate 
research workshop, UCD, Ireland 
2. Zhang Y., Keegan G, McDonagh C and Brennan-Fournet M (2012) Nobel metal 
nanoparticles for immunoassays. Poster presentation delivered at BOC Gases poster 
competition, DCU, Ireland 
3. Zhang Y., Keegan G., Brennan-Fournet M. and McDonagh C. (2013). Highly 
sensitive C-reactive protein assay using metal-enhanced fluorescence. Poster 
presentation delivered at the 4th International Congress Nanotechnology in Medicine 
and Biology, BioNanoMed 2013, Krems, Austria 
  Appendix A 
1 
 
Appendix A  
Estimation of nanoparticle concentration 
1. Triangular nanoplates 
The concentration of nanoplates in a typical sol was estimated, by presuming that all of 
the AgNO3 used in the preparation, was converted to nanoplates of exactly the same 
size, with an edge length of 30 nm and a thickness of 7 nm. The diameter of a silver 
atom was taken as 0.288 nm and the edge length of a unit cell as 0.4086 nm. A unit cell 
consists of 4 silver atoms. According to the following equation, 
                 
                           
                            
 (A.1) 
It was estimated that a typical sol had a concentration of ~ 6 × 10
12
 particles/L for the 
Kelly particles and ~ 3 × 10
14
 particles/L for the alternative nanoplates prepared using 
the method of Zhang et al.. 
 
2. Spherical AuNPs 
For the AuNPs used in the IgG assay, the concentration   was estimated according to 
Beer-Lambert law, 
   
 
  
 (A.2) 
where   is the absorbance,   is the molar extinction coefficient, c is the concentration of 
the absorbing sample and   is the path length through the sample.   was taken as 2.4 × 
10
8
 m
-1
cm
-1
 and   was taken as 1 cm. It was calculated that a typical assay solution 
contained 4.3 × 10
12
 particles/mL.  
  
  Appendix B 
 
2 
Appendix B  
Estimation of antibody concentration in aIgG-
AuTSNP sol 
It was presumed that there was a monolayer of antibody adsorbed on the surface of the 
nanoplates. An antibody has an adsorption density of ~ 2.5 mg/m
2
 on a particle surface.
1
 
The concentration of the nanoplates was taken as 3 × 10
14
 particles/L and the molecular 
weight of antibody was taken as 150kDa. The edge length and the thickness of the 
nanoplates were taken as 30 nm and 7 nm, respectively. Therefore, it was estimated that 
the aIgG-AuTSNP sol contained ~ 1 µg/mL of aIgG. 
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